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The brain is by far the most complicated structure of the human being, and its malfunction is 
characterized by various degrees and types of morbidity. Several brain functions deteriorate with 
increasing age during life. Cognitive decline and age-related brain pathology are common in the 
elderly, but these changes may also become manifest early in life and preceding the onset of clinical 
symptoms of disease. The detection of early changes may be relevant for therapeutic interventions to 
prevent disease, and are therefore also increasingly targeted in genetic research as endophenotypes. 
Endophenotypes are defined as heritable phenotypes that are related to the disease of interest, and 
are typically approached as quantitative outcomes, i.e., instead of hypertension, the endophenotype 
of interest is systolic or diastolic blood pressure. In contrast to classical risk factors in epidemiology, 
an endophenotype is by definition not uniquely associated to a single disease. Blood pressure for 
example, is consistently associated to various clinically relevant outcomes such as stroke, myocardial 
infarction and heart failure. There is an increasing interest in the genetic research of endophenotypes, 
and genome-wide association studies of endophenotypes have been very successful [1,2]. In this 
thesis I focus on cognitive function and age-related brain changes early in life as endophenotypes for 
late-life brain disease and as targets for early prevention.
Cognitive deterioration can be seen in pre-clinical stages of neurodegenerative and 
neuropsychiatric disorders like dementia, schizophrenia, bipolar disorder and attention deficit 
hyperactivity disorder (ADHD) [3-5]. Cognitive function is a broad concept referring to multiple 
cognitive domains, among which memory, language, executive function and visuospatial ability. 
Although the domains are highly correlated, it is known that specific domains are related to 
specific diseases. Cognitive function is in part determined by our genetic make-up. The 
heritability is estimated to around 40% [6] and there have been various studies that have tried to 
identify genes explaining the heritability of cognitive functions. These included candidate gene 
studies [7,8], linkage studies [9-13] and genome-wide association studies [14-17]. The genes 
and chromosomal regions that have been found so far are partly explained by genes related 
to neuropsychiatric disease, and partly by genes related to dementia and Alzheimer’s disease 
(AD) with the Apolipoprotein E gene as genetic factor with one of the strongest effects. In the 
studies presented here, we will focus on a cognitive test battery targeting AD [18]. Dementia is 
one of the most common causes of morbidity and mortality in the Western society (prevalence 
of 25 million cases worldwide), in which Alzheimer disease accounts for over 70% of cases 
[19,20]. Regarding the high prevalence and major impact of these diseases, early diagnosis and 
treatment strategies have a high priority in neuroscience. Identifying risk factors for cognitive 
decline would benefit our increasingly elderly population. 
At postmortem, AD is characterized by neurofibrillary tangles and amyloid plaques [21]. The 
major components of the amyloid plaques are amyloid beta (Aβ) proteins, which are formed after 
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Another approach to study early brain changes is magnetic resonance imaging (MRI), which is 
a sensitive non-invasive imaging technique to visualize brain pathology. Hippocampal atrophy, 
white matter lesions, microbleeds and lacunar infarcts are the most common age-related brain 
changes visible on MRI, and have been associated with hypertension, stroke, dementia and 
cognitive impairment [23-28]. The mechanisms underlying the pathogenesis of these changes 
are largely unknown. Several studies suggest that structural changes in blood vessels in the 
brain lead to ischemic damage, causing white matter lesions and lacunar infarcts, and that 
leakage of red blood cells might lead to microbleeds and subsequent hemosiderin depositions 
[29,30]. Hypertension and atherosclerosis most likely cause damage to blood vessel walls, but 
also amyloid angiopathy plays an important role in vascular related events. [31]. The heritability 
estimates for age-related brain changes are high, ranging from 55 to 71% for white matter lesions 
[32-35] and ranging from 40 to 69% for medial temporal lobe atrophy [36-40].
proteolytic processing of the amyloid precursor protein (APP). Aβ pathology is also found in brains 
of cognitively healthy elderly who may develop the disease later. Aβ levels can be measured in 
plasma probably due to leakage through the blood brain barrier. It has been suggested that 
the plasma Aβ42/Aβ40 ratio may be a suitable marker for early AD pathology [22,23]. Various 
epidemiological studies have show that low Aβ42/Aβ40 ratios in plasma are associated with an 
increased risk of dementia [22,23]. Since also plasma Aβ levels are heritable with estimates 
ranging from 54 to 73% [24], they are interesting endophenotypes for genetic research.
The rationale behind the studies presented in this thesis is to use cognitive function, plasma 
Aβ levels and MRI changes as endophenotypes in the search for new determinants of 
neurodegenerative and neuropsychiatric diseases. We followed different approaches for our 
genetic studies. We used a candidate-gene approach by studying genes that have previously 
been reported in these traits or were involved in a plausible pathway for the disease. In the 
search for unknown genes, we conducted both genome-wide association studies as well as 
linkage studies. The underlying hypothesis for the genome-wide association approach is the 
common-disease common-variant hypothesis. Genome-wide linkage is considered in particular 
valuable in identifying rare variants with large effects. There is an increasing awareness that 
a large part of the heritability remains unexplained despite genome-wide association studies. 
Family-data may contribute to unravelling the genetics of complex traits and add to the data 
derived from current genome-wide associations studies [43]. 
The chapters of this thesis are divided in 4 main parts. 
Part II focuses on determinants of cognitive function. Chapter 2 describes an epidemiological 
study on the relation between common cardiovascular risk factors and cognitive function. 
16
Chapter 3 presents a candidate gene study of APOE. Chapters 4 and 5 present genome-wide 
approaches: a linkage study in chapter 4 and a genome-wide association study in chapter 5.
Part III focuses on genetic determinants of AD. Chapter 6 presents a candidate gene study and 
meta-analysis of the Cathepsin D gene and chapter 7 describes a collaborative study considering 
interactive effects of the transferrin and HFE genes. Part IV focuses on determinants of age-
related brain changes in hypertensive patients. Here, the results of three candidate gene studies 
are presented in chapters 8, 9 and 10. Finally, a short overview of all findings, followed by a 
discussion on the rating of genetic association studies is given in part V. 
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Abstract
Introduction
Background While type 2 diabetes is well-known to be associated with poorer cognitive performance, 
few studies have reported on the association of metabolic syndrome (MetS) and contributing factors, 
such as insulin-resistance (HOMA-IR), low adiponectin-, and high C-reactive protein (CRP)- levels. 
We studied whether these factors are related to cognitive function and which of the MetS components 
are independently associated.
Methods The study was embedded in an ongoing family-based cohort study in a Dutch population. All 
participants underwent physical examinations, biomedical measurements, and neuropsychological 
testing. Linear regression models were used to determine the association between MetS, HOMA-IR, 
adiponectin levels, CRP, and cognitive test scores. Cross-sectional analyses were performed in 1898 
subjects (mean age 48 years, 43% men). 
Results People with MetS had significantly higher HOMA-IR scores, lower adiponectin levels, and 
higher CRP levels. MetS and high HOMA-IR were associated with poorer executive function in 
women (p=0.03 and p=0.009). The most consistent individual component of MetS, contributing to the 
association with executive test scores was systolic blood pressure. 
Conclusions MetS and HOMA-IR are associated with poorer executive function in women. Of the 
MetS components, systolic blood pressure is independently associated with executive function.
Cognitive impairment is a common problem in the elderly and an important predictor of dementia 
(DSM-IV). There are multiple risk factors contributing to cognitive decline. For long, type 2 diabetes 
has been recognized as a major risk factor of dementia [1]. Epidemiological studies indicate that 
hyperinsulinemia and insulin-resistance, which characterize type 2 diabetes, may cause cognitive 
dysfunction [2,3]. Insulin-resistance is also a feature of the metabolic syndrome (MetS) and there is 
increasing interest in the role of MetS in cognition. The syndrome is defined as the presence of at least 
3 out of 5 factors, which include central obesity, hyperglycemia, hypertension, hypertriglyceridemia, 
and low high-density lipoprotein cholesterol (HDL-c) levels [4]. It has a high prevalence of over 22% 
in Western societies [5], and is an important risk factor of cardiovascular disease [6,7]. Potentially, 
MetS is an important, modifiable, determinant of cognitive pathology [8-10]. Previous studies 
have shown associations between cognitive dysfunction and MetS, but results are not consistent 
and predominantly concern elderly people [11]. Of its individual components, hypertension and 
hyperglycemia have proven to be the most consistent determinants of cognitive function in a recent 
review of published studies [12]. 
Adipose tissue also plays an important role in the etiology of MetS. Adipose tissue functions as 
endocrine tissue, among which secretion of adipocytokines and cytokines, which indirectly affect 
C-reactive protein (CRP) levels [13-15]. The visceral fat depot is thought to play an important role in 
adipocytokine secretion and MetS [16]. Several groups have suggested that in particular adiponectin 
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Methods
Study population
Clinical and laboratory assessments
might be a promising biomarker for MetS [17-19]. Whether it is related to cognitive function in humans 
is not known, but animal studies indicate that adiponectin may influence brain metabolism [20]. 
Regarding CRP levels, it has been reported that the association of MetS with cognitive function is 
stronger in those with high levels of CRP [21,22].
In this study, we examined whether MetS, insulin-resistance, plasma adiponectin and CRP- levels 
are related to cognitive function. In addition, we investigated which MetS components attributed 
independently to the association.
The study was performed in the Erasmus Rucphen Family Study (ERF), which is an ongoing family-
based cohort study in a genetically isolated population [23]. The ERF population includes around 
3000 individuals, all living descendents of 22 couples who, at the end of the 19th century had at least 
six children baptized in the community church. Extensive data on cardiovascular risk factors, body 
composition, cognitive functioning, and blood chemistry are available. These data were collected 
between 2002 and 2005. All participants gave informed consent and the study was approved by the 
Medical Ethics Committee at ErasmusMC.
To define MetS, we used the definition proposed by the National Cholesterol Education Program 
Adult Treatment Panel (ATPIII) [4]. Waist circumference was measured exactly halfway the distance 
between the lower costal margin and the iliac crest [24]. Blood pressure was measured twice with an 
automatic device in a sitting position [25]. 
Blood was taken after fasting of at least 8 hours and serum triglycerides (TG), serum HDL-c, and 
plasma glucose (FPG) were assessed. Fasting plasma insulin was analyzed with the INS-Irma kit of 
Biosource (cat.#: KIP1254). Insulin-resistance was determined as homeostasis model assessment 
insulin-resistance (HOMA-IR) [26], which was computed by multiplying fasting plasma insulin (micro-
international units per milliliter) and fasting plasma glucose (millimoles per liter)/22.5. Total plasma 
adiponectin was analyzed with the Human adiponectin RIA kit (cat.#: HADP-61HK) of Linco Research. 
To measure total plasma CRP, we used the US C-reactive protein ELISA (cat.# DSL-10-42100) of 
Diagnostic Systems Laboratories, Inc (expected range within 90th percentile: 254-16104 ng/ml). 
We considered age, gender, smoking, alcohol use, education, depression, and Apolipoprotein E 
genotype (APOE) as possible confounders. Use of alcohol was defined as drinking at least 1 glass 
each day. All subjects were categorized into four groups with respect to level of education: 1. primary 
education; 2. lower vocational education; 3. intermediate vocational education and secondary 
education; and 4. higher vocational education and university training. The years of schooling in the 
first category corresponded to 6 years; in the second to 7-10 years; in the third to 11-14 years; and 
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Cognitive function 
The battery of neuropsychological tests measured different cognitive domains and a Dutch validated 
version was available [27,28]. General cognitive ability was measured with the Dutch Adult Reading 
Test (DART). Memory function was measured with a word learning test with 5 exposure trials from 
which four scores were derived: immediate memory, defined as the number of correctly recalled 
words in trial 1; learning, defined as the total number of recalled words in trials 2 to 5; delayed recall, 
defined as the number of correctly recalled words after 20 minutes; and recognition, defined as 
the number of correctly recognized and correctly rejected words. Executive function was assessed 
with the Trail Making Test parts A and B (TMT), the Stroop Color and Word Test cards I, II and III, 
and verbal fluency tests. TMT and Stroop are time-demanding tasks in which participants had to 
complete the test as quickly as possible either by connecting letters and numbers (TMT) or by naming 
words and colors (Stroop) [29,30]. For analyses, we used time in seconds depicted as the ratios of 
TMT-B/TMT-A and Stroop-III/Stroop-II. These ratios were used to adjust for mental slowness, which 
is mainly reflected in TMT-A and Stroop-II. When participants timed out, scores were imputed for 
TMT-B and Stroop-III (3-8%). The imputation was performed using missing value analysis in SPSS 
through expectation maximization algorithms using age, sex, education and either score on TMT-A or 
Stroop-I and Stroop-II as predictor variables. For the verbal fluency tests, participants had to name 
as many animals and as many words starting with the same letter (D, A and T), each in one minute. 
The score was defined as the total number of correct words on both tasks. Lastly, visuo-spatial ability 
was assessed with the WAISIII block-design subtest. 
In addition to analyzing individual test scores, three composite scores were used: 1. memory 
(z-memory); 2. executive function (z-executive); 3. global cognition (z-global). These scores were 
computed by taking the average of z-scores of the individual tests, which were computed by 
subtracting the mean from the test score divided by the standard deviation [31]. For time-demanding 
tasks, the test score was subtracted from the mean. The composite scores were only computed 
when at least 3 memory scores (z-memory), 2 executive scores (z-executive) and 6 total test scores 
(z-global) were available. In the current study, we excluded participants who had a history of stroke 
or dementia (N=21) or were physically not able to perform a neuropsychological test (e.g. sensory 
handicaps (N=6), illiteracy (N=28), other (N=10)). There were 10 participants with missing test scores 
due to technical problems. 
in the fourth to 15-18 years. 
Depressive symptoms were measured with the Hospital Anxiety and Depression Scale (HADS-D). 
Genomic DNA was extracted from whole blood samples, utilizing the salting out method. Samples 
were genotyped for APOE with a Taqman allelic discrimination Assay-By-Design (Applied Biosystems, 
Foster City, CA). The measurements were performed conform the manufacturers protocols. Clinical 
and laboratory data was not available for 721 participants.
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Cognitive function 
Statistical analysis
The battery of neuropsychological tests measured different cognitive domains and a Dutch validated 
version was available [27,28]. General cognitive ability was measured with the Dutch Adult Reading 
Test (DART). Memory function was measured with a word learning test with 5 exposure trials from 
which four scores were derived: immediate memory, defined as the number of correctly recalled 
words in trial 1; learning, defined as the total number of recalled words in trials 2 to 5; delayed recall, 
defined as the number of correctly recalled words after 20 minutes; and recognition, defined as 
the number of correctly recognized and correctly rejected words. Executive function was assessed 
with the Trail Making Test parts A and B (TMT), the Stroop Color and Word Test cards I, II and III, 
and verbal fluency tests. TMT and Stroop are time-demanding tasks in which participants had to 
complete the test as quickly as possible either by connecting letters and numbers (TMT) or by naming 
words and colors (Stroop) [29,30]. For analyses, we used time in seconds depicted as the ratios of 
TMT-B/TMT-A and Stroop-III/Stroop-II. These ratios were used to adjust for mental slowness, which 
is mainly reflected in TMT-A and Stroop-II. When participants timed out, scores were imputed for 
TMT-B and Stroop-III (3-8%). The imputation was performed using missing value analysis in SPSS 
through expectation maximization algorithms using age, sex, education and either score on TMT-A or 
Stroop-I and Stroop-II as predictor variables. For the verbal fluency tests, participants had to name 
as many animals and as many words starting with the same letter (D, A and T), each in one minute. 
The score was defined as the total number of correct words on both tasks. Lastly, visuo-spatial ability 
was assessed with the WAISIII block-design subtest. 
In addition to analyzing individual test scores, three composite scores were used: 1. memory 
(z-memory); 2. executive function (z-executive); 3. global cognition (z-global). These scores were 
computed by taking the average of z-scores of the individual tests, which were computed by 
subtracting the mean from the test score divided by the standard deviation [31]. For time-demanding 
tasks, the test score was subtracted from the mean. The composite scores were only computed 
when at least 3 memory scores (z-memory), 2 executive scores (z-executive) and 6 total test scores 
(z-global) were available. In the current study, we excluded participants who had a history of stroke 
or dementia (N=21) or were physically not able to perform a neuropsychological test (e.g. sensory 
handicaps (N=6), illiteracy (N=28), other (N=10)). There were 10 participants with missing test scores 
due to technical problems. 
One large pedigree was extracted from the genealogical database for eligible participants. The 
pedigree was cut into smaller pedigrees before analyses with the software PedCut [32]. In total, 1898 
people could be linked to pedigrees with a maximum bit size of 18 and these were included in the 
analyses.
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Results
Baseline descriptive analyses were performed with SPSS version 15.0, using the independent-
samples T-test (continuous variables) and Chi-square statistics (categorical data). Deviations from 
normality were checked using P-P plots and histograms. C-reactive protein levels were transformed 
by taking the common logarithm. Because high levels of CRP could have been caused by acute 
inflammation, all values of the log-transformed variable greater than three times the standard 
deviation above the mean were excluded. 
Possible confounders were first analyzed as single covariates in two regression models with either 
MetS or cognitive test scores as dependent variables. Also, interaction terms of MetS, HOMA-
IR, adiponectin and CRP with age and sex were analyzed in these models. Covariates that were 
significantly associated were then entered simultaneously into a model using backward regression. 
We removed all covariates with a p-value > 0.10. The final model included age, level of education, 
HADS-D score, alcohol use and inbreeding coefficient. The analyses were stratified by sex, because 
the interaction terms of MetS with sex were significant. 
To identify associations between cognitive test scores and MetS, HOMA-IR, adiponectin, and CRP 
and to adjust for family relationships, we performed regression analyses using the SOLAR software 
version 4.1.0 [33]. The MetS was included in the model as a binomial variable, and additionally as a 
continuous variable ranging from 0 to 5 to test the effect of increasing number of MetS components. 
To determine to what extend the association of MetS with cognitive test scores was accounted for 
by its individual components, all individual MetS components were analyzed simultaneously in one 
regression model. The components were entered in the model as continuous variables. We used 
quartiles of HOMA-IR, adiponectin and CRP with the lowest quartile as a reference category to 
estimate the association with adipose tissue endocrine function. 
The mean age of the study population was 47.7 (±14.3) years in women and 49.2 (±14.1) years 
in men, with a range of 18 to 86 years and less than 10% older than 67. Metabolic syndrome was 
present in 227 (21%) women and in 207 (25%) men. Of these, 155 (68%) women and 150 (73%) men 
fulfilled three of the MetS diagnostic criteria, 63 (28%) and 54 (26%) fulfilled four and 9 (4%) and 3 
(1%) fulfilled all five. Null criteria were fulfilled by 282 women and 153 men. One and two criteria were 
fulfilled by respectively 385 and 305 women and 182 and 157 men. With regard to the individual MetS 
components in the total population, central obesity was present in 28% of women and 24% of men, 
hypertension in 49% and 70%, dyslipidemia in 47% and 43%, and finally increased glucose levels in 
5% and 7%. A comparison of the individual MetS components is given in Table 1. 
Table 2 shows the baseline characteristics of men and women with and without MetS regarding 
determinants of cognitive function and vascular and endocrine factors. Individuals with MetS were 
older, had lower education and had higher scores on the depression scale. Men with MetS drank 
alcohol more frequently, whereas women with MetS drank alcohol less frequently. The endocrine 
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Metabolic Syndrome in the Erasmus Rucphen Family study (n=1898) 
Men Women
MetS absent (n=615) MetS present (n=207) MetS absent (n=849) MetS present (n=227)
 
MetS components
    
Waist circumference (cm) 90.1 (9.5) 105.1 (9.3) 78.2 (9.5) 94.5 (10.2)
SBP (mm Hg) 140.7 (17.2) 151.2 (17.3) 131.2 (18.4) 152.9 (21.0)
DBP (mm Hg) 80.3 (9.5) 85.5 (9.4) 76.8 (9.3) 84.0 (10.0)
Use of antihypertensive 
medication (%)
11.7 34.3 9.0 38.3
Glucose (mmol/L, FPG) 4.6 (0.8) 5.2 (1.4) 4.3 (0.7) 5.1 (1.1)
Use of antidiabetic medication 
(%)
0.7 9.7 0.2 8.8
HDL-cholesterol (mmol/L) 1.2 (0.3) 0.9 (0.2) 1.5 (0.4) 1.2 (0.3)
Triglycerides (mmol/L) 1.2 (0.6) 2.3 (1.0) 1.1 (0.5) 1.8 (0.8)
Use of statins (%) 11.4 25.6 5.9 25.6
Values presented as mean (standard deviation). MetS= metabolic syndrome 
2
Metabolic Syndrome in relation to vascular and endocrine factors and determinants of cognitive function  
Men Women
MetS absent (n=615) MetS present (n=207) MetS absent (n=849) MetS present (n=227)
Vascular and endocrine factors     
Smoking (%) 32.7 33.5 46.5 45.1
Insulin (U/ml, FPI) 11.8 (5.6) 19.1 (11.1) ** 11.5 (4.7) 18.0 (9.2) **
HOMA-IR 2.4 (1.4) 4.5 (2.9) ** 2.2 (1.0) 4.1 (2.4) **
Adiponectin (mg/L) 8.5 (4.2) 6.7 (3.7) ** 13.1 (5.8) 9.5 (4.6) **
CRP (mg/L) 3.1 (6.2) 3.5 (5.8) ** 3.4 (5.4) 5.1 (7.4) **
     
Determinants of cognitive function    
Age (year) 47.4 (14.3) 54.4 (11.9) ** 45.3 (13.7) 56.7 (12.6) **
Education level (%) 
    Low 
    Low-intermediate 
    High-intermediate 
    High
 
30.0 
37.9 
24.1 
8.0
** 
37.7 
44.4 
14.5 
3.4
 
26.2 
42.0 
27.3 
4.5
** 
46.9 
40.7 
11.5 
3.7
Alcohol (% frequent users) § 45.0 36.6 * 19.9 12.9 *
HADS-D score 5.7 (4.0) 6.4 (3.8) * 5.4 (4.2) 7.6 (4.6) **
Apoe 4 allele carriers (%) 36.3 42.6 35.5 40.3 
Values presented as mean (standard deviation).  
MetS= metabolic syndrome, FPG = fasting plasma glucose, FPI= fasting plasma insulin, HOMA-IR = homeostatic assessment –insulin resistant model.  
HADS-D: Hospital Anxiety and Depression Scale. § defined as drinking at least one unit of alcohol per day.  
* unadjusted p-value <0.05; ** unadjusted p-value <0.01. 
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Table 1
Table 2
factors were also significantly different between individuals with and without MetS. MetS was 
associated with higher levels of insulin, higher HOMA-IR scores, lower adiponectin levels and higher 
CRP levels. 
Next, we performed regression analysis to study the associations between MetS and cognitive test 
scores. Although all mean test scores which are shown in Table 3 were lower in individuals with 
MetS, the adjusted analysis was significant only for Stroop-ratio and z-executive in women (p=0.03 
and p=0.02). Increasing number of MetS components was associated to lower verbal fluency and 
z-executive scores (p = 0.04 and 0.02) in women. The same trend, however non-significant (p=0.10), 
was seen for Stroop-ratio. 
We followed up on these associations to see which individual MetS components attributed 
independently to our findings (Table 4). Higher systolic blood pressure was related to lower scores 
on Stroop-ratio, verbal fluency and z-executive. Lower HDL-c levels were also associated with 
lower verbal fluency scores. Diastolic blood pressure showed an opposite effect with Stroop-ratio 
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Association metabolic syndrome and cognitive function in men and women  
Cognitive test Men   Women   
 
 
n MetS absent  MetS present n MetS absent MetS present  
 
General cognitive ability 
      
Dutch Adult Reading Test 
 
750 62.1 (19.0) 58.3 (18.5) 993 60.4 (18.2) 52.6 (18.1) 
Memory       
AVLT – Working memory 757 4.3 (1.7) 3.9 (1.5) 999 4.6 (1.7) 4.0 (1.6) 
AVLT – Learning 757 32.1 (8.9) 29.2 (8.3) 999 35.5 (8.9) 31.8 (8.9) 
AVLT – Recognition 759 27.7 (2.2) 27.1 (2.5) 1000 28.3 (2.2) 27.7 (2.4) 
AVLT – Delayed recall 
 
759 7.1 (2.9) 6.4 (2.8) 1000 8.3 (2.9) 7.2 (2.9) 
Executive       
Ratio TMT-B / TMT-A †
 
752 2.7 (1.0) 2.8 (1.0) 996 2.6 (1.0) 2.9 (1.1) 
Ratio Stroop III / Stroop II † 734 1.7 (0.4) 1.8 (0.4) 996 1.7 (0.3) 1.9 (0.6) * 
Verbal fluency 
 
758 63.7 (18.0) 60.0 (17.1) 998 63.0 (17.9)  53.5 (18.7) 
Visuospatial       
Block design 
 
756 30.8 (15.6) 25.7 (13.9) 998 28.7 (15.1) 20.8 (11.2) 
Composite scores       
Memory function 757 0.1 (0.8) -0.2 (0.8) 999 0.1 (0.8) -0.3 (0.9) 
Executive function 759 0.1 (0.7) -0.1 (0.7) 998 0.1 (0.6) -0.4 (0.8) * 
Global cognitive function 
 
758 0.1 (0.7) -0.2 (0.6) 998 0.1 (0.7) -0.3 (0.7) 
Values presented as mean (standard deviation). AVLT=Adult Verbal Learning Test, TMT=Trail Making Test,  
Stroop=Stroop Color and Word Test; †
 
time demanding task: high values represent low test scores. 
p=p-value derived from regression analysis adjusted for age, education, depressive score, alcohol use and family-relationship.  
* p < 0.05 
4
Contribution of individual metabolic syndrome components to executive function in women 
Ratio TMT-B / TMT-A † Ratio Stroop III / Stroop II † Verbal fluency z-executive 
    
Waist circumference 0.006 (0.003) 0.005 (0.004) 0.009 (0.049) -0.002 (0.002)
SBP 0.002 (0.002) 0.009 (0.003) ** -0.120 (0.035) ** -0.005 (0.001) **
DBP -0.001 (0.004) -0.016 (0.005) ** 0.081 (0.063) 0.005 (0.002) *
TG -0.001 (0.048) 0.050 (0.066) 1.342 (0.807) 0.012 (0.029)
HDL-c 0.048 (0.080) 0.005 (0.110) 3.277 (1.423) * 0.064 (0.051)
FPG 0.005 (0.036) 0.024 (0.054) 0.765 (0.630) 0.009 (0.023)
All individual MetS components were entered as continuous variables to the regression model. Results are presented as betas (standard errors).  
TMT=Trail Making Test; Stroop II=Stroop Color Card; Stroop III=Stroop Color and Word card; z-executive= composite score of executive tests;  
SBP=systolic blood pressure; DBP=diastolic blood pressure; TG=Triglycerides; HDL-c=High Density Lipoprotein Cholesterol; FPG=Fasting Plasma Glucose. 
† time-demanding task: positive beta represents negative association.  
* p-value < 0.05; ** p-value <0.01 
Table 3
Table 4
and z-executive, but the association with z-executive disappeared when excluding persons using 
antihypertensive medication. The other associations remained unaltered when excluding people 
using medication.
The findings related to adipose tissue endocrine function are given in Figure 1 with analyses limited 
to executive function. Women with high HOMA-IR scores had lower scores on TMT-ratio, Stroop-ratio 
and z-executive than women with low HOMA-IR scores. Higher adiponectin levels were associated 
with higher scores on z-executive in both men and women and with Stroop-ratio in women only. 
The associations of HOMA-IR with Stroop-ratio and z-executive were more significant (p=0.004 and 
0.007) when analyzing HOMA-IR as continuous variables instead of quartiles. The other associations, 
however, became non-significant. No association between CRP and executive function was found in 
this population.
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  Associations of HOMA-IR (A), adiponectin (B), and CRP (C) with cognitive function in men and women
  Results are presented as mean differences compared to quartile 1. 
  The differences are adjusted for age, education, depressive score, alcohol use and family-relationship. 
  HOMA-IR=homeostatis model assessment insulin-resistance, CRP=C-reactive protein
 * p-value < 0.05; ** p-value <0.01
Figure 1
34
Discussion
The main finding of the current study is that MetS and HOMA-IR is associated with poorer executive 
performance in women. Of the MetS components, systolic blood pressure is independently associated 
with executive function. 
Our findings of association of MetS with cognitive performance confirms previous cross-sectional and 
longitudinal studies [22,34,35]. Although we studied different cognitive domains, mainly executive 
function was associated with MetS. This is in line with two recent studies that found significant 
differences in processing speed, semantic fluency and executive function between persons with and 
without MetS [36,37]. Associations of the MetS with fronto-subcortical syndrome and with frontal 
white matter changes were found by others [10,38]. Damage to cerebral small vessels could be one 
of the  explanations for the observed associations in the current study [39-41], which is supported by 
the independent association of systolic blood pressure with cognitive function [12,34,42]. Whereas 
diabetes has been reported to be associated with cognitive function [12], the low prevalence of 
hypergelycemia in our population could explain the lack of association with cognitive tests. Insulin-
resistance as an early sign of diabetes pathology was more common in our mainly middle aged 
population and was associated with cognitive tests. Although findings on the individual MetS 
components vary, a number of studies find that an increasing number of MetS components is 
associated with lower cognitive scores, which is also confirmed by our observations [10,35,42-44].
An effect of MetS components on the early development of Alzheimer’s disease (AD) pathology may 
be another possible mechanism underlying our observations, since the insulin-degrading enzyme 
(IDE) functions less well in the presence of insulin-resistance, resulting in higher levels of amyloid 
β-peptide (Aβ) [45,46]. Long-term exposure to insulin due to insulin-resistance, may by itself also 
have a direct damaging effect on neurons [47]. Our observed association of HOMA-IR and executive 
function is in line with this. Previous studies on insulin-resistance measured as HOMA-IR have been 
inconsistent [3,48,49]. 
Despite possible pathways through which adiponectin could be linked to cognition, such as 
improvement of insulin-sensitivity, anti-inflammatory effects and effects on brain metabolism and the 
vascular system, our results do not show a consistent association of adiponectin with cognition [50-
55] . Adiponectin levels are however, lower in individuals with MetS in our study and a trend was 
seen with executive function in women, which supports further study on the role of adiponectin in 
cognition. 
Levels of CRP were not related to cognition in the present study, however, data on other markers, 
such as interleukin-6 (Il-6) and α1-antichymotrypsin (ACT) were not available. These markers have 
been related to cognitive decline and increased systemic inflammation has been proposed as a 
possible modifier between MetS and cognition [22,54]. We could not confirm this, which may also 
be due to a more pronounced effect of inflammation on cognition in the elderly than in middle aged 
individuals. 
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Our study shows that there are gender differences in the association of MetS with cognitive function. 
Gender-specific effects of metabolic components on cognitive function have not extensively 
been addressed in previous studies [56], while there is evidence that MetS has greater effect 
on cardiovascular and cerebrovascular disease in women than in men, indirectly supporting our 
observed differences [57-60]. Furthermore, there is evidence that men are treated more aggressively 
for cardiovascular risk factors [61]. As a consequence, men may be less likely to experience the 
adverse effects of MetS. Another factor that could explain gender differences is depression, which 
is highly correlated to cognition and more common in women. Since our analyses were adjusted for 
depressive symptoms, however, we do not think that depression explains the observed differences 
in our study. 
The strength of this study is the population-based design in which participants were not selected 
on the disease of interest. Also, the inclusion of a large sample size and a range of cognitive tests 
allowed detailed study of cognition. The cross-sectional design is a limitation of our study, and it does 
not allow claiming causality. Previous longitudinal studies, however, suggest that MetS might be a 
causative factor in the relationship with cognition [62]. Another limitation is that some of the significant 
p-values could be false-positive findings due to the large number of tests that we performed. However, 
the consistent associations argue against this. 
In summation, the most important findings of our study are that MetS and HOMA-IR are associated 
with executive function in women. Of the MetS components, systolic blood pressure is independently 
associated with executive function. 
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Introduction
Abstract
The ε4 allele of the apolipoprotein E gene (APOE) is a well-established determinant of Alzheimer’s 
disease and cognitive function. We studied the age-specific effects of the APOE*ε4 allele on 
cognitive function in a series of 2208 related individuals from a family-based study conducted in an 
isolated population in the Southwest part of The Netherlands. The effect of the ε4 allele on cognitive 
function was evaluated using standard quantitative genetic analysis under a polygenic model, 
adjusted for cardiovascular risk factors. We found a significant association between the APOE*ε4 
allele and reduced scores on the Adult Verbal Learning Test (AVLT) in persons aged 50 years and 
older (AVLT short-term memory P = 0.01, AVLT learning P = 0.001, AVLT delayed recall P = 0.01 and 
memory compound score P = 0.001). The effect of APOE*ε4 is most pronounced on learning ability, 
starting as early 40 years. The APOE*ε4 allele is also strongly associated to cholesterol levels and 
atherosclerosis. This association did not explain the effect of APOE on cognitive function. Our study 
suggests that APOE*ε4 is an important determinant of vascular and neurological pathology at late 
age.
The epsilon4 allele of the apolipoprotein E gene (APOE*ε4) is the most important genetic risk factor 
for Alzheimer’s disease (AD) [1]. Although its role in AD has long been known, recently a commercial 
genetic test for APOE*ε4 was launched to predict the risk of AD (http://www.labtestsonline.org) [2]. 
However, APOE*ε4 has also an established effect on lipid levels and through this on the risk and 
progression of atherosclerosis. Atherosclerosis and hypertension have been implicated in the AD 
and may partly explain the effects of APOE*ε4 on cognitive function [1]. If the effect of APOE*ε4 on 
neurodegeneration is in part caused by vascular pathology, this pathway opens the opportunity of 
clinical counseling of carriers by screening for vascular pathology. A crucial question in this respect 
is at which age pathology starts. It has been suggested that APOE*ε4 has clinically important effects 
on cognition in those who do not have signs or symptoms clinical AD. An extensive meta-analysis of 
all studies conducted in the period 1993-2004 showed evidence for a role of APOE*ε4 in cognitive 
function in non-demented people over 50 years [3]. APOE*ε4 was significantly related to reduced 
global cognitive functioning, episodic memory and executive function in a dose-dependent way, 
whereas no significant effects were seen for primary memory [3]. Although most studies focused 
on individuals aged 50 years and over, there is some evidence that with increasing age the effect 
of APOE*ε4 on cognition decreased. However, this trend was far from statistically significant in the 
meta-analysis. Animal studies provided significant evidence that apolipoprotein E has effects on early 
brain development [4], suggesting that APOE*ε4 may impact early cognitive reserve. For humans, 
the evidence supporting early effects of APOE on cognitive function is scarce and findings have been 
contradictory.
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Description of the cognitive tests derived from the neuropsychological battery
ecnerefeRnoitinifed erocSnoitpircsed ksaTniamod evitingoCtset lacigolohcysporueN
Individual tests
AVLT Short-term memory Short-term memory Recall immediately after presentation of 
15 words
Number of correctly recalled words Saan and Deelman 
1986
AVLT Learning Learning Recall after 2nd to 5th presentation Total number of correctly recalled words Saan and Deelman 
1986
AVLT Delay Delayed recall Recall after 30 minutes Number of correctly recalled words Saan and Deelman 
1986
AVLT Recognition Recognition Recognize words from a list Number of correctly recognized and rejected 
words
Saan and Deelman 
1986
WAIS Verbal fluency Semantic fluency and 
phonological fluency
Mention words fiting a frame (semantic & 
phonological)
Number of correctly mentioned words Wechsler 2000
Trail-making test (TMT) Cognitive flexibility Connect numbers (A) and together with 
letters in accending order (B)
Ratio of time in seconds to complete part B 
over part A
Reitan 1955
 ylgnorw era hcihw )2 drac( sroloc daeRecnerefretni ot ytilibitpecsuS poortS
named (card 3)
Ratio of time in seconds to complete the card 
3 over card 2
Hammes 1978
WAIS Block design Visuoconstructive abilites Place blocks according to reference Number of replicated blocks Wechsler 2000
Compound scores
Memory performance Average of z-transformation of AVLT short, 
learning, delay, recognition 
Executive function Average of z-transformation of WAIS verbal 
fluency, TMT, Stroop
Overall cognitive function Average of z-transformation of all tests
WAIS: Weschler Adult Intelligence Scale
AVLT: Auditory Verbal Learning Test
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Table 1
Materials and Methods
Study population
In the present study, we evaluated the effects of the APOE*ε4 allele on specific cognitive domains 
and vascular pathology over a wide age-range in a 3 generation family-based study. This design 
provides a powerful setting to address age specific effects of APOE*ε4 in a genetically and 
environmentally homogeneous background.
The Erasmus Rucphen Family (ERF) cohort, which is part of the Genetic Research in Isolated 
Population (GRIP) program, is a family-based study that includes inhabitants of a genetically 
isolated community in the south-western area of the Netherlands [5]. ERF aims to investigate the 
genetic origins of complex disorders and traits. The study population essentially consists of one 
extended family of descendants from 20 related couples that lived in the isolate between 1850 
and 1900 and had at least 6 children. With relatively limited migration until the last few decades, 
the isolate now includes approximately 20,000 inhabitants. All data were collected between 2002 
and 2005. The Medical Ethical Committee of the Erasmus Medical Center Rotterdam approved 
the study and informed consent was obtained from all participants.
46
Data collection
Genotyping
Statistical analysis
Participants underwent extensive medical and neuropsychological examinations at the ERF 
research centre. The examinations included the determination of cardiovascular risk factors, 
such as serum total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, systolic 
and diastolic blood pressure, and common carotid intima media thickness (IMT). Serum markers 
were determined using an automated enzymatic procedure (Boehringer Mannheim System). 
Blood pressure was measured twice on the right arm in a sitting position after at least five 
minutes rest, using an automated device (OMRON 711); the average of the two values was used 
for analysis. IMT was evaluated using ultrasonography according to previously applied protocols 
[6-8]. The outcome variable was defined as the mean IMT of the near and far wall of both 
common carotid arteries. The battery of neuropsychological tests included the Dutch version of 
the Auditory Verbal Learning Test (AVLT) [9], the Trail Making Test (TMT) [10], the Stroop colour-
word test [11], the verbal fluency test [10] and the block design subtest of the Weschler Adult 
Intelligence Scale (WAIS) [12]. These tests were chosen to screen for cognitive deficits related to 
AD and other dementias [13] and cover different cognitive domains (Table 1). We assessed the 
general reading ability of the participants with the Dutch Adult Reading Test (DART) [14]. We also 
computed compound scores for memory performance, executive function and over-all cognitive 
function (Table 1), by averaging the z-transformed scores of several cognitive tests [15]. The 
z-scores were calculated based on the direction of the measurement of test performance. For 
tests where higher scores indicate better performance (AVLT and WAIS tests), z = (x - x) / sd; 
otherwise (TMT and Stroop), z = (x - x) / sd. In this way, higher compound scores indicate better 
performance.
Finally, the education level attained by the subjects within the Dutch educational system was 
determined according to eight ordinal categories from primary school to university [16].
Genomic DNA was extracted from whole blood samples using the salting out method [17]. Samples 
were genotyped for the APOE C112R (ε4 allele) and APOE R158C (ε2 allele) polymorphisms 
with a Taqman allelic discrimination Assay-By-Design (Applied Biosystems, Foster City, CA). The 
assays utilized 5 nanograms of genomic DNA and 2 microliter reaction volumes. The amplification 
and extension protocol included an initial activation step of 10 min at 95 degrees, which preceded 
40 cycles of denaturation at 95 degrees for 15 seconds and annealing and extension at 50 
degrees for 60 seconds. Allele-specific fluorescence was analysed on an ABI Prism 7900HT 
Sequence Detection System with SDS v 2.1 (Applied Biosystems, Foster City, CA). 
A considerable proportion of participants failed to complete the TMT part B test (N = 171, 7.9%), 
ch
ap
te
r 0
3
47
03 The apolipoprotein E gene and its age-specific effects on cogntive function
Results
while some failed to complete the Stroop card III (N = 16, 0.7%) and WAIS block design tests 
(N = 64, 2.9%) within the time limit. We imputed their scores based on correlations between 
sex, age, and education level. We grouped the APOE genotypes based on the number of ε4 
alleles in a dose-dependent manner [3], zero (ε2/ε2, ε2/ε3 and ε3/ε3 genotypes), one (ε2/ε4 
and ε3/ε4 genotypes) and two copies (ε4/ε4 genotype). General characteristics of the study 
population among the genotypic groups were compared using the one-way ANOVA test for 
continuous variables and the chi-square test for dichotomous variables as implemented in SPSS 
V.11.0 (SPSS Inc. Chicago IL). The observed frequencies of the APOE genotypes were tested for 
deviations from Hardy-Weinberg equilibrium using the exact test for multiple alleles [18].
To evaluate the effect of the ε4 allele on cognitive functioning and adjust for family relationships, 
we performed the variable screening analysis under the polygenic model using the SOLAR 
software package version 4.1.0 [19]. SOLAR was chosen for its power in discriminating the 
genetic and environmental effects by utilizing all of the information that is provided by large, 
complex pedigrees. The effect of APOE genotype on cognitive tests was estimated by including 
APOE genotype (0, 1, or 2 number of ε4 alleles) as a covariate in the model, adjusted for 
other covariates including age, age-squared, sex, education, inbreeding, DART score, and 
cardiovascular risk factors (total cholesterol, triglycerides, IMT, and systolic and diastolic blood 
pressure). Inbreeding coefficients were computed based on all available genealogical information 
for the GRIP population (N = 107,091) using PEDIG software [20]. In addition, we investigated 
the interaction between APOE and age using a multiplicative model. Before SOLAR analyses, 
scores from the cognitive tests were normalized using a general rank-transformation [21]. 
To illustrate the age-specific effect of APOE on cognitive function, we smoothed the distribution 
of cross-sectional test scores across age, using locally weighted regression, or the LOESS 
smoother, implemented in the software package SigmaPlot version 8.02 [22]. 
Information on both APOE genotype and cognitive tests is available for 2208 ERF participants in 
our study. We excluded 65 individuals who were illiterate, blind, deaf, retarded or who reported 
having a brain tumour, stroke or severe brain damage. The frequencies of APOE alleles were 
4.8% for the ε2 allele, 74.1% for the ε3 allele and 21.1% for the ε4 allele. The allele and genotype 
distributions were in Hardy-Weinberg equilibrium (P = 0.64). There were no significant differences 
in age, sex, education level and blood pressure between APOE genotype groups (Table 2). 
Heterozygous and homozygous APOE*ε4 carriers had thicker IMT compared to non-carriers (P 
= 0.05, Table 2). Serum levels of total cholesterol (P = 1.75×10-7) and triglycerides (P = 4.80×10-
5) significantly increased and serum HDL levels significantly decreased (P = 4.81×10-5) with an 
increasing number of APOE*ε4 alleles.
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Characteristics per APOE genotype
APOE*4
Characteristics 0 (n=1342) 1 (n=699) 2 (n=102) P-value
Age (years) 49.0 14.9 49.3 14.4 48.8 13.7 0.85
Gender (% male) 42.9 43.9 46.2 0.76
Body mass index (kg/m2) 27.0 4.6 26.8 4.7 27.5 4.8 0.40
Education 3.24 0.05 3.08 0.07 3.00 0.18 0.07
IMT(mm) 0.81 0.21 0.84 0.21 0.83 0.17 0.05
Systolic blood pressure (mmHg/cm) 140.27 20.46 141.08 21.02 141.44 18.25 0.42
Diastoic blood pressure (mmHg/cm) 80.08 10.44 80.30 10.39 82.24 9.67 0.13
Fasting glucose (mmol/l) 4.62 1.03 4.56 0.87 4.62 0.88 0.35
Serum cholesterol (mmol/l) 5.49 1.07 5.70 1.10 5.87 1.22 1.75E-07
Serum Triglycerides (mmol/l) 1.30 0.75 1.41 0.82 1.62 0.95 4.80E-05
Serum HDL (mmol/l) 1.30 0.36 1.25 0.35 1.21 0.34 4.81E-05
Values presented are means and standard deviations or percentages
17
Cardivasular factors and cognitive function
Cognitive domain beta se beta se beta se beta se beta se beta se
Individual tests
AVLT Short-term memory 0.05 0.03 -0.03 0.04 0.17 0.10 -0.40 0.23 -0.002 0.001 -0.003 0.002
AVLT Learning 0.19 0.14 0.17 0.20 0.47 0.45 -3.52 1.09 ** -0.013 0.006 -0.008 0.007
AVLT Delay 0.08 0.05 0.11 0.07 0.07 0.16 -0.65 0.39 0.001 0.002 -0.002 0.003
AVLT Recognition 0.09 0.04 0.10 0.06 * -0.13 0.14 -1.01 0.32 ** 0.002 0.002 0.006 0.002
WAIS Verbal fluency 0.44 0.29 0.07 0.40 0.36 0.93 -10.03 2.26 *** -0.045 0.013 -0.005 0.015
TMT 0.04 0.02 -0.01 0.03 -0.01 0.06 0.00 0.16 -0.001 0.001 -0.003 0.002
Stroop 0.00 0.01 0.00 0.01 -0.03 0.03 0.03 0.06 0.002 0.000 **** 0.000 0.001
WAIS Block design 0.12 0.23 -0.05 0.32 0.03 0.73 -1.94 1.76 -0.008 0.010 -0.013 0.012
Compound scores
Memory performance 0.03 0.01 0.02 0.02 0.03 0.04 -0.32 0.10 ** 0.000 0.001 0.000 0.001
Executive function 0.00 0.01 0.00 0.02 0.04 0.04 -0.21 0.09 -0.002 0.000 ** 0.001 0.001
Overall cognitive function 0.01 0.01 0.01 0.01 0.03 0.03 -0.26 0.07 ** -0.001 0.000 0.000 0.000
se: standard errors
Except TMT and Stroop, higher absolute values indicate better performance 
P values adjusted for age, sex, inbreeding, education, and family relationship 
* P value < 0.05
** P value < 0.001
*** P value < 0.0001
**** P value < 0.00001
SBP DBPCholesterol Triglycerides IMTHDL
Table 2
Table 3
We studied the relationship between cardiovascular factors and cognitive function (Table 3). 
Serum levels of triglycerides were significantly associated with AVLT recognition (P = 0.04). 
There was significant and consistent evidence for association between IMT and multiple cognitive 
domains (AVLT learning, P = 0.01; AVLT recognition, P = 0.01; WAIS verbal fluency, P = 0.0001; 
memory compound score, P = 0.01; and over-all cognitive function compound score, P = 0.01). 
Systolic blood pressure was significantly associated with the Stroop test (P = 0.00001) and 
executive function compound score (P = 0.01). Adjustment for APOE status had little influence 
on the relationship between vascular risk factors and cognitive function.
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Effect of APOE genotype on cognitive tests
APOE*E4
Cognitive domain 0 (n=1342) 1 (n=699) 2 (n=102)
mean se mean se mean se P1 P2
Individual tests
AVLT Short-term memory 4.3 0.05 4.3 0.07 4.1 0.17 0.23 0.19
AVLT Learning 33.0 0.25 32.8 0.35 30.9 0.99 0.07 0.05
AVLT Delay 7.5 0.08 7.5 0.11 6.8 0.29 0.19 0.19
AVLT Recognition 27.8 0.06 27.8 0.09 27.7 0.20 0.68 0.96
WAIS Verbal fluency 61.5 0.51 61.0 0.71 60.8 1.83 0.80 0.98
TMT 2.7 0.03 2.7 0.04 2.7 0.10 0.64 0.64
Stroop 1.7 0.01 1.7 0.02 1.7 0.07 0.31 0.31
WAIS Block design 27.6 0.41 27.5 0.58 27.0 1.52 0.84 0.91
Compound scores
Memory performance 0.00 0.02 -0.01 0.03 -0.16 0.08 0.14 0.15
Executive function -0.01 0.02 -0.04 0.03 -0.02 0.08 0.71 0.92
Overall cognitive function -0.01 0.02 -0.02 0.03 -0.10 0.07 0.23 0.31
se: standard errors
Except TMT and Stroop, higher absolute values indicate better performance 
P2: additionally adjusted for total cholesterol, triglycerides, IMT, and systolic and diastolic 
blood presure
P1: adjusted for age, sex, inbreeding, education, DART, and family relationship
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Table 4
Table 4 presents the effect of the APOE*ε4 allele on cognitive tests. There was a borderline 
significant association between APOE*ε4 and AVLT learning (P = 0.07), which became significant 
(P = 0.05) when adjusting for cardiovascular factors. Test scores generally showed a non-
significant trend of poorer performance with an increasing number of ε4 alleles. Adjusting for 
cardiovascular factors had little influence on these results. 
When studying cognitive function, there was significant evidence for interaction between 
APOE*ε4 and age. The interaction term of age and APOE*ε4 was significant for AVLT short-term 
memory (Pinteraction = 0.01), AVLT learning (Pinteraction = 0.05), and memory compound score 
(Pinteraction = 0.01), while for AVLT delayed recall (Pinteraction = 0.09) and AVLT recognition 
(Pinteraction = 0.07), the evidence was borderline significant.
When stratifying the data by age (Table 5), the ε4 allele was significantly associated with poorer 
memory performance in those over 50 years of age (AVLT short-term memory P = 0.01, AVLT 
learning P = 0.001, AVLT delayed recall P = 0.01 and memory compound score P = 0.001). 
Adjusting for cardiovascular factors had little influence on these effects (Table 5). In younger 
subjects (≤ 50 years of age), none of the tests were significantly associated to cognitive function 
(Table 5).
To illustrate the age-specific effect of APOE on memory performance, we plotted the smoothed 
distribution of test scores across age (Figure 1). Figure 1A shows that APOE has little influence 
on AVLT short-term memory. Only after the age of 65 years does some effect of the genotype 
50
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Effect of APOE genotype on cognitive tests by age category
<=50 years >50 years
Cognitive domain 0 (n=709) 1 (n=362) 2 (n=51) 0 (n=633) 1 (n=337) 2 (n=51)
mean se mean se mean se P1 P2 mean se mean se mean se P1 P2
Individual tests
AVLT Short-term memory 4.99 0.06 5.00 0.09 4.84 0.23 0.64 0.59 3.55 0.06 3.46 0.08 3.30 0.20 0.01 0.01
AVLT Learning 37.22 0.30 37.62 0.40 35.47 1.33 0.72 0.89 28.34 0.32 27.63 0.45 26.28 1.15 0.001 0.003
AVLT Delay 8.66 0.10 8.87 0.14 8.18 0.40 0.63 0.99 6.12 0.11 6.09 0.15 5.38 0.33 0.01 0.04
AVLT Recognition 28.58 0.06 28.77 0.08 28.53 0.22 0.22 0.10 26.96 0.11 26.75 0.16 26.90 0.30 0.07 0.18
WAIS Verbal fluency 69.19 0.64 68.30 0.86 65.35 2.63 0.55 0.57 52.72 0.66 52.86 0.98 56.16 2.39 0.99 0.57
TMT 2.51 0.04 2.52 0.05 2.47 0.12 0.34 0.60 2.87 0.04 2.90 0.06 2.87 0.16 0.56 0.70
Stroop 1.59 0.01 1.59 0.01 1.66 0.12 0.99 0.47 1.88 0.02 1.91 0.03 1.82 0.05 0.45 0.24
WAIS Block design 35.65 0.56 35.14 0.82 33.47 2.35 0.97 0.73 18.70 0.37 19.23 0.52 20.44 1.42 0.55 0.36
Compound scores
Memory performance 0.40 0.03 0.45 0.04 0.28 0.10 0.43 0.54 -0.44 0.03 -0.50 0.04 -0.61 0.10 0.001 0.01
Executive function 0.30 0.02 0.28 0.03 0.19 0.13 0.74 0.75 -0.35 0.03 -0.39 0.04 -0.23 0.09 0.66 0.77
Overall cognitive function 0.37 0.02 0.39 0.03 0.26 0.10 0.66 0.83 -0.44 0.02 -0.47 0.04 -0.47 0.07 0.01 0.07
se: standard errors
Except TMT and Stroop, higher absolute values indicate better performance 
P2: additionally adjusted for total cholesterol, triglycerides, IMT, and systolic and diastolic blood presure
P1: adjusted for age, sex, inbreeding, education, DART, and family relationship
Table 5
become apparent. APOE genotype seems to have the most pronounced effect on AVLT learning. 
The effect starts around age 40 years (Figure 1B). The effects on AVLT delayed recall and 
memory compound score are less pronounced, but there is a trend towards poorer cognitive 
performance with increasing number of APOE*ε4 alleles (Figure 1C and 1D). 
Because a considerable number of people could not complete the TMT-B test (N = 141), we 
investigated the distribution of these missing scores. The E4 allele was significantly associated 
with the proportion of people who could not complete the TMT-B test (none ε4 = 5.4%, one ε4 = 
8.5%, and two ε4 = 9.2%, P = 0.02). This effect was more pronounced in women (P = 0.004).
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Discussion
Figure 1
  Age specific effect of the APOE E4 allele on memory performance
  The distribution of test scores (y-axis) was smoothed across age (x-axis) using the LOESS smoother implemented in the software package   
  SigmaPlot version 8.02. [22]. A: AVLT short-term memory; B: AVLT learning; C: AVLT delayed recall; D: memory compound score.
In this study, we found a significant association between the APOE*ε4 allele and reduced memory 
performance in persons aged 50 years and older. This effect is independent of the effect of APOE 
on cardiovascular factors. In our analyses of cognitive function there is significant evidence for 
interaction between APOE*ε4 and age. The effect of APOE*ε4 increases significantly with age, 
particularly in terms of learning ability. As expected APOE*ε4 was strongly related to lipid levels 
and atherosclerosis, while serum levels of triglycerides, blood pressure and atherosclerosis were 
significantly associated to cognitive function. Additional adjustment for APOE status had little 
influence on the relationship between vascular risk factors and cognitive function.
The extensive meta-analysis of all studies conducted in the period 1993-2004 showed that 
APOE*ε4 was significantly related to reduced global cognitive functioning, episodic memory and 
executive function in a dose-dependent way, whereas no significant effects were seen for primary 
memory [3]. In contrast, in the present study we see a consistent and significant association to 
memory. Our findings are in agreement with a recent prospective, population-based study in 
5804 subjects aged 70-80 years. That study showed that ε4 carriers had significantly poorer 
performance in immediate and delayed recall at baseline as well as greater decline during the 
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3.2 years of follow up [23]. The effect of APOE was less pronounced on attention and processing 
cognitive domains. Another study of 611 elderly clergymen showed that the APOE*ε4 allele had 
a pronounced influence on declines in episodic memory [24]. This study also used a compound 
score, including word list memory, recall, recognition, immediate and delayed recall, which is 
comparable to our compound score for memory. A number of smaller studies found a relation 
between APOE*ε4 and memory performance [25,26]. Furthermore, a family-based study of 
relatives of AD patients showed an effect of APOE*ε4 on memory in those not yet affected [27]. 
Finally, episodic memory loss is a key characteristic of AD [28-30] and several epidemiological 
studies found that measures of delayed recall and learning are predictive of the risk for developing 
dementia [31-33].
Most studies on APOE and cognition in humans have focused on the elderly. Animal studies, 
however, have demonstrated that apolipoprotein E has a role in early brain development [4]. 
In our study, the effect of APOE was not significant in people younger than 50 years of age. Of 
interest, APOE genotype showed some evidence for an early effect on learning ability. The effect 
starts in early middle age, at around 40 years.
Cardiovascular factors may potentially be an intermediate feature explaining part of the association 
between APOE and cognitive function. As expected, we observed a strong association between 
APOE and serum levels of total cholesterol, triglycerides, and HDL. Systolic blood pressure 
and the presence of atherosclerosis as measure by IMT were significantly and consistently 
associated with multiple cognitive domains. Although the relationship between blood pressure 
and Alzheimer’s disease is only observed in prospective studies[34,35], also other studies have 
found a strong relationship between cognitive function to blood pressure [36] and atherosclerosis 
[37,38]. In line with the studies on Alzheimer’s disease that suggest the effect of APOE on the risk 
of disease is determined primarily by the effect on lipid metabolism with the brain, the association 
between APOE and memory performance remained significant after adjusting for serum levels 
of total cholesterol and triglycerides, IMT, and systolic and diastolic blood pressure. Also other 
estimates for the relation between APOE*ε4 and cognitive function did not change when adjusting 
for vascular pathology. This indicates that the effect of APOE on cognitive functioning is not likely 
determined by the effect of APOE on cardiovascular factors. At the same time, the additional 
adjustment for APOE status had little influence on the relationship between vascular risk factors 
and cognitive function. The finding implies that measuring APOE will not be clinically relevant 
for preventive strategies targeting the relationship between vascular risk factors and cognitive 
function. 
In summary, APOE*ε4 is associated with poorer memory performance in older people. The effect 
of APOE*ε4 increases significantly with age and is independent of vascular pathology. The effect 
of APOE*ε4 on learning ability starts as early as the age of 40 years. In light of the commercial 
test recently made available for APOE genotyping, our findings suggest that those who take 
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the test should be informed not only about the risk of AD but also about the effect of APOE 
genotype on cognitive function and vascular pathology. Whether or not the test is clinically useful 
remains to be determined in further studies [2]. Our findings clearly show that independent of 
the test outcome, management of vascular problems will be crucial for maintenance of cognitive 
function.
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Introduction
Abstract
Cognitive function is a complex trait which involves multiple environmental and genetic factors. To 
localize genes involved in cognitive functioning, we conducted genome-wide linkage analyses in a 
large family from a genetically isolated population. A broad range of cognitive test measurements 
were available for 2882 participants. We performed non-parametric linkage analysis in participants 
with low cognitive test scores, defined as a score in the lowest 10% of the distribution. Genome-wide 
significant and suggestive thresholds for linkage were estimated empirically using simulation study. 
Fine-mapping was performed in significant linkage regions comparing participants with low cognitive 
scores to those with high cognitive scores in the same population. Replication analyses were performed 
in an independent study, the Rotterdam Study, which is an ongoing population-based cohort study 
with comparable cognitive estimates. We found significant linkage (LOD > 3.78) of cognition was 
found to chromosomes 1p13.1, 12q24.33, 19q13.43, 20p13, 21q22.13 and 21q22.3. Fine-mapping 
showed significant associations to chromosome 1 (p-value=0.03) and 21 (p-value=0.01) after multiple 
testing correction. The region on 21q22.13 was replicated in the Rotterdam Study (nominal p-value 
0.003). The fine-mapping and replication results pointed to variants within the potassium inwardly-
rectifying channel, subfamily J, member 6 gene (KCNJ6). 
Cognitive function is a broad concept referring to multiple cognitive domains, among which memory, 
language, executive function and visuospatial ability. Impairment of cognitive function is seen in 
patients with various diseases including dementia, bipolar disorder, schizophrenia and attention 
deficit hyperactivity disorder (ADHD) [1-3].The heritability estimates for cognitive function vary 
between 20-79% [4,5], making cognition a potential endophenotype for the various neuropsychiatric 
outcomes [6,7].The genes implicated in cognitive function are poorly understood. Many candidate 
genes have been studied [8,9], and the most consistently reported genetic factor affecting cognition 
is apolipoprotein E (APOE), the major genetic determinant of early- and late-onset Alzheimer’s 
disease [10,11]. The effect of APOE on cognitive function is small, especially compared to its effect 
in Alzheimer’s disease [12]. In search for unknown genes, both genome wide association studies 
as well as linkage studies have been conducted. The three genome wide association studies that 
have so far been conducted, were relatively small including 333 up to 700 persons in the discovery 
set and identified three genes: the sortilin-related receptor gene (SORL1) in relation to abstract 
reasoning[13], the WW and C2 domain containing 1 gene (KIBRA) in relation to delayed recall[14] 
and the sodium channel, voltage-gated, type I, alpha subunit gene (SCN1A) in relation to short-term 
memory[15]. In addition, several linkage studies have been conducted aiming to identify genes with 
a relatively large effect on cognition. There is evidence for linkage of memory to chromosomes 4 
and 12, mental flexibility to chromosomes 5 and 11, IQ  to chromosomes 2 and 6, motor timing to 
chromosomes 2 and 13, processing speed  to chromosome 14, and reading ability to chromosome 18 
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Previous linkage findings on cognitive traits (LOD >= 2.5) in chronological order    
First author Year Family Trait Chromosome LOD
Paunio 2004 Schizophrenia Verbal learning, memory 4q21 3.8
Posthuma 2005 General population Performance IQ 2q24.1-31.1 4.4
   Verbal and full scale IQ 6p25.3-22.3 3.2
Buyske 2006 Alcohol dependence Digit Span Test 11q25 3.1
   Digit Symbol Substitution Task 14q11 6.0
   Digit Symbol Substitution Task 14q24.2 3.9
Dick 2006 Alcohol dependence Full scale IQ 6p 3.3
Luciano 2006 General population Cambridge Contextual Reading Test, Performance IQ 2q24-31 4.2, 3.7
Adolescent twins Arithmetic—verbal subtest 6p 3.3
   Schonell reading test 14q13-21 3.2
   Arithmetic—verbal subtest 21q22 3.0
Singer 2006 Adult twins Prospective memory 12q22 2.8
Seshadri 2007 General population Reading Test, Native intelligence 18p11 5.1
Almasy 2008 Schizophrenia Abstraction, mental flexibility 5q 3.4
Rommelse 2008 ADHD Motor Timing 2q21.1 3.9
   Digit span 13q12.11 4.0
04 Genome-wide linkage screen of cognitive function 
identifies susceptible chromosomal regions 
Table 1
[13,16-23] (Table 1). In contrast to dementia oriented studies of APOE, the linkage studies conducted 
were predominantly using cognitive function as an endophenotype for psychiatric outcomes including 
schizophrenia, alcohol dependence and ADHD. Two general issues of linkage studies is that the 
power of linkage analysis is low, requiring large sample sizes and that the regions of interest that are 
identified are large and single genes cannot be pinpointed. To overcome the first issue, we embedded 
our study within a large family-based program and to overcome the second issue, we combined our 
linkage studies with an association analysis in the area under the peak, allowing us to narrow down 
the region of interest [24]. 
Here, we report the findings of a linkage analysis of various cognitive traits. The analyses were 
conducted in a large family-based study, the Erasmus Rucphen Family study (ERF) including 2882 
persons derived from a genetically isolated population in the Netherlands. This population was not 
selected for any disease and participants were tested with an extensive neuropsychological test 
battery with exclusion of prevalent dementia. Since we are targeting genes with a major effect, we 
selected persons from the extremes of the trait distribution for the linkage analysis. For the fine-
mapping of the region we used dense genotyping in the regions under linkage peak in ERF and 
replicated the findings in a large outbred, population-based cohort, the Rotterdam Study.
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Materials and Methods
Study population
Cognitive evaluation
The study was conducted in a genetically isolated population in the South-West of the Netherlands. 
Participants were part of an ongoing family-based cohort study, the ERF-study, which is embedded in 
a program aiming to identify genetic risk factors of complex diseases. Participants are all descendents 
of a limited number of founders living in the 19th century. Extensive genealogical data is available 
for this population [25,26]. The study protocol included venous puncture for DNA isolation and 
chemistry, cognitive evaluation, cardiovascular examination, eye assessments and body composition 
measurements. All participants gave informed consent and the study was approved by the medical 
ethics committee at Erasmus MC University Medical Center. For the current study, participants with 
a history of cerebrovascular accidents, dementia, brain tumors or other conditions that could have 
influenced reliable neuropsychological assessment were excluded from analysis (N=80). Cognitive 
test data was available for 2882 participants. 
A 50-minute test battery was used including tests that were applicable over a wide age-range and 
for which a Dutch validated version was available [27,28]. General cognitive ability was tested 
using the Dutch Adult Reading Test (DART), which measures the number of correctly pronounced 
words. Memory was tested with a  word learning test (after Rey’s Auditory Verbal Learning test) 
[27] consisting of five exposure trials measuring immediate memory, learning, delayed recall and 
recognition. Immediate memory was defined as the total number of words recalled at the first trial, 
learning was defined as the total number of correctly recalled words in trial 2 to 5, delayed recall was 
defined as the number of correctly recalled words after 20 minutes delay and recognition was defined 
as the sum of the number of correctly recognized and correctly rejected words. Executive function 
was assessed with the time-demanding Trail Making Test (part A and B), the Stroop Colour and Word 
Test (card I, II and III), and with the verbal fluency test. The first two tests are time-demanding tasks, 
in which subjects have to connect numbers and letters (TMT) or name correct words and colours 
(Stroop) as quickly as possible. Verbal fluency was assessed with an animal naming and letter 
naming subtask, in which subjects had to name as many items as possible of the same category 
with a one minute time limit. Visuospatial ability (VSA) was assessed with the WAIS III - Block Design 
Test. The test consisted of reproducing two-dimensional patterns using cubes that have red, white, 
and half-red-half-white faces. The total number of correctly reproduced blocks within a time limit was 
used as a score.
For analyses, we used the ratios of TMT-B and TMT-A, and of the Stroop Color-Word card III and card 
II. People with missing test scores on TMT-B due to exceeding the time limit or misunderstanding of 
test instructions, were given the lowest score of 300 seconds. 
To derive more general measures of cognition for analyses, we also computed three composite scores. 
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Statistical analysis
Linkage analysis
General descriptive statistics were performed with SPSS for Windows (version 15.0) using logistic 
regression or Chi2-statistics for the comparison of cases and controls. 
These scores were based on z-score transformations of test values [29]. A memory composite score 
(zmem) was derived by taking the average of z-scores for immediate memory, learning, delayed 
recall and recognition. An executive composite score (zexec) was derived from average of z-scores 
for verbal fluency, stroop-ratio and TMT-ratio. Finally, a global cognitive function score (zglob) was 
computed by taking the average of z-scores for all tests, but the DART. 
Participants were asked to report their highest level of education. Education was categorized in 8 
categories: 1. primary education; 2. primary education plus a higher not completed education; 3. 
lower vocational education; 4. lower secondary education; 5. intermediate vocational education; 6. 
higher secondary education; 7. higher vocational education; 8. university training. Years of education 
varied from 6 years in the lowest category to at least 16 years in the highest. 
We performed linkage analysis of affected only, for which the cases were defined as 
individuals with the lowest 10% of the distribution of the residuals from the regression of 
the cognitive scores onto age, sex and education. 
All study subjects were part of one large pedigree containing 23612 individuals spanning 
18 generations. For analysis, we constructed smaller subpedigrees with a maximum bit 
size of 18 using the software PEDCUT [30] because of the linkage software restraints. 
Samples were genotyped on the Illumina HumanHap 6k Beadchip linkage panel. Markers 
with a minor allele frequency greater than 5% and callrate higher than 95% were used in 
the analyses. Genotyping errors were checked with MERLIN and PEDCHECK [31,32]. 
Markers showing high Mendelian inconsistency rates were excluded from analysis. In 
case of sporadic errors, inconsistent variants were set to missing. For analyses, there 
were 5250 autosomal SNPs available. The linkage analysis included 233 to 260 cases 
depending on the cognitive trait that was analyzed.
Before running linkage analysis, the data was reformatted with the software MEGA2 to 
derive the correct input format [33]. We performed genome-wide nonparametric linkage 
analysis in MERLIN [31] using a pair-wise approach of estimating IBD allele sharing [34-
36]. 
Thresholds for genome-wide significant and suggestive findings were estimated by 
performing 500 genome-wide simulations on the global cognitive trait (zglob) [37]. For these 
simulations, we used the complete pedigree. The typed marker set was used for simulation 
of the number of markers and intermarker distances using GENEDROP. Simulation linkage 
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Replication
Association analysis
We sought replication in the Rotterdam Study, which includes participants from a population-based 
cohort situated in a rural area of Rotterdam, The Netherlands [41]. The study includes 7983 elderly 
Caucasians aged 55 years or older who were invited for extensive examinations at baseline and three 
follow-up rounds. The study was approved by the local Medical Ethics Committee and all participants 
gave informed consent. Neuropsychological tests included the word learning test, the Stroop Color 
and Word Test, Verbal fluency (animal naming) and the Letter Digit Substitution Task. We computed 
composite scores for memory by using the z-scores of immediate memory and delayed recall. For 
executive, we used the z-scores of Stroop-ratio and verbal fluency test, and we used all tests for 
the estimation of the global cognition composite score (zglob). Cases and controls were defined 
similarly to the discovery study. In the current study, we did not include people who were demented 
or had a stroke prior to the neuropsychological testing. Genotyping was done on the Illumina Infinium 
HumanHap 550-schip v3.0 and the genotype data was used to impute to 2.5 million non-monomorphic, 
autosomal single nucleotide polymorphisms (SNPs) using release 22 HapMap CEU population as a 
reference. For the analyses, we selected SNPs within the linkage peak as described above. Analyses 
were performed in GenABEL (R-library) [39] using logistic regression models. To adjust for multiple 
testing, a Bonferroni corrected p-value <0.05 was considered significant.
Significant regions were further studied in a denser genotype set. We selected SNPs within a region 
around the highest LOD-score minus 1 LOD. A random sample of the population was genotyped 
using the Illumina HumanHap 320 K chip. We performed logistic regression using the extremes of 
the distribution to define cases and controls. Cases were defined as described above; controls were 
participants within the highest 50% of the age, sex and education-adjusted trait. Family-relationship 
was taken into account by adjusting the p-values using genomic control [38]. The genomic control 
inflation factors ranged from 0.98 for immediate memory to 1.86 for DART with a mean of 1.17. 
Analyses were performed in GenABEL(R-library) [39] using the GRAMMAR method [40]. We 
corrected for multiple testing by performing 10,000 permutations.
analyses were done using the same files containing allele frequencies, pedigrees and 
genetic model as were used in the original linkage analysis. Per simulation, the highest log 
of odds (LOD) was extracted and combining the 500 simulations resulted in a LOD score 
of 3.79 corresponding to a genome-wide type 1 error rate of 5% (significant threshold) and 
of 2.72 corresponding to a type 1 error rate of 50% (suggestive threshold). 
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19
Baseline characteristics of the study population by composite scores cognitive function 
Linkage Association
Family-based study Population-based study
zglob zmem zexec zglob zmem zexec zglob zmem zexec
Case Case Case Case Control Case Control Case Control Case Control Case Control Case Control
N 251 248 233 215 1101 224 1115 204 1171 191 955 315 1576 205 1026
Gender (% female) 59.4% 57.3% 58.4% 59.1% 57.1% 55.8% 57.0% 58.8% 56.6% 60.2% 57.9% 57.6% 58.4% 56.2% 57.5%
Age (mean (sd)) 49.2 (17.6) 48.9 (19.1) 50.9 (16.6) 50.2 (17.8) 48.2 (13.7) 51.2 (16.7) 48.8 (13.8) 51.2(16.7) 49.5 (13.4) 63.4 (5.9) 63.7 (5.5) 62.9 (5.6) 63.7 (5.6) 66.2 (6.8) 65.4 (6.5)
Education 34.3% 36.3% 35.6% 34.0% 28.8% 34.8% 29.4% 37.3% 30.5% 15.2% 11.9% 13.7% 12.7% 17.8% 15.2%
(% of only primary education)                
                
Cases are defined as the lowest 10 % of the residuals of the trait regressed on sex, age and education. Controls are defined as highest 50% of the residuals. 
** significant differences between cases and controls (p<0.01) 
† use of antidepressive medication, HADS-D score and APOE 4-carriership were known for less persons than were included in the genetic analysis.  
zmem: composite score for memory; zexec: composite score for executive function; zglob: composite score for global cognition. 
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Genome-wide significant results of linkage analysis in the ERF Study (LOD>3.78) 
Chromosome Variant Physical Position cM* Trait Domain Non-parametric 
model 
Gene Candidate genes in region* 
      LOD   
1p13.1 rs1555793 117358754 135 – 142 Stroop Executive 4.21 IGSF2 PTGFRN, NGF 
         
12q24.33 rs2270928 132238673 170 – 173 Zglob Global 6.36 ZNF10  
    Zmem Memory 5.70   
    WLTD Memory 4.89   
    TMT Executive 4.37   
    Recognition Memory 4.09   
         
19q13.43 rs893186 63660991 110 – 111 DART Global 5.26 ZNF324B SLC27A5, HNG 
    TMT Executive 4.09   
    Fluency Executive 3.99   
    Recognition Memory 3.90   
         
20p13 rs751596 99330 0 – 4 VSA Visuospatial 4.10 intergenic TRIB3 
    WLTI Memory 3.80   
         
21q22.13 rs2835629 37443530 43 – 49 VSA Visuospatial 4.26 TTC3 DYRK1A 
    Zglob Global 4.14  KCNJ6 
    Stroop Executive 3.92   
         
21q22.3 rs2256207 46886508 70 – 79 VSA Visuospatial 4.52 PRMT2 S100B 
    WF Executive 3.78  PCNT 
         
LOD scores in bold pass the significance threshold. 
* boudaries of the linkage peak defined as the highest LOD +/- 1LOD. 
Stroop: stroop-ratio; zglob: composite score for global cognition; zmem: composite score for memory; WLTD: AVLT delayed recall; TMT: trail making test ratio; DART: Dutch Adult Reading Test; 
VSA: Block Design Test; WLTI: AVLT immediate recall; WF: verbal fluency 
04 Genome-wide linkage screen of cognitive function 
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Results
Table 2
Table 3
Baseline characteristics of the cases and controls are shown in Table 2. The descriptives of the 
specific cognitive tests can be found in the Supplementary Material (Supplementary Table 1). The 
mean age of the cases ranged from 48 to 51 years in the ERF Study and from 57 to 63 years in the 
Rotterdam Study. 
Table 3 shows the significant linkage regions with LOD scores greater than 3.79. Evidence for linkage 
to cognition was found on chromosomes 1p13.1, 12q24.33, 19q13.43, 20p13, 21q22.13 and 21q22.3. 
An overview of LOD scores per trait for these six regions is shown in Figure 1. The figure shows that 
the regions on chromosome 12, 19, 20 and 21 are significantly linked to at least 2 different cognitive 
tests. Table 4 gives the results of the fine-mapping analysis of the significant linkage regions in ERF, 
while Figure 2 shows the replication findings in the Rotterdam Study. 
The most consistent findings of linkage and association was found on chromosome 21, where linkage 
was found to VSA, global cognition (zglob), Stroop and verbal fluency. The two regions showed 
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  Heatplot depicting the highest LOD score per trait and region in the ERF Study
  WLTI: AVLT immediate recall; Learn: word learning test trial 2-5; WLTD: AVLT delayed recall; 
  Recogn: AVLT recognition; zmem: composite score for memory; Stroop: stroop-ratio; TMT: trail making test ratio; 
  WF: verbal fluency; zexec: composite score for executive function; VSA: Block Design Test; zglob: composite score for global cognition; 
  DART: Dutch Adult Reading Test. 
Figure 1
significant evidence for association when adjusting for multiple testing by permutation testing (see 
Table 4). In the first region (21q22.13), significant association was seen with global cognition (zglob) 
and executive function (zexec, fluency) to variants within the potassium-inwardly-rectifying-channel-
subfamily-J-member-6 gene (KCNJ6). This region was replicated in the outbred population (Rotterdam 
Study), where a variant (rs2836034) within KCNJ6 was significantly associated with memory 
(zmem) after Bonferonni correction (p=0.04; see Figure 2). In the second region on chromosome 
21 (21q22.3), immediate memory (p=0.04), delayed recall (p=0.01) and recognition (p=0.04) were 
significantly associated to variants within the protein-arginine-methyltransferase-2 gene (PRMT2) 
and the minichromosome-maintenance-complex-component-3-associated-protein gene (MCM3AP). 
The highest LOD scores in the region for these traits were 3.07, 2.59 and 2.10 respectively. This 
region was not replicated in the Rotterdam study.
The peak under the LOD score on chromosome 1p13.1 included an interesting candidate gene, the 
nerve-growth-factor-beta gene (NGF) and significant association was seen with multiple cognitive 
traits after correction for multiple testing in the ERF Study. Although the findings were consistent when 
replicating the association in the Rotterdam Study for two variants  (rs1555793 and rs10801929) in 
the sense that the lowest p-values were found for the same cognitive tests as in ERF (stroop nominal 
p=0.06 and zexec nominal p=0.03). However, these SNPs were not significant after Bonferroni 
correction. 
The chromosome 12q24.33 region, was found to be significantly linked to memory (delayed recall, 
recognition and zmem), executive function (TMT) and global cognition (zglob) and fine-mapping 
pointed to the fibrosin-like-1 gene (FBRSL1) for delayed recall (rs2323982) and to an intergenic 
region between the pseudogene LOC647503 and the zinc-finger-protein-605 gene (ZNF605) for 
Stroop (rs1278607). In the replication sample, the smallest p-value for rs2323982 was also found 
with delayed recall, but was not significant (nominal p-value of 0.06). 
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Results of the association analysis under the significant linkage peaks (highest LOD +/- 1 LOD) in the ERF Study 
Chromosome Best Variant Physical position MAF Trait Domain Nominal p-value P -value† Gene Flanking genes
1p13.1 rs6691374 115444341 0.188 Stroop‡ Executive 5.34E-03 0.033 intergenic TSPAN2, NGF
rs1146179 115560916 0.218 TMT Executive 5.65E-04 0.010 intergenic TSPAN2, NGF
rs699718 117047372 0.156 DART Global 1.94E-04 0.023 intergenic GAPDHL9, IGSF3
rs6657718 114517886 0.156 Fluency Executive 1.64E-03 0.023 intergenic SYT6, MRP63P1
rs10801929 117395987 0.329 Zexec Executive 3.08E-03 0.044 intergenic IGSF2, TTF2
rs2582783 120126518 0.338 WLTD 
Recogn 
Zmem
Memory 2.45E-03 
1.17E-03 
1.22E-03
0.043 
0.032 
0.027
intergenic REG4, HMGCS2
rs10494201 118053780 0.315 VSA Visuospatial 7.84E-04 0.009 intergenic FAM46C, LOC100131261
    
12q24.33 rs10781655 131554987 0.384 Zglob‡ Global 0.02 0.223 MUC8
0.384 Zmem‡ Memory 3.51E-03 0.061 MUC8
rs2323982 131652594 0.324 WLTD‡ Memory 9.60E-04 0.010 FBRSL1
rs11246991 131254068 0.138 TMT‡ Executive 0.01 0.329 GALNT9
rs1132375 131841610 0.430 Recognition‡ Memory 0.10 0.918 ANKLE2
rs1882297 131579207 0.282 WLTI Memory 6.29E-03 0.083 FBRSL1
rs1574157 131640365 0.037 Zexec Executive 0.02 0.245 FBRSL1
rs1278607 132000536 0.448 Stroop Executive 2.43E-03 0.038 intergenic LOC647503, ZNF605
          
19q13.43 rs260470 63496625 0.267 DART‡ Global 0.02 0.367 ZNF8
rs260423 63420161 0.098 TMT‡ Executive 0.01 0.261 ZNF274
rs3915790 63507665 0.198 Fluency‡ Executive 0.04 0.729 intergenic ZNF8, ZSCAN22
rs8100801 63583872 0.049 Recognition‡ Memory 0.03 0.701 ZNF837
rs3810126 63302066 0.272 Zmem Memory 7.97E-03 0.239 ZSCAN18
          
20p13 rs3746807 693963 0.126 VSA‡ Visuospatial 3.20E-03 0.185 C20orf54
rs1418258 11799 0.398 WLTI‡ Memory 1.81E-03 0.019 intergenic DEFB125
rs6085394 608793 0.245 DART Global 1.82E-03 0.070 intergenic SCRT2, C20orf54
          
21q22.13 rs1893654 37267597 0.489 VSA‡ Visuospatial 1.08E-03 0.920 HLCS
rs1892682 38169935 0.256 Zglob‡ 
Zexec
Global 
Executive
6.17E-03 
3.88E-04
0.011 
0.008
KCNJ6
rs2835872 37949142 0.284 Stroop‡ Executive 6.24E-03 0.268 KCNJ6
rs2835933 38045624 0.266 Fluency Executive 2.51E-04 0.025 KCNJ6
          
21q22.3 rs2298694 46474790 0.041 VSA‡ Visuospatial 0.02 0.432 LSS
rs2070429 46786139 0.350 Fluency‡ Executive 0.04 0.534 DIP2A
rs2839376 46897344 0.082 WLTI Memory 1.27E-03 0.041 PRMT2
rs2839182 46510580 0.131 WLTD Memory 4.80E-04 0.013 MCM3AP
rs2839193 46522771 0.212 Recogn Memory 8.91E-04 0.038 MCM3AP
rs2075906 46449972 0.129 Zexec Executive 4.48E-03 0.082 LSS
Results are shown for the traits presented in Table 3 and the significant traits within the region. Significant results are shown in bold. † p-value after 10.000 permutations.   
‡ cognitive tests that were found in the linkage analysis as shown in Table 3.  
WLTI: AVLT immediate recall; Learn: word learning test trial 2-5; WLTD: AVLT delayed recall; Recogn: AVLT recognition; zmem: composite score for memory; Stroop: stroop-ratio;  
TMT: trail making test ratio; WF: verbal fluency; zexec: composite score for executive function; VSA: Block Design Test; zglob: composite score for global cognition;  
DART: Dutch Adult Reading Test. 
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Table 4
At chromosome 19q13.43, we could not pinpoint a significant region with association. There was 
some evidence for association of memory to the zinc-finger-and-SCAN-domain-containing-18 gene 
(ZSCAN18), which was not significant after adjusting for multiple testing. In the Rotterdam Study we 
observed significant associations between executive function (stroop) and rs1051827 located in the 
zinc-finger-protein-606 gene (ZNF606), at 100 kb distance from ZSCAN18 (nominal p=0.001).
Finally, at chromosome 20p13 fine-mapping showed significant association with immediate memory 
to a variant at the terminal end of the chromosome near the defensin beta 125 gene (DEFB125) 
(p after adjustment for multiple testing=0.02). However, the Rotterdam study did not confirm this, 
although nominal significance was found with delayed recall and immediate memory and a variant at 
680 kb distance (nominal p=0.005 and 0.04). 
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  Regional plot for associations in the linkage regions in the Rotterdam Study 
Figure 2
  Chromosomal positions are depicted on the x-axis; the minus logarithms of nominal p-values are depicted on the y-axis. 
  The horizontal line represent the significance threshold (p<0.05). The red dots represent the p-values that were significant after Bonferonni correction. 
  Open symbols represent memory related cognitive tests; filled symbols represent executive function related cognitive tests.
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Discussion
Our linkage analysis of cognitive function in the ERF Study yielded a total of 6 genome-wide significant 
regions. Significant linkage of cognitive tests was found to chromosomes 1p13.1, 12q24.33, 19q13.43, 
20p13, 21q22.13 and 21q22.3. The strongest evidence for a genetic determinant of cognitive function 
in our study is found for chromosome 21q22.13. The two regions on chromosome 21 are implicated 
in the so-called Down’s syndrome critical region, which is an intensively studied region within the 
human genome and is recognized to be crucial for Alzheimer’s disease as the amyloid-precursor-
protein (APP) gene is in the region , however, APP is located 3 Mb from our linkage peak [42-
44]. After fine-mapping of these regions, the region at chromosome 21q22.13 was replicated in an 
independent population-based sample from an outbred population. Earlier, Luciano et al. found 
evidence for linkage of verbal IQ to the 21q22 region [19]. The variant within the highest LOD score 
on chromosome 21q22.13 lies in an intron of the tetratricopeptide-repeat-domain-3 (TTC3) gene. 
This gene is involved in protein metabolism and may play a role in neuronal development [45], but 
associations with cognition or related phenotypes have not been described so far. Other candidates 
in the linkage peak are the KCNJ6 and dual-specificity-tyrosine-phosphorylation-regulated-kinase-1A 
(DYRK1A) genes. Combining the linkage result with that of association (fine-mapping and replication), 
the most convincing evidence concerns the KCNJ6 gene for which 1 intronic variant was associated 
to executive function and global cognition in ERF and to memory in the Rotterdam study. The KCNJ6 
gene is expressed in the brain and may play a role in long term potentiation, which is thought to 
be one of the cellular mechanisms involved in learning and memory [46]. A recent genome-wide 
association study suggests that this gene is associated with bipolar schizoaffective disorder [47]. The 
DYRK1A gene was previously associated with the personality trait of conscientiousness in a genome-
wide association study [48]. Levels of DYRK1A mRNA were elevated in brains of AD patients [49] 
and the gene has been related to learning and memory deficits in Down syndrome mouse models 
[50,51]. 
The other regions which we found in ERF were not replicated in the Rotterdam Study, however, they 
could be of interest, because each contains promising candidate genes. One explanation why we 
could not replicate the findings in the population-based study, could be the different characteristics of 
a family-based study and population-based study. Family-based linkage studies are mainly designed 
to find rare variants associated with the disease, while association studies are more powerful in 
finding common variants [25]. 
Chromosome 21q22.3 contains the S-100-calcium-binding-protein-beta-chain gene (S100B), which 
was associated to cognitive ability previously [52,53]. The gene is located less than 0.4 Mb to the 
most significant variant in the fine-mapping analysis. The region on chromosome 1 was linked to 
Alzheimer’s disease in a large linkage meta-analysis [54] and there are multiple genes of interest in 
this region. The most significant variant in our linkage analysis lies in an intron of the immunoglobulin-
superfamily-member-2 gene (IGSF2), a gene that is involved in the inhibition of T-cell proliferation. 
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Although this is an interesting candidate, there may be other neighboring genes explaining our 
findings. The nerve-growth-factor-beta-peptide gene (NGF), is involved in the regulation of neuronal 
growth and differentiation and has been associated with AD and personality traits [55]. Our fine-
mapping analysis shows some significance of executive function to variants near IGSF2 and NGF. 
The chromosome 12 region which showed significant linkage in our analysis is adjacent to the region 
which was found to be suggestively linked to prospective memory in a previous study [23]. In the 
fine-mapping of this region, an intronic SNP within the fibrosin-like-1 (FBRSL1) gene was associated 
to delayed recall. This gene is expressed in the brain, but its function is largely unknown, asking 
for further research. We could not confirm the region on chromosome 19q13.43 with association. 
Chromosome 20p13, which we found linked to visual spatial ability and memory contains an obvious 
candidate gene, the prion-protein gene (PRNP), which is associated with multiple cognitive traits 
in the general population [56-58]. The highest LOD-score in the current study was found at 4.5 Mb 
distance from PRNP. 
We confirmed some interesting chromosomal regions previously found in related phenotypes and 
found possible new regions. Interestingly, most regions were related to multiple cognitive domains, 
which fits the ‘generalist gene’ hypothesis indicating that there are pleiotrophic pathways involved 
in cognitive function [5]. There are some issues that need to be discussed. First, 3 of the 6 linkage 
peaks were located at the terminal ends of the chromosomes, which may have lead to inflation of 
the estimates, because there are no neighbouring markers. However, there were multiple markers 
contributing to the peaks leading us to believe that the height of the peak was not due to a single 
marker estimate. Second, although we used a linkage panel, the markers were relatively dense 
compared to STR marker sets, which may have caused inflation of peaks due to LD between markers. 
This may partly explain our exceptionally high peaks. Therefore, our results should be interpreted in 
light of the simulation based thresholds for significant and suggestive findings as shown in this paper. 
It is of interest that the variants identified with our association analyses (fine-mapping and replication) 
were intronic variants of KCNJ6 that were significant after adjustment for multiple testing, which may 
imply that they are not directly involved in protein transcription. 
The strengths of the study are the cohort design of the discovery as well as the replication sample, 
and the fact that study subjects were not selected on the trait of interest. Moreover, the population is 
derived from a young genetic isolate, which increases the study power because of the smaller gene 
pool. Yet, the findings can be extended to the general population, because the genetic makeup does 
not differ largely from the general population [25]. 
In summary, our study demonstrates evidence for significant linkage of chromosomes 1p13.1, 
12q24.33, 19q13.43, 20p13, 21q22.13 and 21q22.3 to cognitive function. The region 21q22.13 was 
replicated in an independent sample and is most likely explained by the KCNL6 gene. 
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Introduction
Executive function is an important part of cognitive function. To explore common variants that 
contribute to the normal variation in cognition, we conducted genome-wide association analyses in 
the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium, which 
includes large prospective population-based cohorts.
Neuropsychological testing was available for 13 cohorts. For executive function and processing 
speed tasks, we included the Trail Making Test (TMT) parts A and B and the Stroop Color and Word 
Test in the analyses. All the individual studies used their genotyped data to impute to 2.5 million single 
nucleotide polymorphisms (SNPs). The analyses were performed in Caucasians older than 45 years 
who were free of dementia and clinical stroke at times of cognitive testing. Each study applied an 
additive genetic model using linear regression models adjusting for age and sex. Meta-analyses were 
performed for TMT-A, TMT-B, TMT-B minus TMT-A using fixed-effects models and on Stroop using 
sample-sized weighted models. 
The meta-analysis included 5,477 participants for the TMT-A, 6,212 for TMT-B and TMT-B minus 
TMT-A and 7,777 for the Stroop. The most significant association was found with TMT-B and a SNP 
on chromosome 18. This SNP was just above the genome-wide significant threshold with a p-value 
of 6.95*10-8. When comparing our findings of the GWAS on cognitive function to the GWAS of AD 
and schizophrenia published earlier, we identified two other genes of interest: STXBP6 and PCDH9. 
However, these SNPs did not reach genome wide significance in the present analysis nor in those of 
the disease outcomes.
In conclusion, we found compelling evidence for a region on chromosome 18 that is involved in 
TMT-B and preliminary evidence for STXBP6 and PCDH9. However, our findings await replication 
which is at present ongoing.
Cognitive function is a broad concept referring to multiple cognitive domains, among which are 
memory, language, executive function and visuospatial ability. Normal cognitive ability is an important 
determinant of quality of life. Impairment of these functions is seen in patients with various diseases 
including dementia, bipolar disorder, schizophrenia and attention deficit hyperactivity disorder (ADHD) 
[1-3]. Executive function is one of the major processes of the frontal lobe, and includes a range of 
tasks, among which are response inhibition, attention, cognitive flexibility and planning [4]. Genetic 
factors account for over 20% of the variability in executive function traits [5-9]. Finding susceptibility 
genes for cognitive functioning may provide insight into the normal variation in executive function, but 
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may also increase the knowledge of diseases that are associated with cognitive impairment. 
Although various genes have been identified, consistency is yet to be found, which is due to lack of 
replication and meta-analyses [10]. Of candidate genes, the apolipoprotein E (APOE) gene seems the 
most promising genetic risk factor for executive function and memory [11]. Linkage regions that were 
previously found for executive function tasks were located on chromosomes 2q, 5q, 11q, 13q and 
14q [12-14].  To our knowledge there are currently 4 genome-wide association studies on cognitive 
traits in adults [15-18]. In these studies associations were found of memory with the calsynthenin-2 
(CLSTN2) gene on chromosome 3, with the WW-and-C2-domain-containing-1 (KIBRA) gene on 
chromosome 5 and with the sodium-channel-voltage-gated-type I-alpha subunit (SCN1A) gene on 
chromosome 2. Abstract reasoning was associated with the sortilin-related-receptor (SORL1) gene 
located on chromosome 11. However, no genes were identified for executive function by GWAs. 
Furthermore, the studies of memory and abstract reasoning were small and liberal significance 
thresholds were used. 
To explore common variants that contribute to the normal variation in executive function, we performed 
a large-scale meta-analysis combining GWAS from the Cohorts for Heart and Aging Research in 
Genomic Epidemiology (CHARGE) consortium, including 12 prospective population-based cohorts. 
We present results from four meta-analyses.
The Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium includes 
large prospective population-based cohorts [19]. Each cohort has extensive phenotypic information 
on various traits and genome-wide data available. Guidelines for collaboration were approved and 
phenotype-specific workgroups agreed on phenotype harmonization, the selection of covariates and 
analytic plans for each study and for the overall meta-analyses. Each study obtained approval from 
Institutional Review Boards. All participants gave written consent for study participation and use of 
DNA for genetic research.
Details of cohort selection, risk factor assessment and cognitive testing in the 5 cohorts included in 
the current study have been described previously and included in the supplementary data. Briefly, 
the Aging Gene-Environment Susceptibility – Reykjavik Study (AGES) included 30,795 persons born 
between 1907 and 1937 who lived in Reykjavik at the 1967 baseline examination. Re-examination of 
surviving members of the cohort was initiated in 2002 as part of the AGES-Reykjavik Study (N=2300) 
[20]. The Atherosclerosis Risk in Communities Study (ARIC) included 15792 persons of 45 to 64 
years of age from 4 US communities between 1987 to1989. The study included blacks as well as 
whites (N=11478) [21]. The Austrian Stroke Prevention Study (ASPS) included 2007 persons living 
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Cognitive testing
Genotyping
The study program of each study included neuropsychological testing. We focused on the Trail 
Making Test parts A and B (TMT). The TMT is a time-demanding task in which participants are asked 
to connect a randomly placed series of letters and numbers as quickly as possible. In TMT-A only the 
numbers have to be connected, in TMT-B numbers and letters have to be connected alternately (from 
1 to A, to 2 to B etc). The score was defined as the time in seconds to complete the task. Participants 
who passed the maximum test time for TMT-B were given the maximum time score of 300 seconds. 
There were no participants who timed out on TMT-A. For analysis, we used time in seconds on 
TMT-A and TMT-B. Additionally, we used the time difference between TMT-B and -A (TMT-BminusA). 
The times were transformed by taking the natural logarithm. The Stroop Color and Word Test is also 
a time demanding task consisting of three cards. In card I, participants have to name the right words 
as quickly as possible, in card II they have to name the right colors as quickly as possible and in card 
III they have to name the colors in which the words are printed as quickly as possible. On this card the 
meaning of the word is different than the color the word is printed in (e.g. blue is written whereas the 
word is printed in red). ARIC recorded number of words; AGES, ASPS, ERF and RS recorded time in 
seconds. For analysis, we used the time difference between card III and II (Stroop interference).
The consortium was formed after the individual studies had finalized their GWAS platforms, and the 
studies included used different platforms: the Illumina HumanCNV370-Duo BeadChip® for AGES and 
CHS; the Affymetrix GeneChip SNP Array 6.0® for ARIC; the Illumina Human610-Quad BeadChip® 
for ASPS; the Affymetrix GeneChip Human Mapping 500K Array Set® and 50K Human Gene 
Focused Panel® for FHS; a combination of the Illumina HumanHap 320K array, Illumina HumanHap 
6k Beadchip array, the Illumina Human 370K-Duo SNP array and the Affymetrix GeneChip® Human 
in Graz, Austria. An extended diagnostic work-up was performed in a subset of age 45 to 85 years 
between 1991 and 1994 and between 1999 and 2003 [22,23]. The Cardiovascular Health Study 
(CHS) enrolled persons aged 65 years and older from 4 US communities. Baseline examination was 
either in 1989 to 1999 or 1992 to 1993 (N=5888, including 4925 whites) [24]. The Erasmus Rucphen 
Family study (ERF) enrolled 3000 persons from a genetically isolated population located in the South 
West of the Netherlands. Baseline examination was performed  between 2002 and 2005 [25]. The 
Framingham Heart Study (FHS) included 3 generation of participants from the US. Cognitive testing 
data was collected between 1999 and 2004 for survivors from the Original cohort (N=5209) that has 
been followed since 1948 and the offspring cohort since 1971 (N=5124) [26,27]. The Rotterdam 
Study is a population-based cohort study among inhabitants of a district of Rotterdam (Ommoord), 
The Netherlands. In 1990-1993, 7,983 persons participated and were re-examined every 3 to 4 years 
[28].
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Statistical analysis within studies
All studies included used their genotyped data to impute to 2.5 million non-monomorphic, autosomal 
single nucleotide polymorphisms (SNPs) using release 22 HapMap CEU population as a reference. 
As detailed previously [29], cohort-specific quality controls included filters for call rate, heterozygosity, 
and number of Mendelian errors per individual. SNP-specific quality controls included filters for call 
rate, minor allele frequency, Hardy-Weinberg equilibrium, and differential missingness by outcome or 
genotype (mishap test in PLINK, http://pngu.mgh.harvard.edu/purcell/plink/). The set of genotyped 
input SNPs used for imputation in each study was selected based on their highest quality GWA data. 
We used a call rate >95% in ARIC, >97% in CHS and FHS, and >98% in AGES-Reykjavik, ASPS, 
ERF and Rotterdam; a minor allele frequency >0.01 in each study; a Hardy-Weinberg p>1x10-5 
in ARIC and CHS and p>1x10-6 in AGES-Reykjavik, ASPS, ERF, FHS and Rotterdam; a test of 
differential missingness by the “mishap” test in PLINK p>1x10-9 in each study except ERF and ARIC. 
We used either the Markov Chain Haplotyping (MaCH) package (http://www.sph.umich.edu/csg/
abecasis/MACH, version 1.0.15 or 1.0.16 software) for AGES-Reykjavik, ARIC, ASPS, ERF, FHS 
and Rotterdam for imputation to the plus strand of NCBI build 36, HapMap release #22, or BIM-
BAM15 programs for CHS for imputation to the plus strand of NCBI build 35. For each imputed SNP 
informativity of imputation was estimated as the ratio of the empirically observed dosage variance to 
the expected binomial dosage variance. 
Participants were eligible for the discovery cohort if they did not have prevalent dementia, clinical 
stroke and were Caucasian. Participants were excluded when consent was declined or genotyping 
failed. Only participants aged 45 and older were included.
An additive genetic model was used in each study, fitting a 1-degree-of-freedom test relating 
genotype dosage (0, 1 or 2 copies of the minor allele) to cognitive tests. Linear regression models 
were used adjusting for sex and age and secondary adjusting for age, sex and education. ARIC and 
CHS additionally adjusted for study site; FHS and ERF the additionally adjusted for family structure. 
We did not adjust for additional covariates to avoid adjusting for variables that might be involved in 
the causal pathway. Education was divided into 4 categories corresponding to the years and level of 
education. Category 0 corresponded to less than high school (0-11 years); category 1 corresponded 
to a high school degree (12 years); category 2 corresponded to more than 12 years of education, but 
not a college degree and category 3 corresponded to college degree and above.
Mapping 250K Nsp Array for ERF; and the Illumina HumanHap550-Duo BeadChip® for the Rotterdam 
Study.
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Figure 1
  Quantile-quantile plots of TMT-A, TMT-B, TMT-BminusA and Stroop results
  Q-Q plot of the inverse variance meta-analyses, it shows the distribution of the observed test statistic (negative log of p-values, 
  on the y-axis) plotted against the distribution of test statistic expected under the null-hypothesis (on the x-axis).
We studied quantile-quantile (Q-Q) plots to ensure that the p-value distributions in each of the cohorts 
conformed to a null distribution at all but the extreme tail. We also calculated the genomic inflation 
factor lambda, which measures over-dispersion of test-statistics from association tests indicating 
population stratification and can be used to apply genomic control [33]. The lambda for TMT was less 
than 1.02 for all of the studies. 
Studies were screened for latent population substructure, including cryptic relatedness, using suitable 
programs: EIGENSTRAT in ARIC, FHS and AGES [30,31], an IBD matrix in ASPS and Rotterdam 
[32], and using principal component analysis in CHS. When appropriate, components related to 
the cognitive phenotype under study were included as covariates in the linear regression. In ERF, 
analyses were performed in GenABEL (R-library) [33], using the mmscore method, with a kinship 
matrix that was estimated from the genotype data to adjust for relatedness of the population [34].
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Baseline characteristics by study population  
Cohort TMT-A TMT-B TMT-BminusA Stroop interference
seconds seconds seconds seconds
AGES N - - - 2644
Age - - - 75.9 (5.33)
Gender (% female) - - - 58.9
Test score - - - 41.7 (21.5)
ARIC N 438 436 436 430
Age 72.6 (4.2) 72.6 (4.2) 72.6 (4.2) 72.5 (4.2)
Gender (% female) 59.8 59.6 59.6 60.0
Test score † 41.6 (17.6) 114.6 (49.6) 73.6 (43.1) -29.9 (9.5) †
ASPS N - 830 - 261
Age - 65.2 (8.0) - 65.1 (7.5)
Gender (% female) - 56.9 - 57.1
Test score - 128.0 (60.2) - 47.2 (22.7)
CHS N 1249 1249 1249 -
Age 79.4 (3.8) 79.4 (3.8) 79.4 (3.8) -
Gender (% female) 61.0% 61.0% 61.0% -
Test score 52.3 (22.0) 141.5 (62.5) 89.2 (53.3) -
ERF N 1267 1255 1255 1238
Age 58.7 (8.9) 58.7 (8.8) 58.7 (8.8) 58.6 (8.8)
Gender (% female) 54.8 54.7 54.7 55.5
Test score 45.9 (20.8) 139.5 (78.0) 94.0 (67.2) 54.2 (33.0)
FHS N 2475 2440 2440 -
Age 64.7 (11.9) 64.6 (10.9) 64.6 (10.9) -
Gender (% female) 54.8 54.7 54.7 -
Test score 35.7 (20.2) 92.0 (55.6) 60.0 (46.2) -
RS N - - - 3204
Age - - - 64.4 (6.7)
Gender (% female) - - - 57.9
Test score - - - 32.1 (18.9)
†: score in number of words 
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Table 1
After quality control and filtering within each study, AGES had either genotyped or imputed data for 
2,532,729, ARIC for 2,543,887 SNPS, ASPS for 2,543,887 SNPs, CHS for 2,531,169 SNPs, FHS 
for 2,540,223 SNPs, the Rotterdam study for 2,543,887 SNPs and ERF for 2,543,887 SNPs. We 
restricted our meta-analysis to autosomal SNPs that were common to all studies and had a minor 
allele frequency >0.01 and an imputation quality >0.3. 
We used an inverse-variance meta-analysis as our primary method after applying genomic control 
within each individual study. Beta estimates were weighted by their inverse variance and a combined 
estimate was obtained by summing the weighted betas and dividing by the summed weights. Hence 
results for SNPs imputed with low certainty were down-weighted because the low informativity of 
imputation ensures a large variance. In contrast, studies with large sample sizes and with directly 
genotyped or well-imputed SNPs had a greater effect on the meta-analyses p-value because of 
small variances. In a secondary analysis we used an effective sample size weighted meta-analysis 
technique after applying genomic control within each individual study. For each SNP the z-statistic 
was weighted by the effective sample size (product of the sample size and the ratio of the empirically 
observed dosage variance to the expected binomial dosage variance for imputed SNPs). A combined 
estimate was obtained by summing the weighted z-statistics and dividing by the summed weights. 
Hence results for SNPs imputed with low certainty were down-weighted. In contrast, studies with 
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  Genome-wide plots of TMT-A, TMT-B, TMT-BminusA and Stroop results
Figure 2
  Minus log p-values (x-axis) are plotted  against their genomic position (y-axis). The plot is based the fixed-effects meta-analysis.
large sample sizes and with directly genotyped or well-imputed SNPs had a greater effect on the 
meta-analyses p-value. We undertook the meta-analysis using the METAL software by Abecasis and 
Willer in 2007.
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We estimated the genomic inflation factor lambda after meta-analysis. The estimate of lambda was 
1.010 for TMT-A, 1.022 for TMT-B and 1.024 for TMT-BminusA indicating no significant inflation of 
p-values. The quantile-quantile (Q-Q) plots of our inverse variance meta-analyses results for the 
3 tests show the distribution of the observed test statistic (negative log of p-values, on the y-axis) 
plotted against the distribution of test statistic expected under the null-hypothesis (on the x-axis) 
(Supplementary Figures 1). 
A p-value ≤ 5.0*10-8 was considered genome-wide significant [36] and a p-values between 5.0*10-8 
and 1.0*10-5 were considered highly suggestive associations. P-values <1.0*10-3 were considered 
suggestive associations.
We additionally studied overlap between our suggestive associations and previously reported 
genome-wide data from studies in cognitive function and in diseases for which cognition may be 
an endophenotype. We used three published meta-analyses with publicly available data on various 
cognitive tests [18], Alzheimer’s disease (AD) [37] and schizophrenia (SCZ) [38].
Baseline characteristics of the study populations are depicted in Table 1. The mean age of the study 
population was 68.3 years and 57.6% were women. The mean test score on TMT-A was 43.9 seconds 
among the 5,477 participants that were included in the meta-analysis. The mean test score of the 
6,212 participants included in the TMT-B analysis was 123.1 seconds and the mean time difference 
on TMT-BminusA was 79.2 seconds among 5,377 participants. For Stroop interference, the mean 
test score for the cohorts using time in seconds was 43.8 seconds, the mean test score for ARIC was 
-29.9 words.
Figure 2 shows the genome-wide plots for each trait, depicting the p-values by their genomic position. 
Highly suggestive loci with a p-value smaller than 10-5 are presented in Supplementary Tables 1 to 
4. The most significant finding was seen for TMT-B for a SNP on chromosome 18. This SNP was just 
above the genome-wide significant threshold with a p-value of 6.95*10-8. A detailed plot for all SNPs 
within a region of 250kb is shown in Figure 3, which shows that there are multiple SNPs in the region 
in linkage disequilibrium with this SNP. All cohorts show similar effect sizes and direction of effect for 
this SNP (Figure 4). The p-value for this SNP is 0.09 for TMT-A and of 3.35*10-5 for TMT-BminusA. 
The SNP is intergenic, and located in between two interesting genes.
The lowest p-value for TMT-A was 3.35*10-7 for a SNP on chromosome 13. The second ranked SNP 
with a p-value of 7.69*10-7 was located in a region that was also associated with TMT-B (p-value 
7.30*10-6). For TMT-BminusA, the lowest p-value was 1.11*10-6 for a SNP on chromosome 10. 
Finally, on chromosomes 18 the same SNP was associated with TMT-B and TMT-BminusA (p-value 
1.39*10-6 and 8.19*10-6, respectively). Stroop interference was associated to two regions on 
chromosome 3. The first ranked SNP was associated with a p-value of 2.38*10-7, which is rare 
variant (MAF=0.03). 
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Figure 3
  Forest plot of the results per cohort for the top hit – TMT-B
  The values on the x-axis represent the betas.
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Overlap of the GWAS findings for TMT-A, TMT-B, TMT-BminusA and Stroop interference with GWAS of related outcomes  
SNP Chrom Effect SE MAF Our 
p-value 
Direction Gene Flanking genes AD 
 
SCZ  
 
TMT-A           
SNPa 8 -0.0298 0.0088 0.1980 7.68E-04 ---- C8orf79   1.76E-04 
SNPb 15 0.0268 0.008 0.2521 8.68E-04 ++++  BNC1, SH3GL3 1.79E-04  
SNPc 19 -0.0293 0.0085 0.2658 5.97E-04 ---+ ZNF610  5.28E-04  
TMT-B           
SNPd 1 -0.0448 0.0136 0.36 9.55E-04 ---+- DAB1   8.20E-04 
SNPe 4 -0.0358 0.0106 0.16 7.15E-04 -+--- intergenic BOD1L, AC095052.1  8.67E-04 
SNPf * 6 0.0427 0.0113 0.17 1.56E-04 +++++ intergenic HLA-region 9.32E-04  
SNPg * 14 0.029 0.0083 0.46 4.83E-04 +++++ intergenic STXBP6, NOVA1 9.43E-04  
TMT- 
BminusA 
          
SNPh 3 -0.0519 0.0139 0.38 1.90E-04 ---- CACNA2D3   2.35E-04 
SNPi 10 -0.0497 0.0148 0.23 8.12E-04 -+-- LIPA   3.71E-04 
SNPj 14 -0.0462 0.0133 0.47 5.39E-04 ---- intergenic STXBP6, NOVA1 9.51E-05 
8.22E-04 
(apoe neg) 
 
SNPk * 18 -0.0523 0.0133 0.29 8.70E-05 ---- intergenic C18orf22, ADNP2 5.86E-04 
(apoe neg) 
 
SNPl * 18 0.0412 0.0124 0.42 9.18E-04 ++++ DCC   6.44E-05 
Stroop †  Weight  Z-score        
SNPm 6 7435.37 3.464 0.3311 5.33E-04 +++++ JARID2   0.03 
SNPn 8 7521.56 -3.305 0.2080 9.50E-04 ----- C8orf79   1.76E-04 
SNPo 11 7573.78 3.401 0.0252 6.71E-04 +++++ SORL1  9.70E-03  
SNPp 13 7732.09 -3.916 0.3469 9.02E-05 -+--- PCDH9  5.74E-04 
(apoe neg) 
 
SNPq 15 7720.07 -3.352 0.1405 8.01E-04 ----- intergenic CA12, USP3 6.80E-04 
(apoe neg) 
 
SNPr 15 6967.1 3.512 0.2833 4.44E-04 ++-++ intergenic KLHL25, AGBL1  3.43E-04 
P-values are on the fixed effects meta-analysis adjusted for age and sex. † P-values are based on the sample-size weighted meta-analysis of adjusted for age and sex. 
Highlighted SNPs overlapped between our traits. * More than one SNP showed overlap. 
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Table 2
Discussion
Next, we performed a data mining study comparing our findings to the GWAS findings of the largest 
studies on AD and schizophrenia [35,36]. At the suggestive threshold of 10-3, 2731 SNPs were 
associated with TMT-A, 2790 SNPs with TMT-B, 2761 with TMT-BminusA and 2980 SNPs with 
Stroop. When comparing our suggestive associations (p<10-3) with the disease based genome-wide 
studies (Table 2), we did not see an overlap for the top SNPs identified for TMT-A, TMT-B, TMT-
BminusA or Stroop. However, one putative AD gene, the sortilin-related-receptor 1 gene (SORL1) 
did show some overlap with Stroop. There are two additional interesting findings. First, we found one 
region with overlapping SNPs for both TMT-B and TMT-BminusA. This region on chromosome 14 
overlapped with the findings in Alzheimer’s disease [35] and contains the neuro-oncological ventral 
antigen 1 (NOVA1) and the syntaxin binding protein 6 (STXBP6) genes. Second, the region identified 
in the top ranking of the Stroop data, which concerned SNP within the protocadherin 9 gene (PCDH9) 
(p=8.49*10-6; supplementary table 4), was identified also in the AD GWAS, although a different SNP 
was reported. 
The current study is a large meta-analysis of genome-wide associations studies performed in 7 
cohorts including over 6000 subjects. Although not fulfilling the criteria for genome-wide significance, 
by far the most interesting region is the chromosome 18 region that shows association to TMT-B. We 
found one SNP approaching genome wide significance in the analysis of TMT-B. The SNP is located 
between two interesting genes. Unfortunately, none of the other tests showed p-values that were 
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close to significance. At this stage, our study is awaiting replication for the top ranked SNPs. When 
considering the highest ranked SNPs based on p-values, however, we find little overlap between the 
SNPs associated with the various cognitive tests. The lack of overlap for genes involved in TMT-A, 
in TMT-B and Stroop may be explained by the fact that TMT-A is an outcome related to processing 
speed while TMT-B and Stroop are outcomes related to executive function. There may be several 
explanations for the lack of overlap between the findings for TMT-B and Stroop. We may have lacked 
statistical power to identify true positive SNPs and the top SNPs may primarily represent noise. 
Alternatively, the overlap in brain function as measured by TMT-B and Stroop may be limited. While 
all the measures were timed and likely share a common processing speed factor, the executive 
factors underlying TMT-B and Stroop likely reflect diverse higher order factors. If this is the case, one 
may expect different genes to be involved in different tests. 
Despite the low power, we still see an overlap of our GWAS with previous GWAS on AD and 
schizophrenia, for which cognitive functioning is an endophenotype. It is of interest that not the 
apolipoprotein E gene (APOE) but rather SORL1 pops up in both cognitive function and AD analyses. 
SORL1 as been identified as a gene that may be involved in AD [39,40]. When comparing our findings 
to those of the 4 earlier genome-wide association studies on cognitive traits in adults [15-18], we only 
see an overlap with the relation of SORL1 to abstract reasoning. The gene of most interest in the 
comparative analysis of our findings to those in AD and Schizophrenia is STXBP6 [37]. This gene 
forms non-fusogenic complexes with the synaptosomal-associated-protein-25kDa (SNAP25) and 
syntaxin-1A (STX1A) genes and may thereby modulate the formation of functional SNARE complexes 
and may be involved in exocytosis [41]. SNAP25 has been associated both to schizophrenia and 
Attention Deficit Hyperactivity Disorder (ADHD) [42,43]. Further, a region was identified in the top 
of the GWAs of Stroop data (PCDH9), which overlapped with the AD GWAS. PCDH9 belongs to 
the protocadherin gene family, a subfamily of the cadherin superfamily [44]. The gene encodes a 
cadherin-related neuronal receptor that localizes to synaptic junctions and is putatively involved in 
specific neuronal connections and signal transduction. Protocadherin 9 cadherin-related neuronal 
receptor, predominantly expressed in brain, localizes to synaptic junctions and is involved in specific 
neuronal connections and signal transduction. The gene is also expressed in other tissues in which 
it exerts a developmentally regulated expression pattern.
In conclusion, we found compelling evidence for a region on chromosome 18 that is involved in 
TMT-B. When comparing our findings of the GWAS on cognitive function to the GWAS of AD and 
schizophrenia we identified to other genes of interest: STXBP6 and PCDH9. For these two genes the 
evidence for association is very preliminary as these SNPs did not reach genome wide significance 
in the present analysis nor in those of the disease outcomes. Our findings await replication studies 
that are presently ongoing.
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TMT-A: Listing of all SNPs with a p-value < 10
-5
 
SNP Chrom Effect SE MAF P-value Direction Gene Flanking genes Number of 
SNPs <10
-5
Adusted for age+sex     
SNP1 13 0.0483 0.0094 0.1676 3.01E-07 ++++ MYO16 2
SNP2 4 -0.0379 0.0077 0.71 7.69E-07 ---- ADH5 1
SNP3 12 0.0463 0.0097 0.8324 1.70E-06 +-++ OR6C70 5
SNP4 7 -0.0341 0.0073 0.3707 3.03E-06 ---- AC006397.1
SNP5 14 -0.0537 0.0117 0.818 4.10E-06 ---- intergenic SNX6, 
RPL23AP8, 
CFL2
1
SNP6 8 0.0338 0.0073 0.4737 4.12E-06 ++++ intergenic LOC392180, 
RPL23AP54
3
SNP7 1 0.033 0.0073 0.5565 6.12E-06 ++++ KCND3 0
SNP8 3 0.039 0.0086 0.2207 6.13E-06 ++++ TGM4 0
SNP9 1 -0.0346 0.0078 0.5545 8.60E-06 ---- intergenic KIAA1026, 
PRDM2
          
P-values are based on the fixed effects meta-analysis of CHS, FHS, ERF, and ARIC.  
]Number of SNPs refers to additional SNPs within 250kb of the top SNP. 
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 TMT-B: Listing of all SNPs with a p-value < 10
-5
 
SNP Chrom Effect SE MAF P-value Direction Gene Flanking genes Number 
of SNPs 
<10
-5
Adusted for age+sex     
SNP1 18 0.0725 0.0134 0.1137 6.95E-08 +++++ intergenic PIK3C3, RIT2 6
SNP2 21 0.0378 0.0078 0.4460 1.23E-06 +++++ intergenic CLIC6, RUNX1 0
SNP3 18 -0.0573 0.0119 0.1127 1.39E-06 ----- ADNP2 8
SNP4 4 0.0459 0.0097 0.2094 2.25E-06 +++++ SEPT11 5
SNP5 7 0.0385 0.0081 0.3615 1.99E-06 +++++ intergenic BET1, Col1A2 1
SNP6 4 0.0869 0.0194 0.0459 7.30E-06 +++++ ADH4 0
SNP7 6 0.0572 0.0122 0.2159 2.76E-06 +++++ intergenic LOC728275, LOC728316 0
SNP8 16 0.0615 0.0134 0.0899 4.41E-06 +++++ intergenic A2BP1, LOC283953 2
SNP9 16 0.0589 0.013 0.1163 5.52E-06 +++++ intergenic CDH8 1
SNP10 15 0.035 0.0078 0.3980 7.13E-06 +++++ intergenic SQRDL, SLC24A5 8
SNP11 19 -0.0363 0.0082 0.3403 9.18E-06 ----- intergenic AC022145.1, ZNF730 1
 P-values are based on the fixed effects meta-analysis of ASPS, ARIC, ERF, CHS, and FHS.  
 Number of SNPs refers to additional SNPs within 250kb of the top SNP.  
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 TMT-BminusA: Listing of all SNPs with a p-value < 10
-5
 
SNP Chrom Effect SE MAF P-value Direction Gene Flanking genes Number 
of SNPs 
<10
-5
Adusted for age+sex     
SNP1 10 0.1587 0.0326 0.0532 1.11E-06 ++++ intergenic GPR158, MYO3A 2
SNP2 6 -0.0761 0.0157 0.1946 1.33E-06 ---- PRIM2 BAG2 24
SNP3 8 -0.1512 0.0326 0.0437 3.52E-06 ---- NRG1 0
SNP4 12 -0.1224 0.027 0.0758 5.82E-06 ---- intergenic E2F7, NAV3 0
SNP5 18 -0.0872 0.0196 0.1115 8.19E-06 ---- ADNP2 0
SNP6 4 0.0709 0.0156 0.1891 5.19E-06 ++++ HERC3 0
SNP7 5 0.0596 0.0131 0.3743 5.67E-06 ++++ MAST4 0
SNP8 5 -0.0974 0.0215 0.1039 6.12E-06 ---- intergenic LOC100289569, EFNA5 1
SNP9 1 0.0874 0.0197 0.1630 8.71E-06 ++++ NUAK2
          
 P-values are based on the fixed effects meta-analysis of ARIC, ERF, CHS and FHS adjusted for age and sex.  
 Number of SNPs refers to additional SNPs within 250kb of the top SNP. 
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 Stroop interference: Listing of all SNPs with a p-value < 10
-5
 
SNP Chrom Weight Z-score MAF P-value Direction Gene Nearby* Number of 
SNPs <10
-5
SNP1 3 7184.95 5.106 0.0307 2.38E-07 ++-+++ ATP13A5 0
SNP2 15 7417.36 -4.698 0.4470 2.63E-06 ----- TMOD2 2
SNP3 6 5869.31 4.661 0.094 3.15E-06 +++++ intergenic POPDC3, PREP 1
SNP4 5 7440.17 4.614 0.1168 3.96E-06 +-+++ GPX3 0
SNP5 6 7333.42 -4.613 0.2180 3.96E-06 ----- intergenic LOC100129554, 
RPS3AP24
9
SNP6 6 6560.34 4.526 0.4701 6.03E-06 +++++ intergenic NUFIP1P, RNU7-
66P
0
SNP7 3 7745.52 4.497 0.2397 6.91E-06 ++++++ CPNE4 13
SNP8 9 7416.22 -4.476 0.040 7.59E-06 ----- intergenic LOC392285 
(RPL4P5), 
C9orf123
1
SNP9 13 7729.08 -4.452 0.3639 8.49E-06 ----- PCDH9 11
 P-values are based on the sample-size weighted meta-analysis of AGES, ARIC, ASPS, ERF, RS (N=7,777) adjusted for age and sex.  
 *: nearest gene to snp; number of SNPs refers to additional SNPs within 250kb of the top SNP. SNPs highlighted overlap between the two models. 
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Introduction
Abstract
Cathepsin D (CTSD) is a gene involved in amyloid precursor protein processing and is considered 
a candidate for Alzheimer’s disease (AD). The aim of the current study was to examine if variation 
in CTSD increases the risk of AD. We performed a candidate-gene analysis in a population-based 
cohort-study (N=7983), and estimated the effect of CTSD on the risk of AD. Additionally, a large 
meta-analysis was performed incorporating our data and previously published data. The T-allele of 
CTSD rs17571 was associated with an increased risk of AD (p-value 0.007) in the Rotterdam Study. 
This association was predominantly found in APOE ε4 noncarriers. A meta-analysis of previously 
published data showed a significantly increased risk of AD in carriers of the T-allele of rs17571 (OR 
1.22, 95% CI 1.03-1.44), irrespective of APOE ε4 carrier status. This study adds to the evidence that 
CTSD increases the risk of AD, although the effect size is moderate.
Neurodegenerative diseases like Alzheimer’s disease (AD) are highly prevalent diseases in the 
elderly and a major burden on society [1,2]. Neuropathologically, AD is characterized by neuritic 
plaques (amyloid) and neurofibrillary tangles (hyperphosphorylated tau protein) [3,4]. Progress has 
been made in understanding the etiology of AD, but the exact pathogenesis has yet to be determined. 
Alzheimer’s disease is most likely caused by various interacting environmental and genetic risk 
factors [5]. The best known and most consistently reported genetic risk factor is apolipoprotein E 
(APOE), which is involved in about 50% of late-onset AD cases [6,7]. Other established genes in AD, 
such as the beta amyloid precursor protein gene (APP), and the presenilin 1 and 2 genes (PSEN1 
and PSEN2) [8,9], are mainly implicated in early-onset AD [10]. Although various other genes have 
been reported in AD, most of them lack sufficient replication. There is particular interest in genes 
coding for proteins involved in the cleavage of amyloid precursor protein or clearance of beta-amyloid 
[11-13]. One such protein is cathepsin D, a lysosomal enzyme found in neuritic plaques [14,15]. 
This protein has secretase activity, and presumably, a role in the processing of tau protein, APP, 
amyloid beta and apolipoprotein E [16-19]. A polymorphism in exon two of the gene results in a 
C- to T-transition, resulting in an alanine to valine substitution in the protein. This polymorphism 
is associated with AD, although reports are inconsistent and a meta-analysis failed to show 
an association [20]. An explanation for this inconsistency might be that most previous studies 
used prevalent cases of AD, usually in a clinic-based setting, which might result in biases due to 
selective case-ascertainment, low-response rates and, possibly, case-fatalities.
The aim of the current study was to examine if polymorphisms in CTSD increase the risk of 
incident AD in a population-based setting. Additionally, we studied a set of dense SNPs covering 
a 150kb region flanking CTSD to evaluate the presence of other genetic variants that might be 
associated with AD. Finally, we performed a meta-analysis pooling our results with previously 
published data.
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Materials and Methods
Study population
Genotyping
Ascertainment of incident AD
The current study was performed in the Rotterdam Study, which is an ongoing population-based 
study of 7983 elderly Caucasians (55 years and older). The study aims to find determinants of 
chronic disease in the elderly [21]. At baseline (1990-1993) and three follow-up rounds (1993-
1994, 1997-1999, 2002-2004) participants were invited for extensive examinations. The study 
was approved by the Medical Ethics Committee at ErasmusMC, and all participants gave written 
informed consent. Only people who were not demented at baseline were included in the current 
study (N=6886). 
Genomic DNA was extracted from whole blood samples according to standard methods [22]. 
The samples were genotyped for polymorphisms in APOE and CTSD with Taqman allelic 
discrimination Assays-By-Design (Applied Biosystems, Foster City, CA). All measurements were 
performed in accordance with the manufacturer’s protocols and primer and probe sequences for 
the SNPs are available from the manufacturer. Details on APOE have been published previously 
[23], and for CTSD, 3 SNPs were typed (rs2292963, rs2292962, rs17571). These SNPs as 
tagging SNPs covering the gene were selected based on the blocks that were seen in the CEU 
population available from the HapMap database (release 2005). We selected the functional 
variant and 2 SNPs with a minor allele frequency ≥ 0.05 (http://www.hapmap.org) [24] [25]. All 
genotypes were in Hardy-Weinberg equilibrium. 
To test whether additional SNPs in the region were associated with AD, we also used data from 
a genome-wide screen. This screen was part of a large project on the genetics of complex 
diseases: samples were typed on version 3 of the Illumina-Infinium-II HumanHap550SNP array 
[26]. We utilized SNPs in a 150kb region centered on the CTSD gene. 
The mismatch between the two platforms was previously tested for 24 other SNPs and 
corresponded to 0.3% (range 0.2-0.6%). The cross platform agreement for rs17571 in the current 
study was 99.7%. Only samples of good quality DNA were genotyped, and after genotypic quality 
control 6112 individuals (493 with incident AD) were available for analysis. 
Incident AD was diagnosed with a three-step protocol [27]. During the visits to the research centre, 
all individuals were screened with two cognitive tests (Mini Mental State Examination (MMSE) 
and Geriatric Mental State schedule (GMS)). Further testing with the Cambridge examination for 
mental disorders of the elderly (Camdex) was performed in individuals with scores on the MMSE 
< 26 or on the GMS > 0. When dementia was suspected and additional testing was required for 
the diagnosis, individuals were examined by a neuropsychologist. Additionally, imaging data was 
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Baseline characteristics of the study population (N=6112) 
Controls Cases p-value 
    
N 5619 493  
Sex (% women) 3242 (58%) 366 (74%) <0.01 
Age 68.2 76.3 <0.01 
Mean follow-up 9.6 6.4 <0.01 
APOE 4 carriers (%) 1423 (26%) 203 (43%) <0.01 
    
 
 
Association of CTSD with AD 
SNP Physical  position Controls Cases p-value OR (95% CI) 
              
rs2292963 1732908 CC  TC TT C-allele  T-allele  CC  TC TT C-allele  T-allele    
  3343 1903 269 0.78 0.22 293 161 36 0.76 0.24 0.24 1.10 (0.94-1.28) 
            †0.35 1.08 (0.92-1.27) 
rs2292962 1734897 GG AG AA G-allele  A-allele  GG AG AA G-allele  A-allele    
  3998 1292 89 0.86 0.14 371 101 8 0.88 0.12 0.20 0.88 (0.72-1.07) 
            †0.16 0.86 (0.69-1.06) 
rs17571 1739170 CC  TC TT C-allele  T-allele  CC  TC TT C-allele  T-allele    
  4628 735 32 0.93 0.07 386 81 6 0.90 0.10 0.007 1.36 (1.09-1.71) 
            †0.008 1.38 (1.09-1.75) 
              
†: adjusted for age and sex 
 
Statistical analyses
Table 1
Results
General descriptive statistics were performed with T-tests for normally distributed variables and 
Chi-square statistics for categorical or dichotomous variables (version 15.0 of SPSS). To test 
the associations between the polymorphisms and AD, we used Chi-square statistics and logistic 
regression models adjusted for age and sex. Additionally, we used Cox regression models to 
incorporate time-to-event. To further explore the association, we repeated the analyses stratified 
by APOE ε4 carrier status. A p-value <0.05, adjusted for multiple testing, was considered 
significant.
A meta-analysis was done for CTSD rs17571 using rmeta (R package). To find previously 
published studies, we searched PubMed using the key-words: CTSD, Alzheimer’s disease, gene 
and association. Additionally, we checked the reference lists of these papers and searched the 
AlzGene database (http://www.alzgene.org) [28]. Meta-analysis was conducted on data from 
previously published studies (from 1999 to January 1st 2009) both overall and stratified by APOE 
ε4 carrier status. For the meta-analyses, random effects models were applied.
There were 493 incident AD cases in this population of 6112 individuals with a mean age of onset 
of 82.8 (±6.9) years. The baseline characteristics of the study population are shown in Table 1. 
Cases were older and were mor  often women and carriers of the APOE ε4 allele than control 
subjects.
Table 2 shows the genotype frequencies for the three tested SNPs. Carriers of the T-allele of 
rs17571 had a higher risk of AD (OR 1.36, 95% CI 1.09-1.71). This effect was equally strong in 
the Cox analysis (HR 1.34, 95% CI 1.08-1.64). The two other SNPs were not associated with a 
used when available. A team consisting of a neurologist, a neuropsychologist and a research 
physician finally ascertained the diagnosis of AD according to internationally accepted criteria. 
In addition to the visits to the research center, the population was continuously monitored for 
incident AD through the medical records of general practitioners and the Regional Institute 
for Outpatient Mental Health Care. There were no cases with a family-history suggestive of 
autosomal dominant AD. Follow-up was complete through January 1 2005, during which 493 
persons developed AD.
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Baseline characteristics of the study population (N=6112) 
Controls Cases p-value 
    
N 5619 493  
Sex (% women) 3242 (58%) 366 (74%) <0.01 
Age 68.2 76.3 <0.01 
Mean follow-up 9.6 6.4 <0.01 
APOE 4 carriers (%) 1423 (26%) 203 (43%) <0.01 
    
 
 
Association of CTSD with AD 
SNP Physical  position Controls Cases p-value OR (95% CI) 
              
rs2292963 1732908 CC  TC TT C-allele  T-allele  CC  TC TT C-allele  T-allele    
  3343 1903 269 0.78 0.22 293 161 36 0.76 0.24 0.24 1.10 (0.94-1.28) 
            †0.35 1.08 (0.92-1.27) 
rs2292962 1734897 GG AG AA G-allele  A-allele  GG AG AA G-allele  A-allele    
  3998 1292 89 0.86 0.14 371 101 8 0.88 0.12 0.20 0.88 (0.72-1.07) 
            †0.16 0.86 (0.69-1.06) 
rs17571 1739170 CC  TC TT C-allele  T-allele  CC  TC TT C-allele  T-allele    
  4628 735 32 0.93 0.07 386 81 6 0.90 0.10 0.007 1.36 (1.09-1.71) 
            †0.008 1.38 (1.09-1.75) 
              
†: adjusted for age and sex 
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Association of CTSD with AD, stratified by APOE 4 carrier status 
 APOE 4 carriers APOE 4 noncarriers 
 Controls Cases p OR (95% CI) Controls Cases p 
 
OR (95% CI) 
                 
rs2292963 CC TC TT CC TC TT   CC TC TT CC TC TT   
 847 490 54 122 69 11 0.64 1.06 (0.83-1.36) 2394 1330 206 160 82 24 0.22 1.14 (0.93-1.39) 
       0.91† 1.02 (0.78-1.32)       0.24† 1.131 (0.92-1.40) 
rs2292962 GG AG AA GG AG AA   GG AG AA GG AG AA   
 991 347 19 147 45 5 0.90 0.98 (0.72-1.33) 2862 900 68 207 51 3 0.09 0.78 (0.59-1.04) 
       0.84†  0.97 (0.70-1.34)       0.06† 0.75 (0.55-1.01) 
rs17571 CC  TC TT CC  TC TT   CC TC TT CC TC TT   
 1152 195 5 161 30 3 0.24 1.25 (0.86-1.81) 3314 509 27 207 48 3 0.009 1.48 (1.11-1.99) 
       0.29† 1.24 (0.84-1.83)       0.008† 1.52 (1.12-2.07) 
                 
†: adjusted for age and sex 
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Table 2
Table 3
higher risk of AD. Next, the population was stratified by APOE ε4 carrier status (Table 3). The 
association of rs17517 with AD was predominantly found in APOE ε4 noncarriers (adjusted HR 
1.42, 95% CI 1.09-1.87). No association was found in APOE ε4 carriers.
Additionally, we studied a set of dense SNPs in a 150kb region flanking CTSD to test whether 
other genetic variants explained the association of rs17571 with AD. The results are shown in 
Figure 1. Rs17571 and rs2292963 were the only SNPs within the gene, and rs2292962 was not 
present on the array. The 85 other SNPs in the flanking region were neither in strong LD with 
these two SNPs nor significantly associated with AD. When ranking the p-values of the whole 
genome-wide association study, rs17571 was ranked at the 5115th position, which is within the 
top 10% of the results.
Finally, we performed a large meta-analysis pooling our data with previously published data. 
For this analysis, 26 studies reporting on the association of CTSD with AD in Caucasians were 
identified [13,29-51]. Eight of these [13,31-37] were not analyzed, because they overlapped with 
other published studies or sufficient data was not provided in the published paper. The latter 
concerned three publications, of which one found an association between the T-allele of rs17571 
and AD, one did not find an association and one did not report this outcome. Additionally, one 
study was dropped because the control genotypes were out of Hardy-Weinberg Equilibrium 
(HWE) [44]. An overview of eligible studies is given in Supplementary Table 1. The other 17 
studies included a total of 3798 AD cases and 3865 controls. Thirteen included AD patients 
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Figure 1
  SNPs flanking CTSD in association with AD
diagnosed according to the National Institute of Neurological and Communicative Disorders 
and Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria, 
one study used the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria to 
identify cases, and one study analyzed autopsy confirmed cases only. Most studies included 
sporadic late-onset cases, however, there were studies with combinations of early-onset, late-
onset, sporadic and familial cases. There was one study, which included only non-familiar early-
onset cases [32]. Controls did not have a diagnosis of Alzheimer’s disease, and were selected 
either from a population-based or clinical sample. The T-allele frequency ranged from 0.05 to 
0.11 in controls and from 0.05 to 0.14 in cases. The summary odds ratio of the meta-analysis 
was 1.22 (95% CI 1.03-1.44). There was significant between-study heterogeneity (p=0.002). 
When the original study was excluded, the pooled odds ratio dropped to 1.17 (95% CI 0.99-
1.37), which was borderline significant (p=0.06). When excluding both Emahazion et al. and the 
original report, the between-study heterogeneity disappeared (p=0.09) and the summary odds 
ratio became 1.21 (95% CI 1.05-1.40). To explore how evidence accumulated over time, we 
performed a cumulative meta-analysis, which is shown in Figure 2. The results show a stable 
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Figure 2
Figure 3
  Cumulative meta-analysis of CTSD rs17571 in AD
  meta-analysis of CTSD rs17571 in AD stratified by APOE ε4 carrier status
  *: original study
  *: original study
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Discussion
In this population-based cohort study and meta-analysis, we found that rs17571 in CTSD was 
associated with incident AD. This association was more pronounced in APOE ε4 noncarriers, 
however, a stratified meta-analysis did not confirm this finding. When ranking the p-values of the 
GWAS, rs17571 ranked 5115th, which is within the top 10%.
Evidence for association of CTSD with AD, thus far, has been very inconsistent. Most studies failed 
to replicate the original study, with one even showing a significant opposite effect [32] and only a 
few replicating the original finding [43,49]. Also, meta-analyses thus far did not find a significant 
association (http://www.alzgene.org) [20,52]. Pooling our longitudinal data with previously 
published data strengthens the evidence for an association of CTSD with AD. The meta-analysis 
clearly shows an association in Caucasians, even in a heterogeneous group of early-onset, late-
onset, sporadic and familial cases. The data reported in previous studies do not allow us to perform 
separate analyses in sporadic late-onset AD cases, which would be of interest for further research. 
Although differences in genotype distribution between early-onset and late-onset cases were 
not found in a previous study [41], excluding the study of Emahazion et al., which included only 
early-onset AD cases, reduced between-study heterogeneity. The between-study heterogeneity 
disappeared when additionally excluding the original study. With the accumulation of data over 
time we saw a stabilizing odds ratio and a narrowing of the 95% confidence level boundaries. 
There were no genome-wide association studies (GWAS) with publicly accessible data that 
included the SNP of interest. These studies typed two SNPs in LD with rs17571, but these were 
not associated with AD (rs7938305: p=0.26, OR 0.86; rs17834326: p=0.54, OR 0.97) [53,54]. We 
decided not to include these in the meta-analysis, because we intended to analyze the functional 
SNP for the candidate gene analysis only.
Most studies do not find differences between the effect of CTSD in APOE ε4 carriers and 
noncarriers or a significant interaction between these two genes [29,30,41,42]. Although 
the results in our study show the effect of the T-allele of rs17571 predominantly in APOE ε4 
noncarriers, the meta-analysis does not confirm this finding. In fact, the meta-analysis showed a 
more pronounced effect in ε4 carriers, however, the difference was not significant. 
summary odds ratio of 1.2 since 2006. When we analyze the data without the present study, 
the summary odds ratio is 1.21 with a 95% CI ranging from 1.00 to 1.46 (p-value of 0.053). The 
meta-analysis shown on the Alzgene database (http://www.alzgene.org) presents an OR of 1.17 
(95% CI 0.98-1.41) in Caucasians. The main explanation for the difference with our results is the 
exclusion of the study in which the control genotypes were not in HWE.
For the APOE ε4 stratified analyzes, 6 studies were available [30,38,40,47-49] with a total of 
1446 cases and 1699 controls. The results of this meta-analysis are shown in Figure 3. The 
pooled odds ratio was greater in APOE ε4 carriers than noncarriers, but non-significant. 
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This finding is in line with the suggestion that in AD, CTSD influences APOE independent 
pathways [55]. CTSD encodes a protein found in senile plaques and CSF [14,18,56]. The mRNA 
is upregulated in neurons in brains of AD patients, and the immunoreactivity is greater than 
in normal brains [14,15]. The CTSD protein is able to cleave APP [57] and tau protein [16], 
although the enzyme seems not to be essential for APP processing [58]. Animal studies show 
that mutations in CTSD causing dysfunction of the protein, result in loss of neurons in the brain 
and neurodegeneration [59]. In humans, the biological implication of the polymorphism rs17571 
is not clear, although multiple biological associations have been found. 
None of the published GWAS, including our own, showed genome-wide evidence for a role of 
CTSD in AD, however, rs17571 reached the top 10% of our GWA findings. Most GWAS are 
underpowered to find genes with small effects. The relatively high ranking is in accordance with 
simulations of GWAS by Zaykin et al.[60].
The strength of the current study is the inclusion of a large population-based cohort study, 
which has several advantages over clinic-based case-control studies. The main advantages are 
reduction in biases due to selective case-ascertainment, defining the control group, and low-
response rates. Furthermore, a major advantage is the use of incidence instead of prevalence 
cases, reducing prevalence-incidence bias that may occur when genetic variants are determining 
mortality. A limitation of the study could be misclassification of cases, but this misclassification 
would have occurred randomly and would thus not have lead to an overestimation of the effect 
size. Finally, the population-based design limits the number of cases available.
In conclusion, although the effect of CTSD on the risk of AD is small (OR 1.2), it might be important 
as one of multiple genetic risk factors adding up to a higher risk of AD. Our findings add to the 
evidence of an association with AD, and show that the odds ratio stabilized over time. 
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Overview of studies eligible for the meta-analysis 
First author Year Included in meta-analysis Controls AD Control   Case   Reference 
       N N T-allele 
frequency 
C-allele 
frequency 
C-allele 
frequency 
T-allele 
frequency 
 
*Papassotiropoulos 1999 yes  351 102  0.07 0.93 0.86 0.14 (Papassotiropoulos et al., 
1999) 
McIlroy 1999 yes  187 183  0.05 0.95 0.92 0.08 (McIlroy et al., 1999) 
Bhojak 2000 yes  316 531  0.09 0.91 0.90 0.10 (Bhojak et al., 2000) 
Crawford 2000 yes  120  210  0.08 0.92 0.90 0.10 (Crawford et al., 2000) 
Papassotiropoulos 2000 
(b) 
yes  184  127  0.05 0.95 0.88 0.12 (Papassotiropoulos et al., 
2000b) 
Bertram 2001 yes  182  200  0.09 0.91 0.91 0.09 (Bertram et al., 2001) 
Emahazion 2001 (I) yes  149  120  0.11 0.89 0.95 0.05 (Emahazion et al., 2001) 
Matsui 2001 yes  50 69  0.08 0.92 0.93 0.07 (Matsui et al., 2001) 
Menzer 2001 yes  302  324  0.06 0.94 0.92 0.08 (Menzer et al., 2001) 
Bagnoli 2002 yes  126  197  0.11 0.89 0.88 0.12 (Bagnoli et al., 2002) 
Ingegni 2003 yes  120  142  0.10 0.90 0.87 0.13 (Ingegni et al., 2003) 
Styczynska 2003 yes  100  100  0.05 0.96 0.94 0.07 (Styczynska et al., 2003) 
Beyer 2005 yes  181 206  0.08 0.92 0.92 0.08 (Beyer et al., 2005) 
Blomqvist 2006 yes  173  385 0.06 0.94 0.94 0.06 (Blomqvist et al., 2006) 
Davidson 2006 yes  767  560  0.08 0.92 0.92 0.08 (Davidson et al., 2006) 
Mariani 2006 yes  136  100  0.07 0.93 0.86 0.14 (Mariani et al., 2006) 
Capurso 2008 yes  421  242  0.08 0.92 0.94 0.06 (Capurso et al., 2008) 
Blomqvist 2006 no overlap Emahazion et al. 2001 - - - - - - (Blomqvist et al., 2006) 
Capurso 2005 no overlap Capurso et al. 2008 218  168 - - - - (Capurso et al., 2005) 
Corder 2006 no no data provided 120  180 - - - - (Corder et al., 2006) 
Emahazion 2001 
(II) 
no no data provided 176  116 - - - - (Emahazion et al., 2001) 
Kolsch 2004 no overlap Papassotiropoulos et al. 
1999 
- - - - - - (Kolsch et al., 2004) 
Papassotiropoulos 2000 
(a) 
no overlap Papassotiropoulos et al. 
1999&2000 
- - - - - - (Papassotiropoulos et al., 
2000a) 
Papassotiropoulos 2002 no no data provided 24  41  - - - - (Papassotiropoulos et al., 
2002) 
Prince 2001 no overlap Blomqvist et al. 2005 - - - - - - (Prince et al., 2001) 
Mateo 2002 no deviation from HWE in control group 346  311  0.10 0.90 0.91 0.09 (Mateo et al., 2002) 
              
*Original report; N: number; allele frequencies are reported for rs17571 
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Introduction
Abstract
Brain iron in ageing and in Alzheimer’s disease
Excess iron and oxidative stress
Iron overload may contribute to the risk of Alzheimer’s disease (AD). In the Epistasis Project, with 
1757 cases of AD and 6295 controls, we studied four variants in two genes of iron metabolism: 
haemochromatosis (HFE) C282Y and H63D, and transferrin (TF) C2 and
-2G/A. We replicated the reported interaction between HFE 282Y and TF C2 in the risk of AD: synergy 
factor = 1.75 (95% confidence interval: 1.1-2.8, p = 0.02) in Northern Europeans. The synergy factor 
was 3.1 (1.4-6.9, 0.007) in subjects with the APOEε4 allele. We found another interaction, between 
HFE 63HH and TF -2AA, markedly modified by age. Both interactions were found mainly or only in 
Northern Europeans. The interaction between HFE 282Y and TF C2 has now been replicated twice, 
in altogether 2313 cases of AD and 7065 controls, and has also been associated with increased iron 
load. We therefore suggest that iron overload may be a causative factor in the development of AD. 
Treatment for iron overload might thus be protective in some cases.
Since the 1950s, iron has been reported to increase with age in the brain [1] and has been proposed 
a role in Alzheimer’s disease (AD) [2]. Although a more rapid rise in brain levels of non-haem iron is 
seen in a person’s first 30 years [1], levels of iron and of iron-related proteins continue to rise with 
normal ageing in many, but not all brain regions [3-9]. Disturbances of iron metabolism have been 
widely reported in AD brain (below) and also in autopsy brain tissue and CSF and in mild cognitive 
impairment (MCI) [10,11]. Raised iron levels have been commonly found in AD, e.g. in  the basal 
ganglia [in vivo: [12,13]; autopsy: [14]], in the hippocampus [in vivo: [13,15]; autopsy: [16,17]] and 
in the neocortex [autopsy: [14,17,18]]. Iron has been located in postmortem tissue in and around 
senile plaques and neurofibrillary tangles [19-22]. There have been varying reports concerning a 
possible cellular imbalance of the iron:ferritin ratio [4,7,18,23] and also on the levels and activity of the 
important ferroxidase, ceruloplasmin [24-26] in AD brain. Altered patterns of transferrin expression 
have been reported in AD brain [4,14]. Increased expression of lactoferrin has been found both in 
neurones and glia in numerous regions of AD brain [27]. This may suggest increased use of non-
transferrin routes of cellular iron uptake, e.g. via lactoferrin.
Higher brain iron levels have been correlated with greater cognitive impairment in AD [13,28]. It has 
been proposed that excess iron in AD leads to oxidative damage [29-32]. Such damage to lipids [33-
36], to proteins [37-39] to DNA [40] and to RNA [41] has been found in AD, including early AD, and 
in MCI. RNA oxidation can lead to reduced rates of protein synthesis, which have been reported in 
MCI and AD brain tissue [42]. Markers of lipid peroxidation have also been found in the CSF of MCI 
patients, and in MCI patients who subsequently converted to AD [43,44]. In short, oxidative stress 
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Transferrin and HFE in AD
Methods
Study population
Two genes of iron metabolism have been much studied in AD: transferrin (TF) and its C2 variant 
(rs1049296), and the haemochromatosis gene (HFE) and its C282Y (rs1800562) and H63D 
(rs1799945) variants. These HFE variants affect blood iron status, with the rare 282Y homozygotes 
(frequency < 1%) having the highest transferrin saturation [54]. Since 1993 when an association of 
TF C2 with AD was first proposed [55], there have been altogether 14 independent studies of that 
association. Although most studies have been negative, the AlzGene meta-analysis of the allele 
[56] (http://www.alzforum.org/res/com/gen/alzgene/) currently shows a significant, though low, odds 
ratio of AD: 1.2 (95% confidence interval: 1.04-1.3) (10 December 2009), with a similar pattern in 
Caucasians and East Asians. Also, a large family study [57] supported the association. There have 
been 13 independent, association studies of HFE, with mixed results. The AlzGene meta-analysis 
of the 282Y allele currently gives an odds ratio of AD of 1.04 (0.9-1.2). However, three studies [58-
60] have proposed that the 63D allele may be associated with lower onset age of AD, possibly in 
interaction with apolipoprotein ε4 (APOE ε4). Also, the Oxford Project to Investigate Memory and 
ageing (OPTIMA) reported an interaction between TF C2 and HFE 282Y in the risk of AD [61]. 
This interaction was recently replicated [62] in a large collaborative study. Further, our preliminary 
examination of data from the Rotterdam Study revealed another potential interaction in the risk of 
AD. That was between HFE H63D and a single nucleotide polymorphism (SNP) just two base-pairs 
upstream of the start codon of TF (rs1130459, -2G/A) (data not shown). We therefore examined four 
SNPs, HFE C282Y, HFE H63D, TF C2 and TF -2G/A (Table 1), in the Epistasis Project. This project 
is a collaboration of seven AD research groups, contributing DNA samples from 1757 cases of AD 
and 6295 controls [63].
is seen early in AD, indeed in the pre-clinical stage, and provokes an antioxidant response [45]. 
Moreover, markers of lipid peroxidation in ventricular fluid have been correlated with cortical atrophy, 
reduced brain weight and severity of AD [46]. Excess iron may also contribute to neurodegeneration 
via, for instance, the metabolism and toxicity of β-amyloid [29,47-51], the loss of calcium homeostasis 
[52] and the degradation of a subset of microglia [53].
The Epistasis Project aims primarily to replicate genetic interactions that have been reported to 
affect the risk of AD. Sample-sets were drawn from narrow geographical regions with relatively 
homogeneous, Caucasian populations, by seven AD research groups: Bonn, Bristol, Nottingham, 
OPTIMA, Oviedo, Rotterdam and Santander. All AD cases were diagnosed “definite” or “probable” by 
CERAD or NINCDS-ADRDA criteria. Full details are given in our previous paper [63].
118
Genotyping
Statistical analysis
Genotyping for the six centres other than Rotterdam (below) was performed at the Wellcome Trust 
Sanger Institute, using the iPLEX Gold assay (Sequenom Inc.). Whole genome amplified DNA was 
used for 82% of samples; genomic DNA was used for the 18% of samples that were not suitable 
for whole genome amplification. A Sequenom iPLEX, designed for quality control purposes, was 
used to assess genotype concordance between genomic and whole genome amplified DNA for 168 
individuals. Assays for all SNPs were designed using the eXTEND suite and MassARRAY Assay 
Design software version 3.1 (Sequenom Inc.). Samples were amplified in multiplexed PCR reactions 
before allele specific extension. Allelic discrimination was obtained by analysis with a MassARRAY 
Analyzer Compact mass spectrometer. Genotypes were automatically assigned and manually 
confirmed using MassArray TyperAnalyzer software version 4.0 (Sequenom Inc.). Gender markers 
were included in all iPLEX assays as a quality control metric for confirmation of plate/sample identity. 
Genotyping of rs1130459 was carried out using KASPar technology by KBioscience (http://www.
kbioscience.co.uk). Repeat genotyping of rs1049296 was performed using TaqMan technology 
according to standard conditions (C_7505275_10; Applied Biosystems, Foster City, CA, U.S.A.).
We assessed associations with logistic regression models and synergy factor analysis [65], controlling 
for age, gender, study centre and the ε4 allele of apolipoprotein (APOEε4), using R Version 2.6.1 
(R Foundation for Statistical Computing, Vienna, Austria). Heterogeneity between centers was 
controlled by fitting a fixed effect corresponding to contrasts between the baseline centre and the six 
other centers (having compared models with fixed- and random-effect terms in centre, goodness of 
fit was measured using Akaike’s Information Criterion, which favored using fixed effects only). Over-
dispersion was controlled by fitting generalized linear models with a quasi-binomial family with logit 
link. Where the overall synergy factor was significant at p < 0.05, the seven individual centers and the 
two geographical regions, North Europe and North Spain, were also examined. Power calculations 
were based on the synergy factor values. Comparisons of allelic frequencies between North Spain 
and North Europe were by Fisher’s exact test. Linear regression models were used to compare onset 
ages. Linkage disequilibrium data were estimated using the R genetics library (http://cran.r-project.
Genotyping in the Rotterdam cohort was done on Version 3 Illumina-Infinium-II HumanHap550 SNP 
array (Illumina, San Diego, USA) and additionally, SNPs were imputed using MACH software (http://
www.sph.umich.edu/csg/abecasis/MACH/) with HapMap CEU Release 22 as a reference [64]. The 
reliability of imputation was estimated for each imputed SNP with the ratio of expected and observed 
dosage variance (O/E ratio). Only samples with high-quality extracted DNA were genotyped; 5974 
were available with good quality genotyping data; 5502 of these had reliable phenotypes. For this 
study, rs1800562 and rs1049296 were genotyped, and rs1799945 and rs1130459 were imputed.
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Studied SNPs 
Minor allele frequency in controls Linkage disequilibrium in controls
North Europe North Spain
Gene SNP
North 
Europe
North 
Spain
Difference: 
p D r2 D r2
HFE rs1800562  C282Y 
 
rs1799945  H63D
6.3% (Y) 
 
14.5% (D)
3.45% (Y) 
 
24.0% (D)
0.0003 
 
4.5x10-16
 
0.992
 
0.011
 
0.992
 
0.011
TF rs1049296  C2 = P589S 
 
rs1130459  -2G/A
16.4% (S) 
 
47.2% (A)
17.65% (S) 
 
48.0% (A)
0.34 
 
0.64
 
0.602
 
0.080
 
0.338
 
0.026
SNP = single nucleotide polymorphism; HFE = the haemochromatosis gene; TF = the transferrin gene; D = ratio of observed 
linkage disequilibrium to maximum possible linkage disequilibrium; r = correlation coefficient.   
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Results
Hardy-Weinberg analysis, allelic frequencies and linkage disequilibrium
Table 1
Hardy-Weinberg analysis was performed for the four SNPs of Table 1 in both cases and controls of 
the Rotterdam samples, genotyped by Rotterdam, and of the samples from the other six centres, 
genotyped by the Sanger Institute. In one of these 16 analyses, i.e. of rs1049296 in controls from the 
six centres, the genotypes were not in Hardy-Weinberg equilibrium. These samples were therefore 
retyped by a different method. The two methods, Sequenom and TaqMan, were in 99.6% agreement 
in the 2317 samples and neither were in Hardy-Weinberg equilibrium in controls (p = 0.01). There are 
three reported, overlapping copy number variations, each between 1.3 and 1.7 kb long, all just over 
6 kb downstream of TF and just over 9kb from rs1049296 (TF C2) (Database of Genomic Variants: 
http://projects.tcag.ca/variation/).
org/web/packages/genetics/  index.html). All tests of significance and power calculations were two-
sided.
Table 1 gives the allelic frequencies and structure of linkage disequilibrium (LD) of the two pairs of 
SNPs in controls. The allelic frequencies of HFE were strikingly different between North Europe and 
North Spain (Supplementary Table 1), but the frequencies were rather similar for TF. In contrast, the 
LD structure of HFE was nearly identical in the two regions, but differed somewhat for TF: D’ = 0.6 
versus 0.3 (Table 1). Supplementary Table 2 shows the allele frequencies by country, which were 
largely consistent in North Europe.
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Odds ratios of Alzheimers disease for the four SNPs, i.e. the main effects 
Numbers Adjusted
a
 odds ratios (95% CI, p)
North Europe North Spain
Gene Genotype
Controls AD 
cases
Controls AD 
cases
All North Europe North Spain
HFE 282YY+CY 
282CC 
63DD+HD 
63HH
667 
4830 
1478 
4016
117 
945 
281 
774
30 
428 
193 
267
38 
428 
191 
269
1.0 (0.8-1.2, 0.8) 
 
1.0 (0.8-1.1, 0.6)
0.9 (0.7-1.2, 
0.55) 
 
0.9 (0.8-1.1, 0.4)
1.3 (0.7-2.15, 0.4) 
 
1.1 (0.8-1.4, 0.7)
TF 589SS+PS 
589PP 
-2AA+GA 
-2GG
1647 
3847 
1213 
4258
333 
724 
211 
716
139 
317 
100 
348
163 
296 
141 
297
1.1 (0.96-1.3, 0.2) 
 
1.1 (0.97-1.3, 0.1)
1.0 (0.9-1.2, 0.7) 
 
1.0 (0.8-1.2, 0.9)
1.2 (0.9-1.7, 0.2) 
 
1.6 (1.1-2.2, 0.01)
SNP = single nucleotide polymorphism; HFE = the haemochromatosis gene; TF = the transferrin gene; AD = Alzheimers disease; CI = 
confidence interval.  
a
All analyses controlled for centre, age, gender and genotype of apolipoprotein 4. 
3
Interactions between HFE and TF SNPs in the risk of Alzheimers disease 
NumbersInteraction Dataset
Controls   AD
Power
a
Adjusted
b
 SF   
(95% CI, p) 
HFE 282Y+  
 TF C2+
All 
North Europe 
North Spain
 
  6227 
 
  5723 
    504
 
  1672 
 
  1152 
    520
43% 
34% 
17%
1.4 (0.9-2.2, 0.15) 
1.75 (1.1-2.8, 0.02) 
0.5 (0.2-1.8, 0.3)
HFE 63HH  
 TF -2AA
All 
North Europe 
North Spain
 
  6206 
 
  5706 
    500
 
  1496 
 
  1008 
    488
76% 
58% 
40%
1.5 (1.1-2.1, 0.02) 
2.0 (1.3-3.05, 0.002) 
1.3 (0.7-2.55, 0.4)
SNP = single nucleotide polymorphism; HFE = the haemochromatosis gene; TF = the transferrin gene; SF = synergy factor; CI = 
confidence interval; Y+ and C2+ group the genotypes, YY+CY and C2/C2+C2/-, respectively. 
a
Power to detect an SF of 1.4 (first interaction) or of 1.5 (second interaction) at p = 0.05. 
b
All analyses controlled for centre, age, gender and genotype of apolipoprotein 4. 
Table 2
Main effects: AD risk and onset age
Table 3
We found no significant main effects on AD risk of three of the four SNPs (Table 2). But the genotype, 
TF -2AA+GA, was associated with risk of AD only in North Spain: odds ratio = 1.6 (95% confidence 
interval: 1.1-2.2, p = 0.01). Although we found an apparent association of the HFE 63D allele with 
lower onset age of AD (p = 0.0008) in unadjusted analysis, we did not replicate the association on 
controlling for centre, age, gender and APOEε4 (p = 0.36). In the five centres with data on onset ages 
(Bonn, Bristol, OPTIMA, Santander, Rotterdam: n = 1249), the median onset age was 74.0 years 
(interquartile range: 68.0-80.0, n = 389) in patients with HFE 63D, while it was 76.0 years (69.0-82.6, 
860) in HFE 63H homozygotes. There was no interaction between HFE H63D and APOEε4 in onset 
age.
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Effect on the interaction between HFE 63HH and TF -2AA of stratification by age ± 80 years  
Adjusted* OR: HFE 63HH vs 63D-positive 
(95% CI, p)
Adjusted
a
 SF: HFE 63HH  TF -2AA (95% 
CI, p)
Age TF -2G/A  
genotype
North Europe North Spain North Europe North Spain
< 80 years -2AA 
-2G-positive
1.55 (0.85-2.9, 0.2) 
0.8 (0.55-1.1, 0.2)
 
0.9 (0.4-1.8, 0.7) 
0.9 (0.5-1.4, 0.5)
 
 
2.2 (1.1-4.4, 0.03) 
 
 
1.0 (0.4-2.3, 1.0) 
> 80 years -2AA 
-2G-positive
2.2 (1.2-4.0, 0.01) 
1.0 (0.8-1.3, 0.95)
 
3.1 (0.9-11.2, 0.08) 
1.1 (0.6-2.0, 0.85)
 
 
2.2 (1.1-4.2, 0.02) 
 
 
2.9 (0.8-10.8, 0.1) 
HFE = the haemochromatosis gene; TF = the transferrin gene; OR = odds ratio; CI = confidence interval; SF = synergy factor; 
age is at death or last examination (an age of 80 years is equivalent to an onset age of 75 years in our dataset). Numbers of 
cases and controls are given in Supplementary Table 3. 
a
All analyses controlled for centre, age, gender and genotype of 
apolipoprotein 4.
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Studied SNPs, by genotype 
Gene SNP Subjects Numbers, by genotype Totals
HFE rs1800562  C282Y 
 
rs1799945  H63D 
Controls  
AD  
Controls  
AD
AA:      23 
               7 
GG:    161 
             61
GA:    716 
           166 
CG:  1589  
           464 
GG:  5532 
         1556 
CC:   4512 
         1178
  6271 
  1729 
  6262 
  1703
TF rs1049296  C2 = P589S 
 
rs1130459  -2G/A 
Controls 
 AD  
Controls 
 AD
TT:     196 
             64 
GG:  1711 
           397
CT:   1671 
           482 
GA:  3137 
           735
CC:   4374 
         1136 
AA:  1373 
           386 
  6241 
  1682 
  6221 
  1518
 
SNP = single nucleotide polymorphism; HFE = the haemochromatosis gene; TF = the transferrin gene 
 
Control allele frequencies by country 
Minor allele frequency in controlsGene SNP
Britain The 
Netherlands
Germany Spain
HFE rs1800562  C282Y 
 
rs1799945  H63D 
51/816 
= 6.25% (Y) 
134/802 
= 16.7% (D)
652/10222 
= 6.4% (Y) 
1472/10222 
= 14.4% (D)
23/462 
= 5.0% (Y) 
56/462 
= 12.1% (D)
36/1042  
= 3.45% (Y) 
249/1038  
= 24.0% (D)
TF rs1049296  C2 = P589S 
 
rs1130459  -2G/A
125/800 
= 15.6% (S) 
 358/746 
= 48.0% (A)
1688/10220  
= 16.5% (S) 
4829/10220 
= 47.25% (A)
70/442  
= 15.8% (S) 
209/462 
= 45.2% (A)
180/1020  
= 17.65% (S) 
487/1014 
= 48.0% (A)
 
SNP = single nucleotide polymorphism; HFE = the haemochromatosis gene; TF = the transferrin gene 
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Interactions
Table 4
Supplementary Table 1
We also replicated both interactions in the risk of AD, i.e. the interaction between HFE 282Y and TF 
C2 and that between HFE 63HH and TF -2AA, but only in Northern Europeans (Table 3): synergy 
factors = 1.75 (95% confidence interval: 1.1-2.8, p = 0.02) for HFE 282Y × TF C2 and 2.0 (1.3-3.05, 
0.002) for HFE 63HH × TF -2AA. Neither result was due to any distortion in control frequencies 
(data not shown). In view of reported sex differences in iron status and related genetics [66], we also 
examined these interactions by sex. We found no significant differences between men and women 
in either interaction (data not shown). In the OPTIMA report [61], we had suggested that there might 
be a further interaction between HFE 282Y, TF C2 and APOEε4. Here we found that the interaction 
between these two iron-related SNPs only occurred in subjects with APOEε4, where the synergy 
factor in North Europeans was 3.1 (1.4-6.9, 0.007), but not in APOEε4 negatives, where the synergy 
factor was 1.05 (0.55-2.0, 0.87). However, there were no significant interactions between APOEε4 
and either SNP or both together. 
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Studied SNPs, by genotype 
Gene SNP Subjects Numbers, by genotype Totals
HFE rs1800562  C282Y 
 
rs1799945  H63D 
Controls  
AD  
Controls  
AD
AA:      23 
               7 
GG:    161 
             61
GA:    716 
           166 
CG:  1589  
           464 
GG:  5532 
         1556 
CC:   4512 
         1178
  6271 
  1729 
  6262 
  1703
TF rs1049296  C2 = P589S 
 
rs1130459  -2G/A 
Controls 
 AD  
Controls 
 AD
TT:     196 
             64 
GG:  1711 
           397
CT:   1671 
           482 
GA:  3137 
           735
CC:   4374 
         1136 
AA:  1373 
           386 
  6241 
  1682 
  6221 
  1518
 
SNP = single nucleotide polymorphism; HFE = the haemochromatosis gene; TF = the transferrin gene 
 
Control allele frequencies by country 
Minor allele frequency in controlsGene SNP
Britain The 
Netherlands
Germany Spain
HFE rs1800562  C282Y 
 
rs1799945  H63D 
51/816 
= 6.25% (Y) 
134/802 
= 16.7% (D)
652/10222 
= 6.4% (Y) 
1472/10222 
= 14.4% (D)
23/462 
= 5.0% (Y) 
56/462 
= 12.1% (D)
36/1042  
= 3.45% (Y) 
249/1038  
= 24.0% (D)
TF rs1049296  C2 = P589S 
 
rs1130459  -2G/A
125/800 
= 15.6% (S) 
 358/746 
= 48.0% (A)
1688/10220  
= 16.5% (S) 
4829/10220 
= 47.25% (A)
70/442  
= 15.8% (S) 
209/462 
= 45.2% (A)
180/1020  
= 17.65% (S) 
487/1014 
= 48.0% (A)
 
SNP = single nucleotide polymorphism; HFE = the haemochromatosis gene; TF = the transferrin gene 
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Supplementary Table 3. Effect on the interaction between HFE 63HH and TF -2AA of stratification by age ± 80 years  
 
Numbers
North Europe North Spain
Adjusted* OR: HFE 63HH vs 63D-
positive (95% CI, p)
Adjusted* SF: HFE 63HH  TF -2AA 
(95% CI, p)
Age TF -2G/A  
genotype
Controls AD Controls AD North Europe North Spain North Europe North Spain
-2AA
 
  804
 
  112     59   109 1.55 (0.85-2.9, 0.2)
 
0.9 (0.4-1.8, 0.7)< 80 
years
-2G-
positive
2843
 
  342   200   227 0.8 (0.55-1.1, 0.2) 0.9 (0.5-1.4, 0.5)
 
 
2.2 (1.1-4.4, 
0.03) 
 
 
 
1.0 (0.4-2.3, 1.0)
-2AA   457   115     53     50 2.2 (1.2-4.0, 0.01)
 
3.1 (0.9-11.2, 0.08)> 80 
years
-2G-
positive
1610   447   194   116 1.0 (0.8-1.3, 0.95) 1.1 (0.6-2.0, 0.85)
 
 
 
2.2 (1.1-4.2, 
0.02) 
 
 
 
 
2.9 (0.8-10.8, 
0.1) 
 
HFE = the haemochromatosis gene; TF = the transferrin gene; OR = odds ratio; CI = confidence interval; SF = synergy factor; age is at death or 
last examination (an age of 80 years is equivalent to an onset age of 75 years in our dataset).  
*All analyses controlled for centre, age, gender and genotype of apolipoprotein 4. 
 
 
 
Supplementary Table 4. Odds ratios of Alzheimers disease for interacting genotypes, stratified by each other, in 
Northern Europeans 
NumbersOdds ratio of 
AD for:-
In the subset:-
Controls AD cases
Adjusted* odds ratios of AD 
(95%CI, p) 
HFE 282Y+ TF C2- 
 
TF C2+ 
Y+     500 
Y-    3514 
Y+     199 
Y-    1510
Y+     71 
Y-    725 
Y+     49 
Y-    307
0.8 (0.6-1.04, 0.08) 
 
1.3 (0.9-2.0, 0.2)
TF C2+ HFE 282Y- 
 
HFE 282Y+ 
C2+ 1510 
C2-  3514 
C2+   199 
C2-    500
C2+ 307 
C2-  725 
C2+   49 
C2-    71
1.0 (0.8-1.2, 0.8) 
 
1.8 (1.1-2.9, 0.015)
HFE 63HH TF -2G+ 
 
TF -2AA 
HH  3279 
D+   1167 
HH    906 
D+     354
HH  570 
D+   213 
HH  173 
D+     52
0.9 (0.75-1.1, 0.4) 
 
1.8 (1.2-2.6, 0.004)
TF -2AA HFE 63D+ 
 
HFE 63HH 
AA    354 
G+   1167 
AA    906 
G+   3279
AA    52 
G+   213 
AA  173 
G+   570
0.6 (0.4-0.9, 0.01) 
 
1.25 (1.02-1.5, 0.035)
HFE = the haemochromatosis gene; TF = the transferrin gene; CI = confidence interval; Y+, C2+, G+ and D+ group the 
genotypes, YY+CY, C2/C2+C2/-, GG + GA and DD + DH, respectively. 
*All analyses controlled for centre, age, gender and genotype of apolipoprotein 4. 
Supplementary Table 2
Supplementary Table 3
Note that the second interaction above suggests that HFE 63HH is a risk factor for AD, depending on 
the TF -2G/A genotype, whereas in apparent contradiction, age data suggest that HFE 63HH might be 
associated with higher onset age. We therefore examined this genetic interaction by age. There was 
a clear interaction in our overall dataset between HFE 63HH and age at death or last examination as 
a continuous variable (p < 0.00001) and between that genotype and age ± 80 years [synergy factor = 
1.9 (1.45-2.6, 0.00001)], indicating increased risk associated with that genotype in the older subset. 
However, Table 4 shows that the interaction between HFE 63HH and TF -2AA applied equally to 
both age subsets in Northern Europeans. The Northern Spanish dataset lacked power in this subset 
analysis. However, it was consistent with North Europe in the older subset, but showed no effect in 
the younger subset (Table 4). Stratification by the median age of controls, 76.88 years instead of 80 
years, produced similar results, except that the synergy factor for Northern Europeans in the younger 
subset dropped below significance: 2.25 (0.97-5.2, 0.06).
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Supplementary Table 3. Effect on the interaction between HFE 63HH and TF -2AA of stratification by age ± 80 years  
 
Numbers
North Europe North Spain
Adjusted* OR: HFE 63HH vs 63D-
positive (95% CI, p)
Adjusted* SF: HFE 63HH  TF -2AA 
(95% CI, p)
Age TF -2G/A  
genotype
Controls AD Controls AD North Europe North Spain North Europe North Spain
-2AA
 
  804
 
  112     59   109 1.55 (0.85-2.9, 0.2)
 
0.9 (0.4-1.8, 0.7)< 80 
years
-2G-
positive
2843
 
  342   200   227 0.8 (0.55-1.1, 0.2) 0.9 (0.5-1.4, 0.5)
 
 
2.2 (1.1-4.4, 
0.03) 
 
 
 
1.0 (0.4-2.3, 1.0)
-2AA   457   115     53     50 2.2 (1.2-4.0, 0.01)
 
3.1 (0.9-11.2, 0.08)> 80 
years
-2G-
positive
1610   447   194   116 1.0 (0.8-1.3, 0.95) 1.1 (0.6-2.0, 0.85)
 
 
 
2.2 (1.1-4.2, 
0.02) 
 
 
 
 
2.9 (0.8-10.8, 
0.1) 
 
HFE = the haemochromatosis gene; TF = the transferrin gene; OR = odds ratio; CI = confidence interval; SF = synergy factor; age is at death or 
last examination (an age of 80 years is equivalent to an onset age of 75 years in our dataset).  
*All analyses controlled for centre, age, gender and genotype of apolipoprotein 4. 
 
 
 
Supplementary Table 4. Odds ratios of Alzheimers disease for interacting genotypes, stratified by each other, in 
Northern Europeans 
NumbersOdds ratio of 
AD for:-
In the subset:-
Controls AD cases
Adjusted* odds ratios of AD 
(95%CI, p) 
HFE 282Y+ TF C2- 
 
TF C2+ 
Y+     500 
Y-    3514 
Y+     199 
Y-    1510
Y+     71 
Y-    725 
Y+     49 
Y-    307
0.8 (0.6-1.04, 0.08) 
 
1.3 (0.9-2.0, 0.2)
TF C2+ HFE 282Y- 
 
HFE 282Y+ 
C2+ 1510 
C2-  3514 
C2+   199 
C2-    500
C2+ 307 
C2-  725 
C2+   49 
C2-    71
1.0 (0.8-1.2, 0.8) 
 
1.8 (1.1-2.9, 0.015)
HFE 63HH TF -2G+ 
 
TF -2AA 
HH  3279 
D+   1167 
HH    906 
D+     354
HH  570 
D+   213 
HH  173 
D+     52
0.9 (0.75-1.1, 0.4) 
 
1.8 (1.2-2.6, 0.004)
TF -2AA HFE 63D+ 
 
HFE 63HH 
AA    354 
G+   1167 
AA    906 
G+   3279
AA    52 
G+   213 
AA  173 
G+   570
0.6 (0.4-0.9, 0.01) 
 
1.25 (1.02-1.5, 0.035)
HFE = the haemochromatosis gene; TF = the transferrin gene; CI = confidence interval; Y+, C2+, G+ and D+ group the 
genotypes, YY+CY, C2/C2+C2/-, GG + GA and DD + DH, respectively. 
*All analyses controlled for centre, age, gender and genotype of apolipoprotein 4. 
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Discussion
The interactions 
Supplementary Table 4 shows how the association with AD of each risk factor (genotype) is changed 
by the presence of the interacting factor. For instance, the association with AD of HFE 63HH is 
changed from an odds ratio of 0.9 (0.75-1.1, 0.4) to an odds ratio of 1.8 (1.2-2.6, 0.004) by the 
presence of TF -2AA.
Our results reveal a complex three-way interaction between HFE 63HH, TF -2AA and age (Table 4). 
This explains the paradox that HFE 63HH is a risk factor for AD, contingent on TF -2G/A genotype, yet 
may also be associated with a higher onset age of AD. The explanation is that the risk effect of HFE 
63HH only applies to older people, possibly through additional interactions with survival-promoting 
factors. Nevertheless, we consider that this interaction should remain tentative until replicated in 
another large study.
In contrast, the interaction between HFE 282Y and TF C2 has now been replicated in two large, 
independent studies: Kauwe et al [62] and the present study. Kauwe et al used 1161 cases and 1342 
controls, and they reported a combined synergy factor of 2.4 (1.4-4.2, 0.002), controlling for centre, 
age, gender and APOEε4 (as we did). The discordant results of association studies of these two 
SNPs when examined individually [see the AlzGene meta-analyses [56] may be partly due to this 
interaction. For instance, in our Northern European dataset, TF C2 was only associated with AD risk 
in the presence of HFE 282Y [odds ratio = 1.8 (1.1-2.9, 0.015)], whereas it had no effect in the latter’s 
absence [odds ratio = 1.0 (0.8-1.2, 0.8)] (Supplementary Table 4). It is noticeable that nothing was 
obtained from the examination of the main effects of HFE 282Y and TF C2 (Table 2). But an important 
result has been derived from the study of their interaction. This interaction is so far the only example 
of epistasis in AD to have been consistently replicated in such numbers: altogether 2313 cases and 
7065 controls. 
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The four SNPs: potential mechanisms of the associations with AD
The HFE protein regulates iron metabolism in at least three ways. First, the protein has been shown 
to bind transferrin receptor 1 (TfR1) [70], thereby reducing the affinity of TfR1 for transferrin and 
decreasing cellular iron uptake. Second, HFE has been reported to lower cellular iron levels without 
binding TfR1 [71]. Third, HFE inhibits iron export from various cells, including macrophages [72-74]. 
The most likely mechanism of the association of the 282Y variant with AD may be the loss of the 
first function of HFE above. That is because the variant fails to reach the cell surface and thus to 
bind TfR1 [70,75]. Hence it leaves transferrin free to bind TfR1 with high affinity, leading to increased 
cellular uptake of iron. HFE 282Y may also be defective in the third function above [72]. However, that 
function may be the mechanism of the association of the H63D polymorphism with AD, assuming that 
HFE inhibits iron export from microglia, as it does from macrophages [72,73]. A subset of microglia 
store excess brain iron in ferritin [53]. This role may lead to their dystrophy [53,76] where brain iron 
accumulation is excessive, as in ageing and in AD (Introduction). The proportion of ferritin-positive 
microglia increases with ageing and further increases in AD [53]. However, the 63D variant [73] and 
possibly also 282Y [72] have lost the ability to block iron export, which may result in greater release 
of iron from microglia. H63D may also affect the first function of HFE (above): although the variant 
binds TfR1, it is reported to have little influence on the affinity of TfR1 for transferrin [70]. Other 
potential mechanisms associated with H63D include the promotion of glutamate toxicity [77] and of 
tau phosphorylation [78]. Oxidative stress-related mechanisms of these two variants are consistent 
with three findings of a Rotterdam study [79]. First, that both variants were associated with higher 
Both interactions were found only or mainly in Northern Europeans (Tables 3 and 4). The samples 
used by Kauwe et al were also mainly Northern European. We found differences between North 
Europe and North Spain both in allelic frequencies and in LD structure (Table 1). There are several 
examples of differences between North and South Europe in genetic studies [67-69]. In our meta-
analysis of the indel in the angiotensin 1-converting enzyme in AD [69], we were only able to remove 
the marked heterogeneity in our analyses by geographic stratification. This revealed clear differences 
between North and South Europe. Also in iron metabolism, a higher proportion of haemochromatosis 
patients are HFE 282Y homozygotes in North than in South Europe [67]. Other, as yet unknown, 
genes may modify the associations with AD of our studied SNPs in the Northern Spanish. However, 
we cannot rule out either interaction in that population, in view of the relatively low power in that 
subset (Table 3). 
Although there is some LD between the two SNPs in HFE and also between the two in TF (Table 
1), neither interaction is due to the effects of such LD. We cannot rule out that either interaction is 
due to LD with other polymorphisms. However, we suggest that each interaction may independently 
contribute to AD risk, by separate mechanisms, both of which lead to iron overload. There are a 
number of potential mechanisms, which we outline in the next section.
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Conclusions
The C2 variant of transferrin has also been proposed to increase the risk of oxidative stress [86], but 
the mechanisms remain unresolved. In vitro studies  [87,88] have shown no differences in the iron-
binding properties of the variant. Its changed glycosylation pattern [89] could be relevant, however. 
Glycosylation patterns are altered in CSF in AD [90], notably of transferring [91], which also has 
a higher oxidation index in AD plasma [92]. Although such partial changes in the glycosylation of 
transferrin do not affect its receptor binding [93,94], they may speed its degradation [89]. Changes 
in the glycosylation patterns of transferrin have been reported in various diseases, e.g. rheumatoid 
arthritis [95]. Total iron-binding capacity in blood may be marginally lower in C2 homozygotes [96-
98], although the difference was only significant in one study [96]. In an OPTIMA study [99] with a 
subset of subjects from this study, transferrin saturation was higher in non-demented elderly with 
both HFE 282Y and TF C2, although neither variant alone had any effect. This increased transferrin 
saturation was due rather to raised serum iron in bi-carriers of these variants, than to lower iron-
binding capacity. Iron load did not differ by genetic combination in AD [99]. The C2 variant may also 
have a role in β-amyloid metabolism [100,101]. The function of the -2G/A variant of TF has not yet 
been studied. However, given its position between the start site and the promoter of TF, very close to 
the former, it may well affect the expression of the gene.
serum levels of the antioxidant, bilirubin; second, that serum bilirubin correlated with iron load; and 
third, that high serum bilirubin was associated with reduced mortality in 282Y heterozygotes and 
63D homozygotes. The interaction between HFE 282Y and TF C2 may be modified by APOEε4 (3.3 
above), which itself has been associated with oxidative stress [80-84] and with greater vulnerability 
to Fe2+ ions [85]. 
We suggest that the combination, HFE 282Y with TF C2, and possibly also HFE 63HH with TF -2AA, 
may contribute to iron overload and thus to oxidative stress in the pre-clinical phase of AD. The 
effect of the former combination is influenced by APOEε4 and that of the latter combination depends 
on age. These interactions may partly explain the discordant results of previous studies. There are 
various potential mechanisms to obtain these effects, but these mechanisms remain unproven. 
Further study should include the adequately-powered examination of brain iron levels in subjects 
with these genetic combinations, in AD and particularly in MCI and elderly controls. Excess brain iron 
has also been found in other neurodegenerative conditions, such as Parkinson’s disease [102,103]. 
It may be of interest to examine these genetic interactions in those conditions as well, and also in 
relation to cognitive performance in elderly controls, provided sufficient power is available. To have 
even 50% power to replicate the interaction between HFE 282Y and TF C2 at p = 0.05 in a Northern 
European sample, i.e. with control allelic frequencies similar to those in Table 1, would require 2400 
cases and 2400 controls. It would require an even larger dataset in other populations, which have 
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still lower frequencies of HFE 282Y. The interaction between HFE 63HH and TF -2AA would require 
1025 cases and 1025 controls to have 50% power. However, the former interaction has now been 
replicated twice independently, in samples totalling 2313 cases and 7065 controls, i.e. in Kauwe et 
al [62] and in the Northern Europeans of this study. Risk factors for AD may act many years before 
disease onset, as with high blood pressure [104,105] and with high serum cholesterol [106].  In the 
OPTIMA study cited above [99], the 282Y/C2 combination was also associated with higher iron load 
in non-demented elderly. We may therefore conclude that iron overload can be one of the causative 
factors in the development of AD. In our controls, 3.5% of Northern Europeans have the 282Y/C2 
combination and 15.9% have the 63HH/-2AA combination (but the latter interaction needs further 
replication). Altogether, 18.1% have one or other combination. We suggest that treatment for iron 
overload, e.g. venesection [107] or iron chelation [108,109] might benefit elderly people with these 
genetic combinations and needs to be explored further.
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Asymptomatic cerebral lesions on MRI such as white matter lesions (WML), lacunes and microbleeds 
are commonly seen in the elderly. We examined the role of a series of candidate genes involved in 
blood pressure regulation and amyloid metabolism.
Asymptomatic cerebral lesions, such as white matter lesions (WML), lacunes, and microbleeds are 
common in the elderly, and associated with stroke and cognitive impairment [1-4]. The mechanisms 
underlying the pathogenesis of these lesions are largely unknown. Several studies, however, suggest 
that changes in blood vessels in the brain lead to ischemic damage, causing WML and lacunes, and 
that leakage of red blood cells might lead to hemosiderin depositions or microbleeds [5,6]. Damage 
to vessels is most likely a consequence of hypertension and atherosclerosis, but there is also data 
suggesting that lesions are related to amyloid angiopathy [7]. 
Since hypertension is a risk factor for cerebral small vessel disease (CSVD), various genetic studies 
targeted genes that are involved in blood pressure regulation. Most widely studied are the alfa-
adducin gene (ADD1), which increases renal sodium absorption, and the angiotensin (AGT) and 
angiotensin II type 1 receptor (AGTR1) genes, which play a role in the renin-angiotensin system [8]. 
The study was embedded in a family-based cohort sampled from a Dutch genetically isolated 
population. We selected individuals between 55 and 75 years of age with hypertension (N=129). 
Volumes of WML and presence of lacunes and microbleeds were assessed with MRI. We studied 
3 genes involved in blood pressure regulation (Angiotensin, Angiotensin II type 1 Receptor, alpha-
Adducin), and 2 genes involved in the amyloid pathway (Apolipoprotein E (APOE) and sortilin-related 
receptor gene (SORL1)).
All participants had WML (median volume, 3.1 mL, interquartile range, 1.5 – 6.5 mL), lacunar 
infarcts were present in 15.5% and microbleeds in 23.3%. Homozygosity for the APOE ε4 allele was 
associated with lacunes (OR, 4.8; 95% CI, 1.2-19.3). Individuals carrying two copies of the variant 
allele of 4 SNPs located at the 3’-end of SORL1 (rs1699102, rs3824968, rs2282649, rs1010159), had 
significantly more often microbleeds (highest odds ratio, 6.87; 95% CI, 1.78-26.44). 
The association of SORL1 with microbleeds suggests that the amyloid cascade is involved in the 
etiology of microbleeds in populations with hypertension. 
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Materials and Methods
The study was embedded in a population-based study in a genetically isolated population (Erasmus 
Rucphen Family (ERF)-Study). Considering hypertension as major risk factor for CSVD, we selected 
participants aged 55 to 75 years with hypertension to ensure a high prevalence of pathology. 
Hypertension was defined as systolic blood pressure ≥160 and/or diastolic blood pressure ≥100 
and/or use of antihypertensive medication. Persons with a history of stroke or dementia or with MRI-
contraindications were excluded. A random subset of 261 was invited out of 330 individuals who 
were eligible for the study; 135 agreed to participate. These had higher levels of education than 
nonparticipants (p=0.01). All participants gave informed consent and the study was approved by the 
Medical Ethics Committee.
Brain imaging was done on a 1.5-T MRI scanner (Signa Excite II, General Electric Healthcare, 
Milwaukee, WI, USA) with use of previously described protocols.[18] Volumes of WML were obtained 
by an automatic brain-tissue segmentation method.[19] To take into account differences in headsize, 
these volumes were analyzed as percentage of intracranial volume. Lacunes and microbleeds were 
rated by two trained reviewers; when there was no consensus a neuroradiologist decided. Previous 
agreement rates in our group with the same reviewers and neuroradiologist were good (κ=0.87 
(intraobserver) and κ=0.85 (interobserver)).[14] MRI-scans could not be acquired in 4 participants 
because of physical constraints and 2 persons were excluded from analyses (both had a large 
incidentally discovered brain tumor). In total, complete information was available for 129 individuals.
Cognitive function was assessed with a word learning test, the Trail Making Test (TMT), the Stroop 
Color and Word (CW-) test, verbal fluency tests, and the block-design subtest of WAISIII.[20] From the 
word learning test, we derived four scores: working memory, learning, delayed recall, and recognition. 
From the TMT, a ratio score was computed: time on part B divided by time on part A. This was also 
done for the Stroop CW-test (time on card III divided by time on card II). 
The ADD1-Gly460Trp, AGT-M235T and AGTR1-C573T polymorphisms are associated with increased 
risk of atherosclerosis and CSVD [9-11]. Also genes involved in the amyloidogenic pathway have 
been implicated in CSVD. Two identified genes are the apolipoprotein E (APOE) and sortilin-related 
receptor (SORL1) genes. Although the exact function of APOE in the brain is not fully unraveled 
yet, this gene is thought to aid beta-amyloid clearance [12]. Carriers of the APOE ε4 allele have an 
increased risk of WML and microbleeds [13,14]. SORL1 codes for a neuronal apolipoprotein receptor, 
and is thought to regulate processing of the amyloid precursor protein in the brain [15]. Multiple SNPs 
within SORL1 are associated with Alzheimer’s disease (AD) and cognitive impairment, and recently 
also with cerebral atrophy and cerebrovascular disease [16,17]. We selected the key SNPs from the 
original report for the current study [16].
The aim of the study was to examine the role of genes involved in blood pressure regulation and 
amyloid processing in the development of WML, lacunes, microbleeds and cognitive impairment. 
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1
Individuals with CVSD versus individuals without CVSD 
CSVD - CSVD + p-value
Number 77 52 
Female % 51.9 53.8 0.49
Age 63.3 (4.5) 66.3 (4.1) <0.001
Systolic blood pressure (mmHg) 143.8 (18.6) 149.5 (17.3) 0.08
Diastolic blood pressure (mmHg) 83.2 (10.0) 84.5 (9.2) 0.45
BMI 29.5 (4.7) 28.6 (3.6) 0.29
Cholesterol (mmol/L) 5.2 (1.1) 5.2 (1.2) 0.89
HDL-C (mmol/L) 1.5 (0.3) 1.3 (0.3) 0.32
LDL-C (mmol/L) 3.4 (1.0) 3.3 (1.0) 0.65
Creatinine (mmol/L) 73.3 (20.3) 72.5 (17.9) 0.88
Diabetes (%) 15.6 15.4 0.98
Current smokers (%) 71.4 73.1 0.50
Use of alcohol (%) 62.3 67.3 0.58
Depressive symptoms† (%) 16.9 19.2 0.82
Education (% with primary education) 32.5 36.5 0.71
Values are presented as mean (±sd). CVSD: Cerebral small vessel disease, defined as wml  P75 or lacune or cerebral 
microbleeds. BMI: Body Mass Index † defined as a score on CES-D  16 and/or a score of  11 on HADS-D and/or use of 
antidepressants 
Results 
Table 1
Blood pressure was measured by a mercury-based sphygmomanometer. Blood was taken for 
estimation of levels of total cholesterol, high-density lipoprotein cholesterol (HDL-c) and low-density 
lipoprotein cholesterol (LDL-c).[20] Samples were genotyped for ADD1-Gly460Trp, AGT-M235T, 
AGTR1-C573T, APOE (rs429358, rs7412), and SORL1 (rs668387, rs689021, rs641120, rs1699102, 
rs3824968, rs2282649, rs1010159) with Taqman allelic discrimination Assays-By-Design (Applied 
Biosystems, Foster City, CA).[9,11,20] 
To analyze the association of genotypes with WML volume, lacunes and microbleeds, regression 
models were used. White matter lesion volume was transformed by taking the natural logarithm. 
Haplotypes were derived with the software package SimWalk2 [21]; these haplotypes were 
considered as a fixed factor in a general linear model. Student’s T-test and Chi-square statistics 
were used to perform general descriptive statistics (version 15.0 of SPSS). To compare baseline 
characteristics, we defined CSVD as a WML volume greater than the 75th percentile, or presence 
of lacunes or microbleeds. Analyses were adjusted for age and sex, and p-values were adjusted for 
family relationship. We corrected for multiple testing by performing 10.000 permutations.
The mean age of the participants was 64.5 (± 4.6) years and 52.7% were female. In this hypertensive 
population, WML were seen in all participants (median, 3.11 mL; interquartile range, 1.51-6.50 mL). 
Lacunes were present in 20 individuals (15.5%), and microbleeds in 30 individuals (23.3%) with lobar 
location in 63%. Those with WML greater than the 75th percentile more often had lacunes (p<0.001) 
and microbleeds (p=0.003). Age was associated with larger WML volumes (p<0.001) and presence 
of microbleeds (p=0.02). Other associations between CSVD and cardiovascular risk factors were not 
observed (Table 1). 
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2
Association of AGT, AGTR1, ADD1, APOE and SORL1 with WML, microbleeds and lacunar infarcts  
Gene Genotype WML‡ Lacunar infarcts Microbleeds 
N Mean difference (95% CI) P Absent Present OR (95% CI) P Absent Present OR (95% CI) P 
             
AGT MM 33 ref 28 5 ref 26 7 ref
MT 64 -0.32 (-0.73 – 0.08) 0.12 52 12 1.32 (0.40-4.37) 0.65 48 16 1.37 (0.47-3.97) 0.57
TT 23 -0.25 (-0.76 – 0.26) 0.33 21 2 0.57 (0.10-3.34) 0.53 18 5 1.19 (0.31-4.57) 0.80
AGTR1 TT 24 ref 20 4 ref 20 4 ref
CT 53 -0.10 (-0.57 – 0.36) 0.66 46 7 0.71 (0.18-2.78) 0.62 38 15 1.94 (0.55-6.86) 0.30
CC 42 0.05 (-0.44 – 0.54) 0.84 35 7 1.19 (0.29-4.82) 0.81 33 9 1.60 (0.41-6.20) 0.50
ADD1 GG 77 ref 63 14 ref 54 23 ref
GT/TT 46 -0.22 (-0.56 – 0.12) 0.21 41 5 0.55 (0.18-1.66) 0.29 39 7 0.41 (0.16-1.07) 0.07
APOE 0 copies 4 78 ref 66 12 ref 61 17 ref
1 copy 4 39 -0.01 (-0.37 – 0.36) 0.97 36 3 0.39 (0.10-1.52) 0.18 30 9 0.96 (0.37-2.48) 0.94
2 copy 4 12 0.31 (-0.27 – 0.88) 0.29 7 5 4.77 (1.18-19.32) 0.04 8 4 1.99 (0.50-7.94) 0.33
SORL1 rs668387 CC 30 ref 26 4 ref 22 8 ref
CT 62 -0.04 (-0.45 – 0.38) 0.86 52 10 1.15 (0.32-4.11) 0.83 52 10 0.46 (0.15-1.36) 0.16
TT 31 -0.11 (-0.58 – 0.37) 0.66 25 6 1.32 (0.32-5.42) 0.70 20 11 1.28 (0.41.4.00) 0.67
SORL1 rs689021 GG 26 ref 22 4 ref 19 7 ref
AG 63 -0.07 (-0.51 – 0.36) 0.74 54 9 0.85 (0.23-3.10) 0.80 52 11 0.50 (0.16-1.54) 0.23
AA 31 -0.18 (-0.68 – 0.32) 0.47 25 6 1.12 (0.27-4.64) 0.88 21 10 1.06 (0.32-3.51) 0.92
SORL1 rs641120 CC 29 ref 25 4 ref 21 8 ref
CT 61 -0.07 (-0.49 – 0.35) 0.74 52 9 0.99 (0.27-3.59) 0.99 51 10 0.44 (0.15-1.32) 0.14
TT 31 -0.18 (-0.66 – 0.30) 0.47 25 6 1.26 (0.31-5.18) 0.73 21 10 1.01 (0.32-3.22) 0.99
SORL1 rs1699102 TT 49 ref 40 9 ref 42 7 ref
CT 55 0.15 (-0.22 – 0.51) 0.43 48 7 0.65 (0.22-1.93) 0.34 43 12 1.76 (0.61-5.07) 0.30
CC 17 0.15 (-0.37 – 0.68) 0.56 15 2 0.60 (0.11-3.20) 0.55 9 8 6.81 (1.79-25.97) 0.005
SORL1 rs3824968 TT 51 ref 41 10 ref 42 9 ref
AT 53 0.06 (-0.30 – 0.41) 0.75 47 6 0.50 (0.16-1.52) 0.22 42 11 1.19 (0.43-3.30) 0.74
AA 15 0.28 (-0.25 – 0.81) 0.30 13 2 0.74 (0.14-3.92) 0.72 8 7 5.90 (1.54-22.70) 0.01
SORL1 rs2282649 CC 56 ref 47 9 ref 47 9 ref
CT 49 0.13 (-0.24 – 0.49) 0.49 42 7 0.88 (0.30-2.63) 0.82 38 11 1.60 (0.58-4.46) 0.37
TT 15 0.32 (-0.22 – 0.87) 0.24 13 2 0.96 (0.18-5.15) 0.96 8 7 6.87 (1.78-26.44) 0.005
SORL1 rs1010159 TT 52 ref 43 9 ref 44 8 ref
CT 57 0.30 (-0.05 – 0.65) 0.10 48 9 0.89 (0.32-2.49) 0.83 42 15 2.05 (0.76-5.49) 0.16
CC 20 0.21 (-0.28 – 0.69) 0.40 18 2 0.65 (0.12-3.38) 0.61 13 7 4.17 (1.18-14.70) 0.03
WML: white matter lesion volume, P: p-value adjusted for age, sex and family-relationship. ref: reference genotype. ‡ natural log transformed variable 
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Table 2
The results of the association analyses between the polymorphisms and WML volume, lacunes 
and microbleeds are shown in Table 2. Genotype frequencies of ADD1, AGT and AGTR1 were not 
associated with WML volume, lacunes or microbleeds. Individuals carrying two copies of the APOE 
ε4 allele had more WML, lacunes and microbleeds than those without the ε4 allele; however, the 
effects were small. This difference was significant for lacunes (p=0.04). 
The sortilin-related receptor gene was consistently associated with the presence of microbleeds. 
Individuals carrying two copies of the variant allele of the 4 SNPs located at the 3’-end of the gene 
(rs1699102, rs3824968, rs2282649, rs1010159) more often had microbleeds (highest odds ratio, 
6.87; 95% CI, 1.78-26.44). In this hypertensive population, these SNPs were also associated with 
cognitive function. The SNPs rs1699102 (p=0.001), rs3824968 (p=0.004), rs2282649 (p=0.001), 
and rs1010159 (p=0.002) were all associated with TMT-ratio. The haplotype analysis of the SORL1 
SNPs also showed association with microbleeds (p=0.05), most significantly when the haplotypes 
were based on rs1699102, rs3824968, rs2282649 and rs1010159 only (p=0.03). None of the SORL1 
SNPs showed evidence for association with WML or lacunes. Genotype frequencies for the related 
SNPs were similar for participants and nonparticipants. 
142
Discussion 
This study shows that two genes involved in the amyloidogenic pathway and previously described 
in AD, APOE and SORL1, were associated with CSVD. The presence of two APOE-ε4 alleles 
was associated with lacunes. Given the role of apolipoprotein in the brain, this finding suggests 
involvement of beta-amyloid clearance in the pathogenesis of lacunes.[22] Alternatively, 
the association in this hypertensive population might be explained by the effect of APOE on 
cardiovascular factors.[20] 
Our observation that SORL1 was associated with microbleeds has not been previously reported. 
This gene regulates APP processing and SORL1 deficiency leads to increased levels of beta-
amyloid and enhances amyloid pathology in the brain.[16] In our study, microbleeds were 
predominantly located in lobar brain regions, implying that most of the lesions resulted from 
amyloid angiopathy.[14] In amyloid angiopathy-related AD, the majority of plaques is centered 
on vessel walls or in the immediate perivascular regions.[23] The relationship between SORL1 
and microbleeds is of interest, because of increasing evidence that beta-amyloid plays a role 
in neurodegeneration through perivascular interstitial fluid drainage.[24] Through its role in 
microbleeds, SORL1, may link to dementia.[1] In line with this hypothesis, we found that the 
SNPs associated with microbleeds were marginally associated with cognitive function. This 
indirect role of SORL1 in plaque formation may also explain why the effects of the gene are 
modest in AD (http://www.Alzgene.org). 
The genes involved in blood pressure regulation were not associated with CVSD. Earlier findings 
have been inconsistent.[9,11,25] The lack of an association in our study might be due to the fact 
that all participants were hypertensive, and that the blood pressure ranges were small. Indeed, 
blood pressure itself was not significantly associated with lesions.
The strength of our study is the population-based design, performed in a homogenous group of 
middle-aged individuals with hypertension derived from a genetically isolated population, which 
increases statistical power of genetic association studies. The size of the study is limited, however, 
and allows mainly detecting genetic variants with large effects. The association of SORL1 with 
microbleeds therefore remains to be confirmed. A question that remains to be answered in larger 
populations is whether hypertension interacts with SORL1 in the association with microbleeds, 
which might possibly be an alternative interpretation of our results.
The observed association of SORL1 with microbleeds in our study suggests that the amyloid 
cascade is involved in the etiology of microbleeds in populations with hypertension.
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The sortilin-related receptor gene (SORL1) is an interesting candidate involved in Alzheimer’s disease 
(AD). SORL1 consists of two functional domains, one functions in the cholesterol pathway and the 
other in the APP processing pathway. The gene has been associated to AD and cerebrovascular 
disease. We studied the relationship of SORL1 with hippocampal volume and plasma Aβ levels.
Neurodegenerative diseases like Alzheimer’s disease (AD) are highly prevalent diseases in the elderly 
and a major burden on society [1,2]. Neuropathologically, AD is characterized by neuritic plaques and 
neurofibrillary tangles [3,4]. Neuritic plaques contain amyloid beta (Aβ) proteins, which are formed 
after proteolytic processing of the amyloid precursor protein (APP). Aβ proteins are present in full-
length species (β40 and β42) and in shorter amino-terminal truncated species (βn40 and βn42). 
The latter accounts for 60% of all Aβ species in pre-clinical AD stages [5]. Aβ pathology may also 
be present  in brains of cognitively healthy elderly at postmortem and can visualized with PIB-PET 
during life [6,7]. The deposition and clearance of Aβ in the brain is related to Aβ levels in plasma, but 
the mechanism is not fully understood  [8]. Both increased and decreased risks as well as no effects 
have been reported for Aβ40 and Aβ42 [9-14]. 
Another early biomarker of AD is hippocampal atrophy [15,16]. Although the hippocampus has a low 
Aβ load in non-AD brains [17], the correlation of hippocampal atrophy on MRI with Aβ CSF levels and 
with 11C-PIB uptake in PET studies of AD patients and healthy controls is high [18-20]. 
The heritability of plasma Aβ levels and medial temporal lobe atrophy have both been estimated 
The study was embedded in a family-based cohort sampled from a Dutch genetically isolated 
population. We selected individuals between 55 and 75 years of age with hypertension (N=128). 
Volumes of the hippocampi were assessed with MRI and non-fasting blood sample were taken to 
assess plasma Aβ levels. We studied the effect of 7 variants within SORL1 that were previously 
reported in AD, by performing the variable screening analysis under the polygenic model and 
haplotype analyses.
Three variants located near the 3’-end of SORL1 were significantly associated to hippocampal 
volume. The 3-SNP haplotypes for rs1699102, rs3824968 and rs2282649 (CAT) and for rs3824968, 
rs2282649 and rs1010159 (ATC) were associated to higher hippocampal volumes on MRI. We did 
not find significant associations of single variants with plasma Aβ levels.
Variants near the 3’end of SORL1 are associated to hippocampal volume. Our findings need 
replication in larger cohorts.
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Materials and Methods
Study population
Brain imaging
around 60%, since no major genes have been identified yet, it is of interest to find genetic risk factors 
that influence the variability of these traits [21-25]. Previous studies have suggested overlap between 
genes affecting brain volumes and those affecting blood pressure [26], making it interesting to study 
genetic susceptibility in hypertensive patients.
In the current study, we focused on the sortilin-related receptor gene (SORL1), which is involved in 
the APP pathway. The SORL1 protein may act as a sorting receptor for APP [27,28] and variants 
in the SORL1 gene are associated to AD although the effect size is small and evidence is unstable 
[29-31]. We have recently found association of variants in SORL1 with cerebral microbleeds [32]. In 
addition to a role in APP processing, the SORL1 protein is related to low-density lipoprotein receptors 
and may be involved in atherosclerotic processes [33], which was also suggested by associations 
of variants in SORL1 with cerebrovascular disease and cerebral atrophy reported by a recent study 
[34]. The aim of the current study was to examine whether SORL1 was related to plasma Aβ levels 
and hippocampal atrophy on MRI. We studied this in a hypertensive subset of the Erasmus Rucphen 
Family (ERF) study, which is a family-based study in a genetically isolated population.
The study was embedded in a population-based study in a genetically isolated population in the 
Netherlands: the Erasmus Rucphen Family (ERF)-Study. Participants are all descendents of a limited 
number of founders living in the 19th century. Extensive genealogical data is available to the year 1600 
[35,36]. The current study was designed to find genetic risk factors for cerebral small vessel disease 
(CSVD). Considering hypertension as major risk factor for CSVD, we selected participants aged 55 
to 75 years with hypertension to ensure a high prevalence of pathology. Hypertension was defined 
as systolic blood pressure ≥160 and/or diastolic blood pressure ≥100 and/or use of antihypertensive 
medication. Persons with a history of stroke or dementia or with MRI-contraindications were excluded. 
A random subset of 261 was invited out of 330 individuals who were eligible for the study; 135 agreed 
to participate. The distribution of cardiovascular risk factors was similar among participants and non-
participants. There was a small difference in completed years of education, which was higher for 
participants who had a mean level of 7.5 years compared to 9 years in non-participants (p=0.02). All 
participants gave informed consent and the study was approved by the Medical Ethics Committee at 
Erasmus MC University Medical Center.
Brain imaging was done on a 1.5-T MRI scanner (Signa Excite II, General Electric Healthcare, 
Milwaukee, WI, USA) with use of a previously described protocol [37]. Volumes of the hippocampi, 
normal white matter (WM), white matter lesions (WML), grey matter (GM) and cerebrospinal fluid 
(CSF) were obtained by an automatic brain-tissue segmentation method which which was validated 
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Aβ measurements
Covariates
Genotyping
Non-fasting blood samples were obtained, which were immediately cooled on ice. From the samples 
plasma was extracted and stored at -80 ºC. Plasma Aβ concentrations were measured using a 
fluorimetric bead-based immunoassay using xMAP® technology (Innogenetics®). We obtained 
Aβ40, Aβ42, and the truncated forms Aβn40 and Aβn42. For analyses, we also used Aβ42/Aβ40 
ratio. In total, complete information was available for 128 individuals.
Body weight and height were measured in centimeters and the body-mass index (BMI) was calculated 
from these measurements. Blood was taken for estimation of levels of total cholesterol, high-
density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c) and creatinine 
in serum (Roche®). Glycosylated hemoglobin (HbA1c) was measured from full blood obtained in 
vacucontainers containing sodium citrate (Bio-Rad®) and analyzed using High-Performance Liquid 
Chromatography.
Genomic DNA was extracted from whole blood samples using the salting out method [40]. Samples 
were genotyped for APOE (rs429358, rs7412), and SORL1 (rs668387, rs689021, rs641120, 
rs1699102, rs3824968, rs2282649, rs1010159) with Taqman allelic discrimination Assays-By-Design 
(Applied Biosystems, Foster City, CA) [41].
The SNPs within SORL1 were chosen, because we considered them as the key SNPs from the 
original report [31].
previously [38,39]. The hippocampal formation included CA1 to CA4, the gyrus dentatus, and the 
subiculum. Volumes of the left and right hippocampus were measured with an automatic segmentation 
method based on intensity and regularity energy models. All samples were visually checked and 
when necessary manually segmented with specific software (http://www.bic.mni.mcgill.ca/software/) 
on coronal slides with continuous reference to all orientations. For analyses, the volumes of the left 
and right hippocampus were summed. To take into account differences in headsize, hippocampal 
volumes were analyzed as percentage of intracranial volume, which was defined as the total volume 
of WML, WM, GM and CSF. MRI-scans could not be acquired in 4 participants because of physical 
constraints and 2 persons were excluded from analyses (both had a large incidentally discovered 
brain tumor). 
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Descriptive characteristics of the study population  
N 128
Sex (% women) 52.3%
Age 64.6 (4.5)
BMI 29.2 (4.3)
HDL-c (mmol/L) 1.3 (0.3)
Creatinine (mol/L 73.0 (19.4)
HbA1c (%) 5.8 (0.6)
White matter lesion volume* 0.49 (0.56)
APOE E4 carriers (%) 39.1%
   
BMI: body-mass index, APOE: Apolipoprotein E gene.  
*percentage of intracranial volume 
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Statistical analyses
Results
Table 1
General descriptive statistics were estimated with one-way ANOVA and Chi-square statistics as 
implemented in the software SPSS (version 15.0). The observed frequencies of the genotypes were 
tested for deviations from Hardy-Weinberg equilibrium (HWE) by exact test. All genotypes were in 
HWE (p>0.05).
We first estimated whether plasma Aβ levels were associated to hippocampal volume on MRI with 
linear regression models. Second, to analyze the association of the genotypes with hippocampal 
volume and plasma Aβ levels, we performed the variable screening analysis under the polygenic model 
using the SOLAR software version 4.1.0 [42]. This software allows adjusting for family-relationships 
taking into account the pedigree structure. To reduce computational time, the large pedigree was 
cut into smaller subpedigrees of 18 bitsize before analysis [43]. One person could not be linked to 
these subpedigrees. The analyses in SOLAR were adjusted for age, sex and inbreeding coefficient, 
which was estimated from the genealogical data of the complete pedigree of the population using 
the software PEDIG [44]. The genotypes were entered in the model as a covariate with the reference 
genotype group coded as 0, the heterozygote genotypes coded as 1 and the other genotype group 
coded as 2. For APOE, 0 was used for the ε2/ε2, ε2/ε3 and ε3/ε3 genotypes, 1 for the ε2/ε4 and ε3/
ε4 genotypes and 2 for the ε4/ε4 genotype. 
Haplotypes for SORL1 were derived with the software package SimWalk2 [45]. Haplotypes with a 
frequency >5% were implemented as binary factors in the models and analyzed in SOLAR. To adjust 
for multiple testing we used Bonferroni correction adjusting for 7 independent tests.
Baseline characteristics of the study population are shown in Table 1. The mean age was 64.6 years 
and there were slightly more women than men. Hippocampal volume was not significantly associated 
to plasma levels of Aβ.
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Figure 1
  Regional plots depicting the associations of SORL1 with hippocampal volume (first) and Aβ levels (second)
  The x-axis depicts the physical position on the chromosome (kb); the y-axis depicts the minus log p-values.
The SORL1 gene was significantly associated with hippocampal volume (Table 2). Single SNP 
analyses showed that subjects with the minor genotype of 3 SNPs located near the 3’-end of SORL1 
had significantly higher hippocampal volumes than subjects with the major genotype (Figure). 
Additional adjustment for the APOE genotype resulted in greater effect size and more significant 
p-values for these associations. 
Haplotype analyses revealed significant associations of the 3-SNP haplotypes for rs1699102, 
rs3824968 and rs2282649 (CAT) and for rs3824968, rs2282649 and rs1010159 (ATC) with higher 
hippocampal volumes (Table 3). These haplotypes were the second most frequent in our population 
(18.5% and 19.3% respectively). The p-value of the CAT-haplotype remained significant after 
adjustment for multiple testing. Additional adjustment for APOE genotype did not change these results. 
The haplotypes consisting of the 3 SNPs located at the 5’-end of SORL1 (rs668387, rs689021 and 
rs641120) were not significantly associated. 
The SORL1 SNPs were not significantly associated with plasma Aβ levels (Table 4 and Figure). The 
results were similar when adjusting these analyses additionally for creatinine, high-density lipoprotein, 
HbA1c, BMI and white matter lesion volume (data not shown).
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Association of SORL1 with hippocampal volume  
Gene variant Genotype Hippocampal volume‡
N Mean (SD) P1 P2
SORL1 rs668387 CC 36 CC 0.52 (0.03) 0.55 0.58
CT 60 CT 0.53 (0.06)
TT 31 TT 0.51 (0.06)
SORL1 rs689021 GG 34 GG 0.51 (0.05) 0.80 0.83
AG 62 AG 0.53 (0.05)
AA 31 AA 0.51 (0.06)
SORL1 rs641120 CC 36 CC 0.51 (0.05) 0.73 0.76
CT 60 CT 0.53 (0.05)
TT 31 TT 0.51 (0.06)
SORL1 rs1699102 TT 55 TT 0.51 (0.05) 0.01 0.01
CT 55 CT 0.52 (0.05)
CC 17 CC 0.54 (0.06)
SORL1 rs3824968 TT 59 TT 0.51 (0.05) 0.04 0.03
AT 53 AT 0.52 (0.06)
AA 15 AA 0.55 (0.03)
SORL1 rs2282649 CC 63 CC 0.51 (0.05) 0.03 0.02
CT 49 CT 0.52 (0.06)
TT 15 TT 0.55 (0.03)
SORL1 rs1010159 TT 51 TT 0.51 (0.04) 0.10 0.07
CT 56 CT 0.52 (0.07)
CC 20 CC 0.54 (0.04)
       
 P1: p-value adjusted for age, sex and family-relationship. P2: P1 additionally adjusted  for APOE genotype.  
 ‡ percentage of intracranial volume 
3
Association SORL1 haplotypes gene with hippocampal volume‡  
SNPs Haplotype Frequency P* Effect P**
% (N)    
rs668387- rs689021- rs641120 CGC 37.8 (96) 0.61 - 0.63
CAT 33.5 (85) 0.90 +
TAT 7.9 (20) 0.53 +
TGC 7.5 (15) 0.73 +
      
rs1699102-rs3824968- rs2282649 TTC 53.5 (136) 0.21 - 0.16
CAT 18.5 (47) 0.005 +
CAC 6.3 (16) 0.43 -
CTT 5.1 (13) 0.60 +
CTC 5.1 (13) 0.58 -
      
rs3824968- rs2282649- rs1010159 TCT 50.4 (128) 0.10 - 0.25
ATC 19.3 (49) 0.05 +
TCC 8.3 (21) 0.53 +
TTC 5.9 (15) 0.60 +
ACT 5.9 (15) 0.74 +
      
 P: p-value adjusted for age, sex and family-relationship. ‡ percentage of intracranial volume. *p-value for haplotype; **p-value 
for region. Effect: direction of effect. The + sign refers to increased hippocampal volumes and the – sign to decreased 
hippocampal volumes. 
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Association of SORL1 with plasma A levels 
Gene variant Genotype A40 (pg/mL) A42 (pg/mL) An40 (pg/mL) An42 (pg/mL) A42/Ab40
N Mean (SD) P N Mean (SD) P N Mean (SD) P N Mean (SD) P N Mean (SD) P
SORL1 rs668387 CC 34 172.24 (43.60) 0.94 35 39.15 (14.75) 0.77 35 168.74 (39.21) 0.64 33 27.33 (6.14) 0.71 34 0.24 (0.08) 0.46
CT 61 182.59 (43.07) 61 41.83 (11.97) 61 178.48 (40.71) 56 28.78 (7.80) 61 0.24 (0.07)
TT 31 175.15 (27.93) 31 43.11 (14.74) 31 174.31 (29.25) 30 26.76 (4.82) 31 0.25 (0.07)
SORL1 rs689021 GG 32 175.12 (39.07) 0.85 33 41.59 (16.27) 0.65 33 175.63 (30.76) 0.59 33 28.13 (6.03) 0.43 32 0.25 (0.07) 0.99
AG 63 182.50 (43.91) 63 41.33 (12.12) 63 176.95 (43.34) 57 28.43 (7.81) 63 0.24 (0.08)
AA 31 171.71 (31.88) 31 41.36 (13.17) 31 169.46 (32.43) 29 26.46 (4.86) 31 0.24 (0.06)
SORL1 rs641120 CC 34 173.53 (40.92) 0.94 35 41.11 (16.33) 0.75 35 172.47 (36.82) 0.69 34 27.90 (6.09) 0.53 34 0.25 (0.09) 0.97
CT 61 183.62 (42.92) 61 41.60 (11.91) 61 178.81 (40.79) 56 28.58 (7.80) 61 0.23 (0.07)
TT 31 171.71 (31.88) 31 41.36 (13.17) 31 169.46 (32.43) 29 26.46 (4.86) 31 0.24 (0.06)
SORL1 rs1699102 TT 55 174.53 (40.52) 0.44 56 41.69 (14.38) 0.22 56 169.50 (38.34) 0.76 53 28.64 (6.72) 0.45 55 0.25 (0.07) 0.21
CT 54 184.19 (37.86) 54 41.83 (13.40) 54 183.52 (37.21) 50 27.16 (6.45) 54 0.23 (0.09)
CC 17 169.34 (44.34) 17 39.13 (10.59) 17 164.42 (33.31) 16 27.51 (7.63) 17 0.24 (0.04)
SORL1 rs3824968 TT 59 173.28 (40.10) 0.21 60 41.86 (14.24) 0.30 60 169.84 (38.12) 0.55 57 28.50 (6.47) 0.44 59 0.25 (0.06) 0.12
AT 53 184.54 (38.27) 53 41.33 (13.27) 53 182.39 (37.24) 49 27.22 (6.69) 53 0.23 (0.09)
AA 14 172.81 (45.37) 14 39.76 (11.17) 14 167.16 (35.40) 13 27.55 (8.07) 14 0.24 (0.04)
SORL1 rs2282649 CC 63 175.97 (42.13) 0.35 64 41.63 (14.10) 0.36 64 173.09 (38.96) 0.89 60 28.39 (6.38) 0.50 63 0.25 (0.07) 0.21
CT 49 182.01 (35.91) 49 41.58 (13.38) 49 179.16 (36.98) 46 27.27 (6.84) 49 0.23 (0.09)
TT 14 172.81 (45.37) 14 39.76 (11.17) 14 167.16 (35.40) 13 27.55 (8.07) 15 0.24 (0.04)
SORL1 rs1010159 TT 52 175.92 (43.42) 0.55 52 41.75 (12.71) 0.27 52 170.69 (39.69) 0.95 48 27.88 (6.70) 0.90 52 0.24 (0.07) 0.31
CT 56 181.93 (36.84) 56 42.55 (14.05) 56 181.60 (37.46) 53 27.94 (6.70) 56 0.24 (0.09)
CC 18 171.57 (40.20) 19 37.09 (13.46) 19 165.87 (30.75) 18 27.61 (7.17) 18 0.23 (0.04)
                 
 P: p-value adjusted for age, sex and family-relationship. SD: standard deviation
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Discussion
The present study shows that variants in SORL1 are associated to hippocampal volume with a 
protective effect of the AT-haplotype consisting of rs3824968 and rs2282649. This is in line with the 
results of a previous study  reporting associations of SORL1 with cerebrovascular disease and brain 
atrophy [34]. Although not significant in our study, Cuenco et al. also found that lower hippocampal 
volumes were associated with the TC-haplotypes of these SNPs. Since neuronal loss in AD can be 
seen as hippocampal atrophy on MRI, these SORL1 variants may exert their effect on the processing 
of APP [46,47], however, the cross-sectional design of the current study limits the interpretation of 
underlying pathophysiological mechanisms. The haplotypes constructed from the SNPs at the 5’-end 
of SORL1 were not significantly associated to hippocampal volume, but the direction of effect was 
similar to the direction seen in AD, in which the CGC-haplotype was associated to an increased risk 
and the TAT-haplotype to a decreased risk of AD [31]. The opposite effects of these haplotypes on the 
risk of cerebrovascular disease that were found in a previous study [34] may suggest that one of the 
functional domains in SORL1 could be involved in the cholesterol pathway and the other in the APP 
processing pathway [48]. This may explain the heterogeneous findings in AD and MRI-traits (http://
www.Alzgene.org) [30,34]. 
Our study did not find an association of SORL1 with plasma Aβ. One explanation could be that plasma 
Aβ, although linked to brain Aβ may not accurately reflect brain Aβ pathology. Studies measuring 
Aβ levels in CSF or postmortem studies may provide more accurate measurements of brain Aβ 
pathology. Also, the effect of SORL1 on AD pathology may be contributable to other mechanisms in 
the APP-pathway than Aβ generation. Plasma Aβ may be an indicator of vascular damage, rather 
than neurodegeneration, since it has been associated to white matter lesions and cerebral small 
vessel disease [49,50]. Increased levels of plasma Aβ could be a cause of microvascular damage, 
but could also be a consequence if damage to small vessels results in leakage of Aβ from the brain to 
the circulation. The effect of SORL1 on CSF Aβ levels warrants further study and may elucidate the 
role of SORL1 and Aβ in cerebrovascular and neurodegenerative disease processes. 
Our observation of a strong association of SORL1 with hippocampal volume in hypertensive patients 
may reflect a possible interaction of SORL1 with hypertension, which is also supported by previous 
findings of a stronger effect of SORL1 with AD in patients with cerebrovascular disease [34].The 
pathophysiology of AD is likely multifactorial with vascular as well as neurodegenerative factors 
influencing the disease process [51]. Both cerebrovascular disease and hippocampal atrophy 
are associated with an increased risk of dementia and cognitive dysfunction [52-55]. This may be 
due to interaction between vascular and neurodegenerative processes in their effect on dementia 
[56], as has been demonstrated by increased white matter lesion volumes in patients with greater 
hippocampal atrophy [57]. 
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The strength of our study is that it was performed in a homogenous group of middle-aged individuals 
with hypertension derived from a genetically isolated population, which increases statistical power 
of genetic association studies. The size of the study is limited, however, and allows mainly detecting 
genetic variants with large effects. A question that remains to be answered in larger populations is 
whether hypertension interacts with SORL1.
To summarize, variants near the 3’end of SORL1 are associated to hippocampal volume on MRI. Our 
findings need replication in larger cohorts.
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The renin-angiotensin system (RAS) has been implicated in Alzheimer’s disease (AD) and degradation 
of amyloid beta (Aβ). Genetic studies focused on the angiotensin converting enzyme gene (ACE). 
Less is known for the other genes implicated in the RAS system. We studied the association of three 
commonly studied genetic variants with circulating Aβ. 
Alzheimer’s disease (AD) is characterized by neuritic plaques of which amyloid beta (Aβ) is the main 
component [1-3]. Aβ is present in full-length species (Aβ40 and Aβ42) and in shorter amino-terminal 
truncated species (Aβn40 and Aβn42). The latter concerns proteins which may predominantly be 
spliced to pathogenic forms and account for 60% of all Aβ species in pre-clinical AD stages [4]. 
Aβ pathology is also found in brains of cognitively healthy elderly at postmortem examination and 
visualized during life using PET studies [5,6]. The deposition and clearance of Aβ in the brain is 
related to Aβ levels in plasma, but the mechanism is not fully understood  [7]. 
The renin-angiotensin system (RAS) is mainly involved in the regulation of blood pressure and salt 
homeostasis, but has also been implicated AD [8]. In AD brains, RAS is activated [9] and receptors for 
angiotensin II are present in brain tissue [10]. The gene encoding the angiotensin converting enzyme 
(ACE), is one of the most studied genes involved in the RAS system and has consistently been 
associated with AD [11,12]. There is experimental evidence for a role of ACE in the degradation of 
The study was embedded in a family-based cohort sampled from a Dutch genetically isolated 
population. We selected individuals between 55 and 75 years of age with hypertension (N=128). Non-
fasting blood sample were taken to assess plasma Aβ levels using xMAP® technology. We studied 
the effect of 3 variants within the angiotensin, angiotensin II type 1 receptor and adducin genes (AGT-
M235T, AGTR1-C573T and ADD1-Gly460Trp) that were previously reported in cerebrovascular and 
cardiovascular disease. 
The AGT-M235T TT-genotype was significantly associated with higher levels of plasma Aβ42 
(p=0.008) and truncated Aβn42 (p=0.02). The association to Aβ42 remained significant after 
adjusting for potential confounders and multiple testing. Persons with the variant genotype of ADD1-
Gly460Trp tended to have lower levels of Aβn40 than persons with the wild type genotype (p=0.02), 
but this association did not remain significant after adjustment for confounders and multiple testing. 
No associations were found between plasma Aβ and AGTR1-C573T.
Our study shows that the AGT-M235T polymorphism is associated to plasma Aβ levels in hypertensive 
patients. 
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Materials and Methods
Study population
amyloid beta (Aβ) in the brain [13,14] and inhibition of ACE activity results in increased Aβ deposition 
in the brain [15].  
Far less is known for the other genes implicated in the RAS system in relation to AD pathology. 
The main other genes that have been studied are the angiotensin (AGT) and angiotensin II type 
1 receptor (AGTR1) genes. These genes play a role in RAS by affecting the protein translation 
[16,17] and specific polymorphisms (AGT-M235T and AGTR1-C573T) have been associated to 
increased risk of cardiovascular and cerebrovascular disease [18-23]. Another gene that could be 
of interest given its strong link to RAS is the alfa-adducin gene (ADD1). ADD1 has been associated 
to increased renal sodium uptake [24]. Alfa-adducin is highly expressed in brain regions, including 
the hippocampus [25]. Different expression of the adducin subunits (α, β and γ) has been related 
to impaired learning, impaired motor function and synaptic plasticity in the hippocampus of mice 
[26]. We have previously shown a relationship of the ADD1-Gly460Trp variant and ischemic brain 
changes, mainly in hypertensive patients [27]. The reason why RAS genes interact with hypertension 
is far from clear. Hypertension early in life has been associated to AD at old age [28,29]. This may 
suggest that hypertensive patients are at increased risk of early AD pathology, despite the fact that 
they do not show symptoms of AD or cognitive decline[30]. Early amyloid pathology, however, may 
induce increased levels of Aβ in the blood.
To follow-up our work and that of others on the role of RAS genes other than ACE in Aβ pathology, 
we conducted a study relating these genes to plasma Aβ levels in individuals with hypertension. In 
the current study, we were interested in the role of Aβ to genes that we earlier implicated in MRI 
pathology: AGT-M235T, AGTR1-C573T and ADD1-Gly460Trp. We studied the association of these 
variants with plasma Aβ levels in individuals with hypertension from the Erasmus Rucphen Family 
(ERF) study, which is a family-based study in a genetically isolated population. 
The study was conducted in a family-based study in a genetically isolated population in the 
Netherlands: the Erasmus Rucphen Family (ERF) study. Participants are all descendents of a limited 
number of founders and extensive genealogical data is available [31,32]. The current study was 
designed to find genetic risk factors for cerebral small vessel disease and included participants 
aged 55 to 75 years with hypertension. Hypertension was defined as systolic blood pressure ≥160 
and/or diastolic blood pressure ≥100 and/or use of antihypertensive medication. Persons with a 
history of stroke or dementia or with MRI-contraindications were excluded. Two-hundred sixty one 
persons were invited; 135 agreed to participate. The distribution of cardiovascular risk factors was 
similar among participants and non-participants. There was a small difference in completed years of 
education, which was higher for participants who had a mean level of 7.5 years compared to 9 years 
in non-participants (p=0.02). All participants gave informed consent and the study was approved by 
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Aβ measurements
Covariates
Genotyping
Statistical analyses
Non-fasting blood samples were obtained during the visit at the research center, following standardized 
protocols. Samples were immediately cooled on ice. Plasma was extracted within the same day 
and stored at -80 ºC. Plasma Aβ concentrations were measured using a fluorimetric bead-based 
immunoassay using xMAP® technology (Innogenetics®) using the manufacturers protocols. We 
obtained Aβ40, Aβ42, and the truncated forms Aβn40 and Aβn42. For analyses, we also used Aβ42/
Aβ40 ratio.
We evaluated the association of Aβ levels to covariates that were reported in earlier studies [33,34]. 
Body weight (kilograms) and height (centimeters) were measured and the body-mass index (BMI) 
was calculated from these measurements. Blood pressure was measured twice in sitting position 
by one physician using a sphygmomanometer. Blood was taken for the assessment of levels of 
high-density lipoprotein cholesterol (HDL-c) and creatinine in serum (Roche®) [35]. Glycosylated 
hemoglobin (HbA1c) was measured from full blood obtained in vacucontainers containing sodium 
citrate (Bio-Rad®) and analyzed using High-Performance Liquid Chromatography.
Genomic DNA was extracted from whole blood samples using the salting out method [36]. Samples 
were genotyped for ADD1-Gly460Trp, AGT-M235T, AGTR1-C573T, with Taqman allelic discrimination 
Assays-By-Design (Applied Biosystems, Foster City, CA) [19,27]. Samples were also genotyped for 
Apolipoprotein E (APOE) (rs429358, rs7412) to assess ε4 carrier status. In total, complete information 
was available for 128 individuals.
The observed frequencies of the genotypes were tested for deviations from Hardy-Weinberg 
equilibrium using the exact test for multiple alleles [37]. For all genetic variants, the allele and 
genotype distribution were in Hardy-Weinberg equilibrium (p>0.05).
General descriptive statistics were estimated with one-way ANOVA and Chi-square statistics 
as implemented in the software SPSS (version 15.0). Correlation coefficients between Aβ levels 
and covariates were assessed using SPSS. To analyze the association of the genotypes with and 
plasma Aβ levels, we performed the variable screening analysis under the polygenic model using 
the SOLAR software version 4.1.0 [38]. This software allows adjusting for family-relationships taking 
into account the pedigree structure. To reduce computational time, the large pedigree was cut into 
smaller subpedigrees of 18 bitsize before analysis [39]. One person could not be linked to these 
the Medical Ethics Committee at Erasmus MC University Medical Centre.
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1
Descriptive characteristics of the study population  
N 128
Sex (% women) 52.3%
Age 64.6 (4.5)
BMI 29.2 (4.3)
HbA1c (%) 5.8 (0.6)
Creatinine (mol/L 73.0 (19.4)
HDL-c (mmol/L) 1.3 (0.3)
APOE 4 39.1%
   
BMI: body-mass index. SBP: systolic blood pressure; DBP:  
diastolic blood pressure; HbA1c: Glycosylated hemoglobin;  
HDL-c: high-density lipoprotein cholesterol;  
APOE 4: carriers of the apolipoprotein 4 allele.  
Values represent percentages or mean (standard deviation).
2
Correlation between plasma A levels and covariates 
 A40  An40 A42  An42 A42/A40 Sex Age BMI HbA1C Creat HDL-C 
(mmol/L)
APOE
A40 1 0.77*** 0.40*** 0.23** -0.38*** 0.01 -0.02 0.24* 0.05 0.08 -0.18* 0.13
An40 1 0.32*** 0.38*** -0.31*** 0.05 -0.01 0.20 0.16 0.15 -0.18* 0.10
A42 1 0.35*** 0.66*** -0.14 -0.01 0.10 0.12 0.04 0.04 -0.13
An42    1 0.22** -0.09 -0.02 0.04 0.05 0.10 0.03 -0.10
A42/A40     1 -0.22* 0.04 -0.11 0.07 0.02 0.19* -0.21*
Significant correlations are depicted in bold. Significant correlations are depicted in bold. * p<0.05; ** p<0.01; ***p<0.001. 
BMI: body-mass index; HbA1c: Glycosylated hemoglobin; Creat: Creatinine; HDL-c: high-density lipoprotein cholesterol;  
LDL-c: high-density lipoprotein cholesterol; APOE: Apolipoprotein E gene defined as having 0, 1 or 2 copies of the 4 allele. 
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Table 1
Table 2
subpedigrees, therefore we could analyze 128 persons. The analyses in SOLAR were adjusted for 
age, sex and inbreeding coefficient, which was estimated from the genealogical data of the complete 
pedigree of the population using the software PEDIG [40]. In a second model, we adjusted additionally 
for creatinine, HDL-c, HbA1c and BMI. The genotypes were entered in the model as a covariate with 
the reference genotype group coded as 0, the heterozygote genotypes coded as 1 and the rare 
homogeneous genotype group coded as 2. 
Table 1 shows the baseline characteristics of the study population. The mean age was 64.6 years 
and 52.3% were women. Correlations between the different Aβ measurements and covariates are 
given in Table 2. Of the covariates, sex and HDL-c were significantly associated to the Aβ42/Aβ40 
ratio. HDL-c and BMI were related to Aβ40 and Aβn40. APOE was correlated to the Aβ42/Aβ40 ratio 
(R=-0.21; p=0.03), but not to single Aβ measurements. As expected, the different Aβ proteins were 
highly correlated (all p-values <10-5) and there was a strong correlation between Aβ42 and the Aβ42/
Aβ40 ratio (R=0.66; p=3.03*10-17). 
Table 3 shows mean Aβ levels per genotype group for each gene. AGT-235T was significantly 
associated with higher levels of Aβ42 (p=0.008) and Aβn42 (p=0.02). Individuals with the MM-
genotype had mean Aβ42 plasma levels of 39.3 pg/mL compared to 48.0 pg/mL in individuals with 
the TT-genotype. For Aβn42 levels, a mean of 25.9 pg/mL was seen in individuals with the MM 
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Association of AGT, AGTR1, and ADD1 plasma abeta levels 
Gene Genotype A40 A42 An40 An42 A42/A40 
N Mean (SD) P N Mean (SD) P N Mean (SD) P N Mean (SD) P N Mean (SD) P
AGT MM 40 179.0 (36.7) 0.57 41 39.3 (14.2) 0.008 41 176.6 (31.8) 0.98 39 25.9 (5.9) 0.02 40 0.23 (0.08) 0.15
MT 63 171.6 (35.6) 63 40.4 (11.7) 63 169.9 (37.5) 58 28.3 (6.1) 63 0.24 (0.07)
TT 23 193.6 (52.6) 23 48.1 (14.9) 23 185.0 (46.7) 22 30.2 (8.7) 23 0.25 (0.07)
                 
AGTR1 TT 32 182.9 (35.3) 0.17 33 40.2 (15.1) 0.82 33 174.8 (29.8) 0.99 30 29.3 (6.1) 0.15 32 0.23 (0.08) 0.18
CT 52 184.4 (42.2) 52 41.9 (13.4) 52 178.7 (41.3) 50 27.6 (6.8) 52 0.23 (0.06)
CC 42 166.3 (39.0) 42 41.7 (12.4) 42 169.9 (39.4) 39 27.2 (7.1) 42 0.26 (0.08)
                 
ADD1 GG 81 182.9 (41.7) 0.06 82 42.1 (14.2) 0.64 82 179.8 (38.3) 0.06 78 28.4 (6.8) 0.31 81 0.24 (0.08) 0.49 
GT/TT 45 169.1 (35.4) 45 40.1 (11.9) 45 165.6 (35.3) 41 26.9 (6.5) 45 0.24 (0.06)
                 
 P: p-value adjusted for age, sex and family-relationship. Values are in pg/mL. 
: reference genotype; : heterozygote; x: homozygote
AGT
-40
-30
-20
-10
0
10
20
30
40
A
Ab40 Ab42 Abn40 Abn42
 MM  MT x TT
AGTR1
-40
-30
-20
-10
0
10
20
30
40
B
Ab40 Ab42 Abn40 Abn42
 TT  CT x CC
ADD1
-40
-30
-20
-10
0
10
20
30
40
C
Ab40 Ab42 Abn40 Abn42
 GG  GT / TT
Table 3
  Associations of AGT, AGTR1, and ADD1 with plasma Aβ levels, adjusted for covariates
  Genotypes for AGT-M235T (A), AGTR1-C573T (B) and ADD1-Gly460Trp (C) are depicted on the x-axis. Values on the y-axis represent the 
  differences in the mean plasma Aβ levels compared to the reference genotype with 95% confidence intervals. The differences were adjusted
  for age, sex, family-relationship, creatinine, high-density lipoprotein cholesterol, glycosylated hemoglobin and body mass index.
Figure 1
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Discussion
genotype and 30.2 pg/mL in those with the TT-genotype. ADD1 was associated with Aβn40 (p=0.02). 
Individuals with the GT/TT genotype had significantly lower levels of Aβn40 (165.6 pg/mL) than 
persons with the GG genotype (179.8 pg/mL). No significant association was seen to the Aβ42/Aβ40 
ratio for any of the genes.
The Figure shows the differences in the mean Aβ levels compared to the reference genotype, 
adjusting for additional covariates. The findings remained significant for the relation of AGT with Aβ42 
and Aβn42. Regarding the Aβ40 levels and the Aβ42/Aβ40 ratio there was no significant trend (A). 
After adjusting, no association was seen between AGTR1 and plasma Aβ (B) and the association of 
ADD1 with Aβn40 became borderline significant (p-value 0.06) (C). 
The present study shows that individuals with the AGT-M235T TT-genotype have significantly higher levels 
of plasma Aβ42 and Aβn42. There was also some evidence, although not significant after adjusting, that 
individuals with GT/TT genotypes of the ADD1-Gly460Trp variant have lower levels of Aβn40, but there was 
no association between AGTR1 and Aβ. APOE was correlated to a lower Aβ42/Aβ40 ratio.
Before interpreting the findings, a few methodological issues need to be addressed. First, we did not do a 
formal Bonferroni correction of the threshold p-value, because the Aβ outcomes were all related (Table 
2). Correcting the p-value for the number of association analyses (Table 3; N=15) would therefore 
have been a too conservative approach. Alternatively, when using for example the 3 genes and 2 Aβ 
outcomes (Aβ40 and Aβ42), the p-value observed for AGT would be below the 0.0083 threshold that 
is then obtained. 
Second, the sample size of the current population was relatively small. In this respect our finding 
that APOE was correlated to a lower Aβ42/Aβ40 ratio is important, serving as a proof of principle. 
However, also the allele distributions are important when considering the power of the study. Because 
some genotypes were less frequent than APOE ε4, the small sample size may explain that the 
major differences in mean Aβ levels between the genotype groups of AGTR1 and ADD1 that were 
observed were not significant. For example, large differences in the mean Aβ40 levels were observed 
for AGT and ADD1 (Figure 1) and for ADD1 large differences were observed for Aβn40, but none 
of the differences reached significance. Because these relationships do have biological plausibility, 
replication of our findings in larger datasets is warranted.
It is also important to realize that the associations of plasma Aβ levels with dementia have been 
inconsistent. Increased risk has been reported for high plasma levels of both Aβ40 and Aβ42, but also 
decreased risk for high levels of Aβ42 have been found [33,34,41-45]. An increased risk with higher 
levels of plasma Aβ42 has also been reported for cognitive decline [43]. One of the explanations 
for these discrepancies may be that plasma Aβ levels increase with aging, but not necessarily with 
disease progression [44]. It is thought that with disease progression Aβ42 is increasingly deposited 
in the brain and levels are consequently lower in plasma. In a young population with an increased 
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risk of AD pathology like ours, higher levels of Aβ42 could then be expected in persons carrying 
risk genotypes. The age of the study population and timing of Aβ measurements may be important 
contributors to the inconsistencies in literature. 
From a biological perspective it is of interest that we found higher levels of plasma Aβ42 in persons 
with the TT-genotype of AGT-M235T. This genotype was previously described to increase the risk 
of cerebrovascular small vessel disease [23]. Previous studies have also reported a role in large 
vessel disease, but a recent meta-analysis did not confirm these findings [46]. This may imply that 
AGT exerts its effects via an independent brain RAS system [47] and not through increased levels of 
AGT II affecting atherogenic processes [48]. Not many groups have studied this gene in relation to 
dementia, and the findings are not convincing [49,50] with possibly an increased risk in patients with 
the AGT-M235T TT-genotype [51]. The RAS proteins have been implicated in AD pathology, because 
receptors for angiotensin II are present in brain tissue and RAS is activated in AD brains [9,10]. Along 
with cerebrovascular effects, RAS could thus have a direct effect on brain pathology and possibly on 
Aβ. Indirect evidence is given by the association of ACE, another gene involved in this system, with 
AD [11,12] and the role of ACE in the degradation of Aβ in the brain [13,14]. It has been shown that 
inhibition of  ACE activity results in increased Aβ deposition in the brain [15]. Like RAS, alfa-adducin 
also plays a role in the brain [25,26]. Our results are suggestive for an association of the variant allele 
of ADD1-Gly460Trp to lower levels of Aβ40, but these findings should be interpreted with caution as 
they were not significant when adjusting for multiple testing using Bonferroni correction. Whereas it 
is an interesting candidate for AD pathology [26], the evidence was found in animal studies and no 
human studies have been conducted to our knowledge. The role of ADD1 in AD amyloid pathology is 
not known and as mentioned, inconsistent associations have been reported between plasma Aβ40 
and dementia. Our findings therefore warrant further study. 
Alternative explanations of our findings are possible. Aβ may have a direct effect on brain vasculature 
and vascular damage may have contributed to our findings, since the studied variants are all 
implicated in atherogenic effects [52]. Associations have been reported for Aβ with cerebral small 
vessel disease [53,54] and vascular dysfunction has been suggested in AD pathology [55]. On the 
other hand, damage to cerebral small vessels due to other processes may result in leakage of Aβ 
causing higher levels of circulating Aβ. We found moderate correlations between plasma Aβ and 
cardiovascular factors, which have been shown to be highly correlated to cerebral small vessel 
disease, and adjusting for these factors did not affect our main finding. The studied variants and Aβ 
are also both correlated to renal function, however, adjusting for creatinine as a measure for kidney 
function did not alter our findings.
The strength of our study is the family-based design, performed in a homogenous group of middle-
aged individuals with hypertension derived from a genetically isolated population, which increases 
statistical power of genetic association studies. The size of the study is limited, however, which 
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increases the chance of false-positive and -negative findings. In sum, we found a consistent 
association of the AGT-M235T TT-genotype to plasma Aβ42 and Aβn42. A question that remains to 
be answered in longitudinal data is the role of AGT and ADD1 in midlife plasma Aβ levels and the 
effect of changing Aβ levels on AD pathology. 
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In this thesis I describe my research on genetic determinants of cognitive function and age-related 
brain changes. I have used outcomes that are highly heritable as endophenotypes for my studies of 
Alzheimer’s disease, including cognitive function, Aβ plasma levels and age-related brain changes 
as visible on magnetic resonance imaging (MRI). Different study-designs were chosen to investigate 
our research questions including candidate gene studies, genome wide linkage analysis and genome 
wide association studies. In the following chapter, I will discuss the main findings of this thesis.
One of the most extensively studied candidate gene in Alzheimer’s disease is the apolipoprotein E 
gene (APOE) [1-3]. The ε4 allele of this gene is a well-established determinant of AD with a large effect 
on disease risk. Based on the hypothesis that cognitive function may be a relevant endophenotype 
for AD, we studied the relation between APOE and cognitive function in chapter 3. We found that the 
APOE*ε4 allele was significantly associated with lower test scores on the Adult Verbal Learning Test 
in individuals older than 50 years of age. This effect of APOE*ε4 was independent of the effect of 
APOE*ε4 on vascular risk factors and most pronounced on learning ability. Similar to the findings of 
others [4], we found that the APOE*ε4 allele has an effect on cognitive function, but that in contrast to 
AD the effect is relatively small. We focused our gene discovery studies on cognitive function, since 
this outcome showed the most consistent association to APOE [4] and may therefore be the most 
promising endophenotype.
To explore new susceptibility regions for cognitive functioning without prior assumptions of pathways 
involved, we conducted a hypothesis-free genome-wide search on a range of cognitive tests. In 
chapter 4 we present the findings of a non-parametric linkage analyses in the Erasmus Rucphen 
Family (ERF) Study, which is a family-based study in a genetically isolated population. Since we 
were targeting genes with a major effect, we selected individuals from the lower extremes of the 
trait distribution for the linkage analysis. Thresholds for significant and suggestive linkage were 
estimated by a simulation study. Significant linkage (LOD > 3.78) to cognitive functioning was found 
on chromosomes 1p13.1, 12q24.33, 19q13.43, 20p13, 21q22.13 and 21q22.3. For the fine-mapping 
of the region, we used dense genotyping in the regions under the linkage peak in ERF and replicated 
these findings in a large outbred, population-based cohort, the Rotterdam Study (RS) [5]. Fine-
mapping showed significant associations to chromosome 1 (p-value=0.03) and 21 (p-value=0.01) 
after correction for multiple testing, and association with the latter region on 21q22.13 was replicated 
in the Rotterdam Study (nominal p-value 0.003). Both fine-mapping and replication pointed to variants 
within the potassium inwardly-rectifying channel, subfamily J, member 6 gene (KCNJ6). 
Whereas linkage analysis in the extremes of the distribution specifically targets variants with larger 
effects, we conducted a genome-wide association study of cognitive function as a continuous outcome 
in search of common variants with small effects. In chapter 5 we describe a meta-analysis of different 
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genome-wide association studies performed in the Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE) consortium. This consortium includes large prospective population-based 
cohorts. Neuropsychological testing was available for 13 cohorts. In this thesis, we focussed on 
executive function and processing speed tasks including the Trail Making Test (TMT) parts A and B 
and the Stroop Color and Word Test in the analyses. All individual studies used their genotyped data 
to impute to 2.5 million single nucleotide polymorphisms (SNPs). The analyses were performed in 
Caucasians older than 45 years who were free of dementia and clinical stroke at times of cognitive 
testing. The most significant finding was found with TMT-B and a SNP on chromosome 18. This 
SNP was just above the genome-wide significant threshold with a p-value of 6.95*10-8 and located 
between two plausible candidate genes. We further conducted an exploratory analysis in which we 
searched for overlap between our findings and the genome-wide association analyses published 
for AD and schizophrenia. Overlap with previous genome-wide association studies was found for 
multiple other SNPs with a p-value smaller than 1.0*10-3, of which the sortilin-related-receptor-1 
(SORL1), the syntaxin-binding-protein-6 (STXBP6) and the protocadherin-9 (PCDH9) genes are the 
most interesting genes. The genes in the regions that we identified in this study may provide further 
insights into the pathways involved in the normal variation of cognition. Our findings, however, await 
replication, which is currently ongoing. 
A preliminary comparison between the findings of the genome-wide linkage and association analysis 
suggests no overlap in genes, which may be expected in light of the mechanisms underlying the 
methods. Linkage is designed to target rare variants with large effects and association on the other 
hand is designed to find common variants with moderate effects. 
Of interest is also that we did not find evidence for a role of APOE, or the recently discovered AD 
genes, PICALM, CRI and CLU [11,12] in cognitive function in our genome-wide association analyses. 
This finding reveals, again as expected, that findings on endophenotypes cannot be translated 1:1 
to the disease of interest. Another issue to realize is that tests assess different aspects of cognitive 
function. Indeed we found that APOE was associated to the Adult Verbal Learning Test in chapter 3 
but non-significantly to TMT-A, B or Stroop. 
Having studied cognitive function as endophenotype, we further studied age-related brain changes as 
a second group of endophenotypes. We considered plasma Aβ levels as biomarkers for the presence 
of senile plaques and amyloid angiopathy, and asymptomatic brain lesions on MRI as age-related 
brain changes. We have focused on lacunar infarcts, white matter lesions (WML), microbleeds and 
hippocampal atrophy. All are associated with hypertension, stroke, dementia and cognitive impairment 
[13-18], and are also found in healthy elderly. 
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We examined the role of candidate genes involved in blood pressure regulation and in amyloid 
metabolism. We studied APOE, the renin-angiotensin system (RAS) related genes (Angiotensin, 
Angiotensin II type 1 Receptor, alpha-Adducin) and the sortilin-related receptor (SORL1) gene.
RAS genes are involved in the regulation of blood pressure and salt homeostasis and the RAS proteins 
have also been implicated in Alzheimer’s disease [19]. Receptors for angiotensin II are present in 
brain tissue [20] and an increased activation of RAS is seen in AD brains [21]. As already mentioned, 
APOE has consistently been associated with AD and there is increasing evidence that also SORL1 
is associated with AD [4,22,23]. SORL1 consists of two functional regions, one functioning in the 
cholesterol pathway and the other in the APP processing pathway [24,25]. Interestingly, the gene has 
also been associated to cerebrovascular disease in a previous study [26] and also emerged in our 
comparative analysis in the genome-wide association study (chapter 5).
Third, we studied the association of the three variants within the angiotensin, angiotensin II type 1 
receptor and adducin genes (AGT-M235T, AGTR1-C573T and ADD1-Gly460Trp) in the same middle-
aged hypertensive subset of ERF. Variants in these genes were previously reported in cerebro- 
and cardiovascular disease in relation to circulating levels of plasma Aβ (chapter 10). The AGT-
M235T TT-genotype was significantly associated with higher levels of plasma Aβ42 (p=0.008) and 
truncated Aβn42 (p=0.02). The association to Aβ42 remained significant after adjusting for potential 
First, we studied all five variants in relation to the MRI endophenotypes: volumes of WML and 
presence of lacunes and microbleeds in a subgroup of the ERF study aged 55 and 75 years with 
hypertension (chapter 8). WML was present in variable severity in all participants, whereas lacunar 
infarcts were present in 15.5% and microbleeds in 23.3%. Homozygosity for the APOE ε4 allele was 
associated with lacunes (OR, 4.8; 95% CI, 1.2-19.3). Individuals carrying two copies of the variant 
allele of 4 SNPs located at the 3’-end of SORL1 (rs1699102, rs3824968, rs2282649, rs1010159), had 
an increased risk of microbleeds (highest odds ratio, 6.87; 95% CI, 1.78-26.44), which is suggestive 
for the hypothesis that the amyloid cascade is involved in the etiology of microbleeds in populations 
with hypertension. 
Second, in chapter 9 we studied SORL1 in relation to hippocampal volume and plasma Aβ levels 
in the same subgroup of the ERF study. Hippocampal volumes were quantitatively measured on 
MRI and plasma Aβ levels were determined in non-fasting blood samples. We studied the effect 
of 7 variants within SORL1 that were previously reported in AD. Three variants located near the 
3’-end of SORL1 were significantly associated to hippocampal volume. The 3-SNP haplotypes for 
rs1699102, rs3824968 and rs2282649 (CAT) and for rs3824968, rs2282649 and rs1010159 (ATC) 
were associated to higher hippocampal volumes when adjusting for multiple testing. We did not find 
significant associations of single variants with plasma Aβ levels. 
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Taken together, the most interesting finding of our studies may be the associations that were found for 
SORL1 in various study designs. Our candidate gene analyses showed association of SORL1 with 
cognition as well as microbleeds and hippocampal volume. SORL1 also emerged in our genome-
wide association meta-analyses of cognitive function.  A word of caution is, however, needed: our 
candidate gene studies were performed in a small sample size and were restricted to hypertensive 
individuals. These findings therefore need replication in larger cohorts in the general population.
Finally, we conducted two candidate gene studies in Alzheimer’s disease to elucidate the role of two 
interesting pathways. Iron overload may contribute to the risk of Alzheimer’s disease. We earlier 
have studied the genes implicated in hemochromatosis in relation to AD [27]. We found an effect of 
the hemochromatosis gene (HFE) on the age of onset of AD. The HFE-63D mutation was related to 
an earlier onset in APOE*ε4 carriers, but not to the disease risk. Other groups reported evidence in 
other variants in hemochromatosis genes HFE-C282Y and -H63D, and transferrin (TF) [22]. In the 
Epistasis Project, with 1757 AD cases and 6295 controls, we studied four variants in two genes of iron 
metabolism: HFE-C282Y and -H63D, and TF-C2 and -2G/A (chapter 7). We replicated the interactive 
effect between HFE-282Y and TF-C2 on the risk of AD in Northern Europeans. We also found an 
interaction between HFE-63HH and TF-2AA, which was markedly modified by age. The interaction 
between HFE-282Y and TF-C2 has now been replicated twice, in a total of 2313 cases of AD and 
7065 control. There are a number of limitations of this study that hamper firm conclusions. 
confounders and multiple testing. No significant associations were found between AGTR1-C573T or 
ADD1-Gly460Trp and plasma Aβ. 
First, both interactions were found mainly or only in Northern Europeans. In fact, there was an absence 
of a relation between HFE and AD in a Northern Spanish population. From a statistical perspective, 
the exclusion of the Spanish data is problematic. Although the allele frequencies in Northern Spain 
differed from those in the Northern Europeans, this does not imply that the relation to AD should be 
different. A second problem is that although we pooled the data, the numbers are small and as a 
consequence the study power is low, making the analysis susceptible to false positive findings.  
We also studied the Cathepsin D gene (CTSD) in relation to AD (chapter 6). CTSD is involved in 
amyloid precursor protein processing and is therefore considered a candidate for AD. We performed a 
candidate-gene analysis in the Rotterdam Study, which is a population-based cohort-study (N=7983) 
and estimated the effect of CTSD variants on the risk of AD. Additionally, we performed a large meta-
analysis incorporating our data and previously published data. The T-allele of CTSD rs17571 was 
associated with an increased risk of AD (p-value 0.007) in the Rotterdam Study. This association was 
predominantly found in APOE ε4 noncarriers. A meta-analysis of previously published data showed 
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Besides these genetic studies, in chapter 2 we also performed a classical epidemiological study in 
which we studied a combination of cardiovascular risk factors as composed in the metabolic syndrome 
(MetS) in relation to cognition. While type 2 diabetes is known to be associated with poorer cognitive 
performance [28,29], fewer studies have reported on the association of MetS and contributing factors, 
such as insulin-resistance (HOMA-IR), low adiponectin-, and high C-reactive protein (CRP)- levels 
[30,31]. We studied whether these factors are related to cognitive function and which of the MetS 
components are independently associated. Also this study was performed in the ERF study where 
extensive data on physical examination, biomedical measurements and neuropsychological testing 
were available. Linear regression models were used to determine the association between MetS, 
HOMA-IR, adiponectin levels, CRP, and cognitive test scores. We found that predominantly women 
with MetS and high HOMA-IR had lower scores on executive function tests (p=0.03 and p=0.009). 
The most consistent individual component of MetS, contributing to the association with executive 
test scores was systolic blood pressure. We interpret these results with caution, however, since the 
design was cross-sectional and with very strict multiple testing adjustment using Bonferroni would 
result in only borderline significant p-values. Longitudinal studies will be needed to gain insight in the 
causality of our reported findings and may result in more conclusive findings. 
A huge challenge in genetic and epidemiological research, especially in the candidate gene studies 
and an exploratory study such as we conducted for MetS, is how to improve the quality and validation 
of candidate genes in AD. This will be discussed in the next chapter.
a significantly increased risk of AD in carriers of the T-allele of rs17571 (OR 1.22, 95% CI 1.03-1.44), 
irrespective of APOE ε4 carrier status. 
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Abstract
Background
Materials and Methods
Results
Conclusion
Introduction
The epidemiological credibility of genetic associations in Alzheimer’s disease (AD) in the ‘top list’ 
of the Alzgene database is graded using the so-called Venice criteria. We aimed to evaluate the 
robustness of these criteria
Hypothetical results from simulated studies were added to the meta-analyses of these associations 
that were graded with strong credibility or with moderate or weak credibility due to inconsistency of 
replication (high between-study heterogeneity (I2)) or low summary odds ratio (0.87 < OR < 1.15). 
Robustness was quantified as the sample size needed to change the grading.
For 5 out of 8 associations graded with strong credibility, the grade changed to weak credibility 
because of small summary OR after the addition of studies with effects similar to the lowest/highest 
published OR and sample sizes ranging from 80 to 2000 . For 4 out of 8, new studies could introduce 
large I2 when their sample sizes were 400 to 1600. These associations ended up with a small 
summary OR and one became non-significant. Two out of four associations graded with moderate 
and weak evidence because of I2 >25%, could not become strong evidence because of one outlier in 
each analysis. Finally, associations with weak credibility due to small OR only became non-significant 
when new studies with no effect had sample sizes ranging over 3400 to 6600. 
The Venice criteria are very helpful criteria to grade the credibility of genetic associations, but its 
practical usefulness may be limited due to outliers and small effects. Further guidance is needed on 
how to deal with these situations.
Unraveling the genetic basis of Alzheimer’s Disease (AD) has proven a major challenge. After the 
discovery of the three genes that cause Mendelian forms of the disease (APP, PSEN1 and PSEN2) 
and the major susceptibility gene Apolipoprotein E (APOE) there have been no further major 
breakthroughs. Also, the first large-scale genome-wide association studies (GWAS) did not identify 
loci other than APOE [1-4], but recent large consortia meta-analyses discovered several new loci 
[5,6], including CR1 on chromosome 1, CLU on chromosome 8 and PICALM on chromosome 11. 
One of the reasons for the absence of gene discoveries is that many genetic association studies in 
AD were too small to detect low-risk susceptibility variants. Meta-analyses combining the results of 
multiple small studies are therefore more powerful and necessary approaches for the identification 
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of AD susceptibility genes. To facilitate these meta-analyses, the online Alzgene database was 
constructed (www.alzgene.org). This database currently includes 1,236 studies covering almost 600 
genes and 2,400 polymorphisms (accessed 1th December 2009) [7]. 
It is likely that not all genetic associations reported are true associations, because some meta-
analyses were rather small in sample size and some associations were only borderline significant. 
Distinguishing true from false positive findings is one of the greatest challenges in genetic epidemiology 
[8,9]. Recently, new guidelines were developed by a consensus workshop of the Human Genome 
Epidemiology Network for grading the epidemiological strength of cumulative evidence on genetic 
associations [10]. These so-called Venice criteria have recently been implemented in the Alzgene 
database to grade the credibility of epidemiological evidence for the genetic associations. Alzgene 
reports a ‘top list’ of 35 significant genetic associations (Table 1).
The Venice criteria value genetic associations based on 1. the amount of evidence; 2. consistency 
of replication and 3. protection from bias. Significant meta-analyses in large populations with 
little heterogeneity between the results of the individual studies and without evidence for bias are 
considered strong evidence for genetic association, whereas any violations to these three criteria 
result in moderate or weak evidence. 
The Venice criteria are very useful to highlight quality differences between meta-analyses, but they 
may face limitations when applied too strictly. First, the criteria suggest that genetic associations 
with moderate or weak evidence can only be valued higher and that genetic associations with strong 
evidence cannot change to moderate or weak evidence after updating the analyses with newer 
studies. Second, according to the criteria genetic associations with small effect sizes (0.87< OR 
<1.15) are by definition graded as weak evidence because bias cannot be ruled out, except when 
they are investigated in consortia, which are considered protected from bias [11]. It is clear that a 
single study with a small OR has limited credibility, but when multiple large studies show the same 
small OR there may be less reason to consider these hampered by bias. Third, the criteria provide no 
guidance on how to handle outlying studies and subgroup analyses. The latter is particularly relevant 
with regard to genetic heterogeneity which may show genetic associations in some ethnic groups 
but not in an overall analysis. The aim of our study was to investigate the practical implications of 
these limitations. We evaluated the robustness of the Venice grades of genetic associations in AD 
by adding hypothetical results of simulated studies to the meta-analyses. The research questions 
that were addressed are: 1. what sample size is needed to change a grade of strong evidence to 
moderate evidence due to increased heterogeneity or to weak evidence due to small OR?; 2. what 
sample size is needed to change associations with weak evidence into non-significant associations?; 
3. to what extent are grades of moderate or weak evidence due to high heterogeneity determined by 
the effect of a single study?
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Materials and Methods
Venice criteria
Alzgene database
Analyses
The Venice criteria grade the strength of the epidemiological evidence for genetic associations taking 
account of the amount of evidence, consistency of replication and protection from bias [10]. For 
amount of evidence, associations receive an A when the combined number of cases and controls 
in the minor genetic group exceeds 1000, a B when the number is between 100 and 1000, and a C 
when it is below 100. For consistency of replication, the degree of between study heterogeneity in 
study results (I2) is considered. Point estimates of I2 below 25% receive an A, I2 between 25% and 
50% receive a B and I2 exceeding 50% receive a C. A C is also given to non-significant associations. 
For protection from bias, the guidelines propose to consider potential sources of bias at the level of 
individual studies including errors in phenotypes, genotypes and confounding, and at the level of 
meta-analysis including publication and other selective reporting biases [10]. Associations receive an 
A when bias is not likely to affect the presence of the association, a B when there is no demonstrable 
bias, but important information is missing for its appraisal and a C when there is demonstrable clear 
or potential bias that had invalidated the association. Meta-analyses also receive an A when the OR 
deviates more than 1.15-fold from the null (>1.15 or <0.87). Strong epidemiological evidence for 
significant association was given to the meta-analyses that received three A’s, moderate evidence 
to those that received any B, but not any C, and weak to those that received a C in any of the three 
criteria.
The Alzgene database is a publicly available database of published genetic association studies in AD 
[7]. The studies are identified through systematic literature searches, which are continuously updated. 
The database includes studies that are published in English in peer-reviewed journals. Meta-analyses 
are conducted for associations that have been investigated in at least four independent samples. All 
genetic associations with a significant summary OR for at least one polymorphism are presented in 
a ‘top list’. The epidemiological credibility of all loci in the top list is graded using the Venice criteria. 
The criteria are implemented as described above with the amount of evidence defined as the number 
of minor alleles.
We performed meta-analyses on loci presented in the Alzgene’s ‘top list’ (Table 1), that were graded 
with strong and moderate epidemiological credibility and on associations with weak epidemiological 
credibility due to high I2 or a small OR. We used data available from the Alzgene database [7], but 
excluded studies in which control genotypes were out of Hardy-Weinberg Equilibrium (HWE). To test 
the robustness of these grades, we updated the meta-analyses with results of simulated studies. 
Robustness was quantified as the sample needed to change the reported grades, which could be a 
ch
ap
te
r 1
2
193
12 Grading the credibility of genetic associations in Alzheimer’s disease
using the Venice criteria: practiccal considerations following from the Alzgene database 
result of an increased I2, a smaller OR below the threshold of 1.15 or a non-significant summary OR. 
When the required sample size is large, substantial evidence is needed to change the credibility of 
the associations. 
The meta-analyses were performed in R using the Rmeta library (www.r-project.org) using random 
effect models. The degree of heterogeneity between studies was assessed using the I2 statistic 
[12]. Fixed effects meta-analyses were used in the analysis of APOE with simulated data and in 
the meta-analysis with simulated data introducing high I2 in order to prevent adjustment of induced 
heterogeneity.
For the simulated data, we assumed that the allele frequencies of the controls were equal to the 
overall allele frequency in the meta-analysis from the Alzgene database. The allele frequencies in 
cases were calculated from the frequencies in controls and the OR, assuming HWE and a 50:50 
case/control ratio. The betas were calculated by taking the natural logarithm of the OR and the 
standard errors were calculated by dividing the beta by the square root of the chisquare, which in turn 
was estimated from a contingency table of the observed and expected allele frequencies in cases 
and controls. Beta and standard error were then added to the meta-analysis. This was repeated with 
increasing sample sizes until an effect was seen on the summary OR or I2. 
First, we addressed the robustness of associations graded with strong evidence by investigating the 
sample size needed to change this grade to moderate due to increased I2 or to weak due to small 
OR. To study the sample size needed to increase I2 >25%, we examined two scenarios in which we 
added a study with an effect similar to the lowest and highest OR observed in published studies. To 
study the sample size needed to change the summary OR towards the null, defined by the Venice 
criteria as 0.87 < OR < 1.15 [10] or to non-significance, we added the same hypothetical studies as 
mentioned above. Additionally, we investigated a scenario where we added a hypothetical study that 
showed no effect (OR=1).
Next, we addressed the robustness of associations with moderate and weak evidence by investigating 
the sample size needed to reduce I2 or to get a non-significant summary OR.
For I2, we studied the addition of simulated data with an effect similar to the current published 
summary OR. We investigated two scenarios, adding a single study and adding multiple studies with 
a sample size of 2000. For an effect on the summary OR, we examined whether the small effect size 
remained significant using two scenarios in which we added a study with no effect and a study with 
an effect similar to the lowest/highest OR observed in published studies.
Finally, we studied whether high I2 in associations with moderate and weak evidence were due to the 
effect of one single study by removing one study at a time. 
194
Top findings of genetic associations with Alzheimer's disease listed at Alzgene.org 
# Gene  Ethnicity  Polymorphism  N minor 
(Grade)  
I2 
(Grade)  
Bias Reason (Grade)  Overall 
Grade 
OR Number of 
studies 
1 APOE ( 2/3/4)  Caucasian apoe  82 )92.4-83.3( 18.3  gnortS )A( )A( 0 )A( 5253 4/3/2
2 CLU   8 )98.0-28.0( 58.0 gnortS )A( )A( 0 )A( 17202 00063111sr llA
3 PICALM   6 )19.0-38.0( 78.0 gnortS )A( )A( 0 )A( 53331 854145sr llA
4 TNK1   6 )39.0-08.0( 68.0 gnortS )A( )A( 9 )A( 3435 8494551sr llA
5 ACE   4 )29.0-86.0( 97.0 gnortS )A( )A( 0 )A( 1731 4670081sr naisacuaC
6 TFAM   5 )49.0-27.0( 28.0 gnortS )A( )A( 0 )A( 4061 4066032sr llA
7 CST3   8 )31.1-00.1( 61.1 gnortS )A( )A( 4 )A( 3021 9304601sr naisacuaC
8 IL1B   5 )93.1-40.1( 81.1 gnortS )A( )A( 0 )A( 6021 4363411sr naisacuaC
9 CR1   7 )82.1-90.1( 91.1 etaredoM )A( )B( 44 )A( 3566 1046566sr llA
 4 )44.1-60.1( 32.1 etaredoM )A( )A( 0 )B( 867 8093091sr llA  0419302GCh 01
 9 )94.1-60.1( 62.1 etaredoM )A( )A( 7 )B( 086 46358221sr naisacuaC  1LROS 11
 4 )09.0-05.0( 76.0 etaredoM )A( )A( 0 )B( 722 8735484sr llA  2BNRHC 21
 4 )84.1-40.1( 42.1 etaredoM )A( )A( 0 )B( 765 978006sr llA  1SCROS 31
14 DAPK1  All rs4878104 4219 (A) 0 (A) Low OR, Regr (C) Weak 0.88 (0.82-0.95) 7 
15 PRNP  Caucasian rs1799990 3521 (A) 7 (A) Low OR, HWE (C) Weak 0.91 (0.83-0.99) 10 
16 MTHFR  All rs1801133 8120 (A) 22 (A) Low OR (C) Weak 1.13 (1.04-1.24) 25 
17 GAB2   5 )88.0-45.0( 96.0 kaeW )A( )C( 87 )A( 1171 49239701sr naisacuaC
18 LOC651924  All rs6907175 5072 (A) 3 (A) Low OR (C) Weak 0.89 (0.82-0.96) 6 
19 GWA_14q32.13  All rs11622883 5031 (A) 35 (B) Low OR (C) Weak 0.88 (0.80-0.97) 6 
20 BDNF  Caucasian rs6265 4145 (A) 0 (A) Low OR (C) Weak 1.09 (1.02-1.17) 16 
21 NEDD9  All rs760678 5336 (A) 39 (B) Low OR, Regr (C) Weak 0.89 (0.81-0.97) 8 
 7 )39.1-80.1( 44.1 kaeW )C( rgeR )C( 56 )B( 927 00531sr llA  H52HC 22
23 IL1A  Caucasian rs1800587 4749 (A) 32 (B) Low OR (C) Weak 1.09 (1.00-1.19) 18 
 41 )33.1-40.1( 81.1 kaeW )C( rgeR )B( 03 )A( 4282 6929401sr llA  FT 42
25 LOC439999  All rs498055 5288 (A) 49 (B) F, HWE (C) Weak 1.15 (1.03-1.29) 7 
 01 )53.1-30.1( 81.1 kaeW )C( F )C( 86 )A( 3254 7106892sr naisacuaC  1MHLAC 62
27 TNF  All rs4647198 1515 (A) 0 (A) F, HWE (C) Weak 1.35 (1.04-1.76) 4 
28 PGBD1  All rs3800324 550 (B) 0 (A) Regr, F (C) Weak 1.21 (1.02-1.24) 7 
29 THRA  All rs939348 3248 (A) 0 (A) Low OR, Regr (C) Weak 1.10 (1.01-1.19) 6 
30 ENTPD7  All rs911541 2241 (A) 1 (A) Low OR, F (C) Weak 1.10 (1.01-1.21) 4 
 4 )99.0-27.0( 48.0 kaeW )C( F )C( 36 )A( 6985 33629711sr llA  33LI 13
 4 )00.1-57.0( 78.0 kaeW )C( F )C( 15 )A( 3262 3716084sr llA  SHDPAG 23
 01 lamosomorhc-X kaeW )C( F )A( 81 )B( 573 9043695sr llA  CTO 33
34 GALP  All rs3745833 4132 (A) 62 (C) Low OR, Regr (C) Weak 1.13 (1.00-1.29) 6 
35 PSEN1  All rs165932 13867 (A) 54 (C) Low OR, HWE (C) Weak 0.92 (0.86-1.00) 43 
Derived from www.alzgene.org; accessed 1st Dec 2009. In bold: the associations that were studied in the current study. 
Grade: based on Venice criteria [10]. OR: odds ratio, Regr: modified regression test to assess positive publication bias, HWE: deviations from Hardy-Weinberg Equilibrium, F: exclusion of first 
study diminishes the association 
 
 
Table1
Descriptives
Results
Of the 35 significant associations presented in Table 1, eight were graded with strong evidence 
for association, five with moderate evidence and 22 with weak evidence for association. The 8 
associations with strong evidence included 3 loci identified in GWAS and 5 loci identified in meta-
analyses of candidate gene studies. Figure 1A and 1B show that the effect sizes of the polymorphisms 
that were graded with strong evidence remained unchanged when the number of minor alleles was 
higher than 1,000. With the exception of APOE, most ORs were close to the 1.15 threshold specified 
in the Venice criteria. 
There were only two reasons why genes were graded with moderate evidence. Four out of five genetic 
associations had insufficient amount of data and the fifth, CR1, had high I2. Of the 22 associations 
that were graded with weak evidence, three did not have a sufficient amount of data, and 19 had 
high I2, small OR or presence of biases. The associations graded with weak evidence due to HWE 
deviations, TNF, LOC439999, PRNP and PSEN1 were no longer significant after the studies in which 
controls were out of HWE were removed from the meta-analysis. Five associations were graded with 
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Sample sizes needed to obtain an I2 higher than 25% for loci that are graded  
with strong evidence of association 
Range of published OR When OR=lowest* When OR=highest*
Gene Sample size Sample size
CLU 0.76-0.93 4400 10 000
PICALM 0.83-0.95 >1 000 000 6000
TNK1 0.76-1.05 1,600 520
TFAM 0.60-1.00 400 1600
ACE 0.74-0.84 >1 000 000 >1 000 000
CST3 0.88-1.60 620 500
IL1B 1.09-1.64 >1 000 000 560
OR range: minimum and maximum odds ratio available from published studies included 
in the meta-analyses listed in Table 1. Sample size: number of cases and controls (50:50).  
* OR of the added hypothetical studies was the lowest/highest of the range of published OR.  
4
Samples size needed to obtain a summary OR lower than 1.15 or non-significant result for loci that are graded with strong  
evidence of association  
    Small OR Non-significance
Published When OR=1 When OR=lowest/highest* When OR=lowest/highest*
Gene OR 95% CI OR range Sample size Sample size Sample size
APOE4 3.83 3.30-4.45 2.17-9.93 39000 Not Possible Not Possible
CLU 0.86 0.82-0.89 0.76-0.93 4000 9000 Not Possible
PICALM 0.87 0.83-0.91 0.83-0.95 600 2000 Not Possible
TNK1 0.86 0.80-0.93 0.76-1.05 800 600 6000
TFAM 0.82 0.72-0.94 0.60-1.00 1000 1000 2500
ACE 0.79 0.68-0.92 0.74-0.84 1200 Not Possible Not Possible
CST3 1.15 1.01-1.33 0.88-1.60 160 80 150
IL1B 1.19 1.04-1.36 1.09-1.64 600 1500 Not Possible
OR: summary odds ratio of meta-analysis; 95% CI: 95% confidence interval; OR range: minimum and maximum odds ratio from  
published studies included in the meta-analyses listed in Table 1. Sample size: number of cases and controls (50:50);  
* OR of the added hypothetical studies was the lowest/highest of the range of published OR. 
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Table 2
Robustness of strong evidence 
Table 3
weak evidence only because of high I2 or small OR. Figure 2 shows that the cumulative OR of CR1 
did not change in time, but the cumulative OR of GAB2 did. The cumulative ORs for LOC651924, 
GWA_14q32.13, BDNF and Il1A fluctuated around a stable value (0.89 and 1.09) after the number 
of minor alleles reached 2500. 
Table 2 shows that for ACE it was impossible to change its strong evidence to moderate evidence 
because of increased I2, because I2 could not increase over 25%. For PICALM and IL1B it was only 
possible when the study had the same effect as the published outlier and for CLU it was only possible 
with relatively large sample sizes. These findings did not change when we added multiple studies 
with moderate sample sizes (N=2000 each) instead of one single large study (data not shown).For 
TNK1, TFAM and CST3 even small sample sizes could increase I2 and change the grading from 
strong to moderate. In addition, the new summary OR became small (0.87 < OR <1.15) and for CST3 
non-significant.
196
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Sample sizes needed to obtain an I2 lower than 25% for loci that are graded with moderate or weak evidence because of high I2 
Published When adding one study* When adding multiple studies (N=2000)*
Gene OR 95% CI OR Range Sample size Studies added
CR1 1.18 1.07-1.29 0.99-1.29 >1 000 000 8
GAB2 0.64 0.47-0.86 0.51-0.91 >1 000 000 8
GWA14q32.13 0.89 0.80-0.97 0.76-1.00 200 Not relevant
IL1A 1.09 1.02-1.18 0.71-2.33 200 Not relevant
OR: summary odds ratio of meta-analysis; Sample size: number of cases and controls (50:50);  
* OR of the added hypothetical studies was the summary published OR  
6
Sample size needed to obtain a non-significant OR for loci that are graded with weak evidence  
because of small effect size 
Published When OR=1 When OR=lowest/highest*
Gene OR 95% CI OR Range Sample size Sample size
LOC651924 0.89 0.82-0.96 0.78-0.99 6000 6200
GWA_14q32.13 0.89 0.80-0.97 0.76-1.00 5600 5600
BDNF 1.09 1.02-1.17 0.66-1.90 6200 400
IL1A 1.09 1.02-1.18 0.71-2.33 3400 200
MTHFR 1.12 1.03-1.22 0.88-1.97 6600 1200
OR: summary odds ratio of meta-analysis; 95% CI: 95% confidence interval; OR range: minimum and  
maximum odds ratio available from published data on Alzgene Sample size: number of cases and controls (50:50).  
* OR of the added hypothetical studies was the lowest/highest of the range of published OR. 
Robustness of moderate and weak evidence
Table 4
Table 5
Of the studies that were graded with moderate or weak evidence because of high I2, for 2 associations 
(CR1 and GAB2), it was impossible to reduce I2 below 25% with the addition of one study, but I2 
could be reduced by the addition of 8 studies each with a sample size of 2000 (Table 4). For the other 
2, GWA14q32.13 and IL1A, small sample sizes of only 200 participants were sufficient to reduce 
I2.  Table 5 shows that for LOC651924, GWA_14q32.13, BDNF, IL1A and MTHFR, a sample size 
between 3400 and 6600 was needed to obtain a non-significant meta-analysis result after adding a 
study in which OR=1. A non-significant meta-analysis could be obtained at smaller sample sizes with 
the addition of studies with an effect size similar to the published ORs, however, for BDNF and IL1A 
these ORs were major outliers. 
Finally, we investigated whether high I of associations with moderate or weak grades could be 
attributed to one single study. For CR1 and GAB2, the high I2 was indeed due to one contributing 
study, which showed an opposite direction of effect. Excluding the respective study from the meta-
analysis reduced the heterogeneity from 48% to 0% for CR1 and from 78% to 0% for GAB2. The 
Table 3 shows that a small study could lower the summary OR below the threshold of 1.15, except for 
APOE, CLU and ACE. For APOE, only a very large study with no effect could lower the summary OR 
below the threshold, while for CLU and ACE a smaller study could. Yet for all three genes, an OR of 
1 is outside the range of published ORs. For more realistic OR values, it was impossible to lower the 
summary OR of APOE and ACE and required a large study for CLU. For the other 5 genes, studies 
with 80 to 2000 participants were sufficient to lower the summary OR and change the grading from 
strong to weak. Three associations, TNK1, TFAM and CST3, became non-significant.
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Figure 1a
  Cumulative association of loci with strong evidence for association with AD from candidate gene studies
  OR: cumulative odds ratio; N minor: number of minor alleles
Figure 1b
  Cumulative association of loci with strong evidence for association with AD identified in genome wide association studies
  OR: cumulative odds ratio; N minor: number of minor alleles
Figure 2
  Cumulative association of loci with moderate or weak evidence for association with AD
  OR: cumulative odds ratio; N minor: number of minor alleles 
summary OR also became stronger with less wide 95% confidence intervals. For the two other 
associations that were graded with weak evidence, the grading did not change when only one study 
was removed at the time.
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Discussion
The Venice criteria are very useful in valuing genetic associations with AD. By assessing the sample 
size, heterogeneity and the presence of bias, the criteria identify potential short-comings in the data 
synthesis that have to be solved before one can rely on the associations found. However, our data 
show that there are some concerns and limitations. First, genetic associations that are graded with 
strong evidence can change to weak evidence when the analyses are updated with hypothetical, 
but realistic new data when the summary OR becomes smaller than the threshold of 1.15. Second, 
a number of genetic associations with small significant effect size seem robust, but would still be 
graded with weak evidence because of low OR. Third, for some genetic associations, the weak or 
moderate grade is determined by the effect of a single study with outlying effect.
The Venice criteria grade the strength of the epidemiological evidence for genetic associations taking 
account of the amount of evidence, consistency of replication and protection from bias [10]. The 
definition of the amount of evidence as defined in the criteria as the number in the minor genetic 
group could be specified more clearly. The Alzgene database is currently using the number in the 
minor allele group, which is obviously twice the size of the minor genotype group, which may as well 
be considered as the minor genetic group. The sample size is, however, a measurable estimate of 
the amount of evidence and the only debate could be the sample size that is used as a cut off, since 
it appears from our study and recent genome-wide association studies that larger sample sizes than 
1000 are needed to find a robust estimate. 
The consistency of replication as depicted in the I2, is also a measurable estimate of evidence. Our 
data show, however, that the associations with strong evidence can change to moderate evidence 
because the addition of future studies can result in an increased I2. Especially for associations that 
do not include large sample sizes (TNK1, TFAM and CST3) realistic sample sizes of only hundreds 
can cause an increased I2. Moreover, just one study can influence I2 and when removed associations 
graded with moderate and weak evidence can change to strong evidence, as is seen for CR1 and 
GAB2 in our analysis. Also, the grades can change with the addition of future studies causing I2 to 
decrease below 25%, which is what one could expect. Studies with sample sizes of only 200 could 
result in strong evidence for GWA14q32.13 and IL1A. Although our data show that a threshold of 
25% is reasonable in real data, the application of a between-study heterogeneity threshold may be 
misleading. It should of course be taken into account when meta-analyzing genetic associations 
[13,14], but it may also reveal inconsistencies in study-designs rather than inconsistencies of genetic 
associations. We argue that when heterogeneity is present, finding genuine heterogeneity is very 
important, but using heterogeneity as a sole argument in grading genetic associations may not be 
sufficient [15]. Moreover, even in the presence of heterogeneity, if the direction of effect is the same 
among studies and only the effect sizes are different, the results may point to a true association. At least 
the latter will not affect the overall conclusion. Another argument is that most tests for heterogeneity 
lack power when sample sizes are small, resulting in relatively high estimates in large studies and 
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are therefore hard to interpret reliably [16,17]. It has been suggested by others to include confidence 
intervals of the heterogeneity measurement to better evaluate meta-analyses and including such 
boundaries in the criteria would be of additional value [12]. 
In addition to considering potential sources of bias on the level of individual studies and meta-analyses, 
the criteria also propose the use of an OR threshold. The underlying idea being that studies with small 
effects are more likely biased. This criterion results in weak grading for all genetic associations with 
an OR smaller than 1.15 (or greater than 0.87). Our results show (below), however, that a number of 
these associations are robust. Strong evidence is currently given to 8 genetic associations with AD. 
While the published OR-ranges of the majority of strong graded associations are close to 1, future 
studies can affect the grading. In the current study, 5 associations are graded with weak evidence 
after the addition of new data and 3 associations even become non-significant. Only for APOE, 
ACE, and CLU large (unrealistic) samples sizes are required. Weak evidence because of a small 
OR is given to 5 associations with AD, but our data show that the associations will only become 
non-significant with the addition of either very large sample sizes or studies with an unrealistic OR. 
Therefore these associations may be true findings, underlining the importance to consider genetic 
associations with small effects. Moreover, genes with small effects are expected in light of the results 
from recent GWAS [18]. 
A valuable addition to published meta-analyses would be performing cumulative meta-analyses and 
plotting the results can be a useful application [17]. One could expect that with time evidence will 
accumulate leading to a stabilizing either significant or non-significant association. There is no easy 
solution for tackling the robustness of genetic associations, but initiating large consortia or meta-
analyze published data as we have shown, seem to be the most promising methods [11]. 
We limited ourselves to the Alzgene database and genes that were published in the top list at the 1st 
of December 2009 and meanwhile new associations have emerged. During the preparation of this 
manuscript there was an update of the Alzgene database. The new top list, however, reassures our 
conclusions rather than compromising them. In the top list there are 4 new associations graded with 
strong evidence. Three are new (SORL1, IL8, LDLR) and the other is GWA_14q32.13, which moved 
up the list due to exclusion of one single study resulting in a greater summary OR (0.84 instead of 
0.89). The 3 new genes graded with strong evidence are small studies or show only a large OR in 
a specific ethnic group (SORL1), and these will likely change with the addition of future data. Two 
associations dropped from strong to weak evidence, just like we predicted. IL1B dropped because of 
the addition of one non-significant study (N=465, OR=0.98), resulting in a non-significant OR when 
excluding the studies out of HWE. TFAM dropped because of the addition of one non-significant 
study with an OR beyond the published OR range so far (N=485, OR=1.15), causing increased I2 
and first study bias. 
To summarize, the Venice criteria are useful criteria for the appreciation of meta-analyses of genetic 
associations. However, clarification is needed on how to handle the grading in the presence of outliers 
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and when genetic variants have small effects. Our study evaluates the Venice criteria specifically 
in AD, and although many findings could be extrapolated to other diseases, the criteria should be 
evaluated in many field synopses. With the emerging of new data, associations should be re- and 
meta-analyzed and guidelines should be re-evaluated [17]. 
In conclusion, associations with strong credibility could change with the addition of new future data 
and some associations with weak credibility due to small OR may have sufficient amount of evidence. 
The practical usefulness of the interim Venice criteria may therefore be limited and further guidance 
is needed on how to deal with these situations.
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Genetic epidemiologic research in neuroscience has many challenges and there are also many 
opportunities for research in the genomics era. A first step of research is genome-wide association 
study, which are present ongoing for many neurological diseases including stroke [1,2], Alzheimer’s 
disease (AD) [3,4], frontal lobe dementia [5] and even for rare outcomes such as Creutzfeldt-Jakob 
disease [6]. Although these studies of stroke and AD have been successful and have revealed three 
new genes, the heritability of the disease is far from explained completely. The recent identified 
genes involved in AD, PICALM, CLU and CR1 contribute little to the discrimination of persons who 
will and will not develop disease (unpublished data). Age, sex and the apolipoprotein E (APOE) gene 
remain the main predictors for developing AD. 
How to take this research further? There are ample opportunities for finding new genes by enlarging 
the data sets studied in terms of the number of patients included as well as the number of markers 
studied. The experience in other outcomes such as lipid levels and blood pressure is that enlarging 
the study sample still allows the identification of new genes with small effects. Also, preliminary studies 
show some improvement in findings using the data of the 1000 genomes as a base population for 
imputations instead of HAPMAP. The variation captured with HAPMAP is limited, because it is based 
on 60 individuals. Considering the successes of genome-wide association studies of quantitative 
outcomes (e.g. blood pressure), such studies have the potential to become more successful than 
those of binary outcomes (e.g. hypertension). Similarly, there are opportunities for genome-wide 
association of endophenotypes as cognitive functioning and brain imaging data such as hippocampal 
volumes, generalized brain atrophy and microbleeds.
In the near future, an important trend in neurogenetic research will be the formation of large consortia 
with samples sizes of thousands of participants. An important question that remains to be addressed is 
the genetic architecture underlying diseases such as AD and related disorders. Rare mutations have 
been implicated in the amyloid precursor protein (APP), and presenilin 1 (PSEN1) and 2 (PSEN2) 
genes in familial forms of AD. Further in sporadic AD, APOE is a common variant with a large effect 
while PICALM, CLU and CRI are common variants with small effects. The GWA studies conducted 
to date do not show evidence for common variants with effects comparable to that of APOE [3,4], 
whereas these studies had sufficient statistical power to reveal those. However, there are two types 
of variants for which the present studies were underpowered: 1. variants with small effect, similar or 
smaller than PICALM, CLU and CR1, and 2. rare variants with large effects. A first step that should 
be taken in the near future is to examine the evidence for a polygenic form of inheritance in which 
there are a large number of variants with very small effect covering the full genome. Recently, a new 
method to evaluate polygenic effects has been developed and applied successfully in schizophrenia 
and bipolar disorder [7].  
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High throughput sequencing offers opportunities to evaluate the presence of rare variants with large 
effects. The cost of high throughput sequencing is and will go down allowing the sequencing of 
larger groups of patients. However, data analysis is still a challenge. Based on our findings, the 
first regions of interest will be the sortilin-related receptor 1 gene (SORL1). Evidence is increasing 
for a role in Alzheimer’s disease and cerebrovascular disease [8-10].  However, there are other 
regions for which there is consistent evidence for linkage in families and subsequent association 
that remain to be elucidated by deep sequencing including chromosome 10, chromosome 1 and 
chromosome 3 [11-14]. The latter region is identified in our own study. One may even argue that the 
chromosome 19 region, around APOE, requires further sequencing, as we and others have identified 
signals in genome wide association studies independent of APOE (unpublished data). Sequencing of 
the whole genome would also be of interest to target rare variants. The highest chances of success 
are probably to be expected in younger cohorts and family data. Studying rare variants would add to 
the field and may unravel new pathways involved in the disease. It goes without saying that it is of 
great importance to follow-up on the genome-wide results. Not only by performing replication studies 
and deep sequencing, but also by performing functional studies. Animal studies, for example can add 
much knowledge to the expression and function of newly discovered variants.
In future neuroscience research, genetic epidemiology has to explore whether alternative genetic 
mechanisms explain part of the missing heritability. Are there common or rare structural variants that 
explain part of the missing heritability? These have been implicated in various psychiatric outcomes 
and APP duplication has been seen in AD [15]. Another important question is whether there are 
epigenetic effects or post-translational modifications that are relevant for these disorders. Last but not 
least, the evidence for gene-interactions is to be explored. So far, no convincing evidence for gene-
gene interaction has been found. Although technically it is possible to study interactions across the 
whole genome, there are still major computational problems to be resolved. 
Gene-environment interactions have been Holy Grail in the field of genetic epidemiology. Large scale 
gene-environment interactions are within the scope of genetic epidemiological research. Although 
susceptible to false-positives, statistical approaches using robust standard errors have been 
developed and have enabled gene-interaction studies. However, in recent years there has been 
little progress in finding environmental risk factors that are consistently implicated in AD and related 
disorders. A point of consideration is how to develop the field of epidemiology to find consistent 
environmental risk factors. In the last few years, genetic epidemiology has been involved in genome-
wide association studies. Large consortia were formed to improve the power to pinpoint SNPs that 
were replicated across different studies. To move the field of epidemiological research further, such 
large consortia should also be formed to target classical environmental risk factors. These consortia 
are thus not only needed to find new genetic risk factors, they are also needed to find consistent 
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evidence for environmental risk factors. Needless to say that there is an urge to find risk factors that 
can be used for early prevention of a devastating disease like Alzheimer’s disease. The large number 
of non-replicable findings in epidemiology, however, has raised questions whether epidemiology is 
facing its limits. The lesson to be learned from genomic research: 1) target lower p-values as they 
have positive predictive values; 2) replicate findings before publication; 3) form large consortia to be 
able to meet 1 and 2.
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Dit proefschrift beschrijft ons onderzoek naar genetische determinanten van cognitieve functie en 
aan veroudering gerelateerde hersenenveranderingen. Voor dit onderzoek hebben we gebruikt 
gemaakt van uitkomsten die in hoge mate erfelijk zijn en deze gebruikt als endofenotypes voor de 
studie van de ziekte van Alzheimer, met inbegrip van cognitieve functies, Aβ plasma waarden en 
aan veroudering gerelateerde hersenenveranderingen die zichtbaar zijn op magnetische resonantie 
beeldvorming (MRI) van de hersenen. Verschillende studie ontwerpen werden gekozen om onze 
onderzoeksvragen te benaderen, zoals kandidaat-gen, genoom-wijd linkage en genoom-wijd 
associatie onderzoek. 
Eén van de meest bestudeerde kandidaat-genen in de ziekte van Alzheimer (AD) is het Apolipoproteïne 
E gen (APOE) [1-3]. Het ε4 allel van dit gen is een bekend en consistent gerapporteerde risicofactor 
voor AD. Gebaseerd op de hypothese dat cognitieve functies relevante endofenotypes zijn voor AD, 
bestudeerden we de relatie tussen APOE en cognitieve functies in hoofdstuk 3. We vonden dat 
het APOE*ε4 allel significant geassocieerd was met lagere testscores op de Adult Verbal Learning 
Test bij personen ouder dan 50 jaar. Dit effect van APOE*ε4 was onafhankelijk van het effect van 
APOE*ε4 op vasculaire risicofactoren en het meest uitgesproken op het leervermogen. Vergelijkbaar 
met de bevindingen van anderen [4], vonden we dat het APOE*ε4 allel een effect heeft op het 
cognitief functioneren, maar dat dit effect in tegenstelling tot AD relatief klein is. We hebben ons in de 
studies naar het ontdekken van nieuwe genen gericht op cognitieve functies, omdat deze uitkomsten 
de meest consistente associaties toonden met APOE [4], wat zou kunnen betekenen dat cognitief 
functioneren het meest belovende endofenotype is. 
Om nieuwe genetische regio’s voor cognitieve functioneren te onderzoeken zonder voorafgaande 
aannames van de onderliggende pathofysiologie hebben we een hypothese-vrije genoom-wijde 
studie verricht op verschillende cognitieve testen. In hoofdstuk 4 presenteren we de bevindingen 
van een genoom-wijde linkage analyse in de Erasmus Rucphen Family (ERF) Studie, dat een familie-
studie is in een genetisch geïsoleerde populatie. Aangezien we geïnteresseerd waren in genen met 
een groot effect, hebben we alleen personen met lage cognitieve scores geincludeerd deze linkage 
analyse. Afkapwaarden voor statistische significantie en suggestie werden bepaald met simulatie 
studies. Een significant resultaat (LOD> 3,78) werd gevonden met regio’s op chromosoom 1p13.1, 
12q24.33, 19q13.43, 20p13, 21q22.13 en 21q22.3. Voor het verder definiëren van genen in de 
regio’s, analyseerden we de regio’s onder de piek met dichtere genotypering en probeerden we deze 
bevindingen in een groot populatie cohort, de Rotterdam Studie, te repliceren [5]. Deze analyses 
resulteerden in significante associaties op chromosoom 1 (p-waarde = 0,03) en 21 (p-waarde = 
0,01) in ERF en de laatstgenoemde regio op 21q22.13 werd gerepliceerd in de Rotterdam Studie 
(nominale p -waarde 0,003). Deze regio bevat het kalium kanaal familie J 6 gen (KCNJ6). 
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Linkage analyse in de laagste cognitieve scores is vooral gericht op het vinden van zeldzame 
genetische varianten met een groot effect. Om vaker voorkomende genetische varianten met een 
klein effect te vinden, verrichten we een genoom-wijde associatie studie op iedereen met cognitieve 
functie scores en daarbij gebruikten we deze scores als continue variabelen. In hoofdstuk 5 
beschrijven we een meta-analyse van verschillende genoom-wijde associatie studies uitgevoerd in 
de cohorten voor het Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. 
Dit consortium bevat grote prospectieve bevolkings-cohorten. Neuropsychologische testen waren 
beschikbaar voor 13 cohorten. In dit proefschrift, hebben we ons gericht op executieve functies en 
snelheidstaken: de Trail Making Test (TMT) deel A en B en de Stroop Kleur-en Woord-Test. De 
analyses werden uitgevoerd in blanke deelnemers ouder dan 45 jaar, die geen dementie hadden en 
geen tekenen van herseninfarcten of –bloedingen ten tijde van de cognitieve testen. De belangrijkste 
bevinding werd gevonden met TMT-B en een SNP op chromosoom 18. Deze SNP had een p-waarde 
net boven de genoom-wijde significante afkapwaarde met een p-waarde van 6,95*10-8. Deze SNP 
is gelegen tussen twee plausibele kandidaat-genen. Wij hebben daarna een verkennende analyse 
uitgevoerd waarin we gezocht hebben naar overlap tussen onze bevindingen en andere genoom-
wijde associatie analyses gepubliceerd voor AD en schizofrenie. Overlap met vorige genoom-
wijde studies werd gevonden voor meerdere andere SNPs met een p-waarde kleiner dan 1,0*10-
3, waarvan de sortilin-related-receptor-1 (SORL1), de syntaxin-bindend-eiwit-6 ( STXBP6) en de 
protocadherine-9 (PCDH9) genen het meest interessant zijn. De genen in de regio’s die in onze 
studies werden gevonden, kunnen nieuwe inzichten geven in de mechanismen onderliggend aan de 
normale variatie in het cognitief functioneren. Onze bevindingen moeten echter gerepliceerd worden, 
wat momenteel gaande is. 
Een eerste vergelijking tussen de bevindingen van de genoom-wijde linkage en associatie studies 
toont geen overlap in genen. Overlap zou men ook niet mogen verwachten, omdat de mechanismen 
die ten grondslag liggen aan de beide methoden verschillen. Linkage is vooral bedoeld om zeldzame 
varianten met groot effect te vinden en associatie is vooral geschikt om veel voorkomende varianten 
te vinden met klein of matig effect. 
Van belang is ook dat we in onze genoom-wijde associatie studie geen bewijs vinden voor een 
rol van APOE, of voor de recent ontdekte AD genen, PICALM, CR1 en CLU [11,12] in cognitieve 
functie. Deze bevinding toont, dat de resultaten van analyses op endofenotypes niet één op één kan 
worden vertaald tot de ziekte. Ook is het van belang te vermelden dat cognitieve testen verschillende 
aspecten van het cognitief functioneren beoordelen. Zo vonden we inderdaad dat APOE geassocieerd 
was met de Adult Verbal Learning Test in hoofdstuk 3, maar niet-significant geassocieerd was met 
TMT-A, TMT-B of Stroop. 
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Na het onderzoeken van cognitieve functie als endophenotype, bestudeerden we de aan veroudering 
gerelateerde hersenveranderingen als een tweede groep van endofenotypen. We hebben plasma Aβ 
waarden gebruikt als biomarkers voor de aanwezigheid van seniele plaques en amyloïd angiopathie, 
en asymptomatische laesies die zichtbaar zijn op MRI van de hersenen als leeftijd-gerelateerde 
hersenenveranderingen. We hebben ons in dit gedeelte van het onderzoek gericht op witte stof 
laesies (WML), lacunair infarcten, microbloedingen en hippocampus atrofie. Al deze parameters zijn 
geassocieerd met een hoge bloeddruk, beroerte, dementie en cognitieve stoornissen [13-18], maar 
worden ook gevonden in gezonde ouderen. 
We onderzochten de rol van enkele kandidaat-genen die betrokken zijn bij de regulatie van bloeddruk 
en amyloid metabolisme. We bestudeerden het APOE gen, genen gerelateerd aan het renine-
angiotensine systeem (RAS) (Angiotensine, angiotensine II receptor type 1, alfa-Adducin) en het 
sortilin-gerelateerde receptor gen (SORL1). 
Het is bekend dat RAS-genen betrokken zijn bij de regulatie van de bloeddruk en zout-homeostase 
en dat RAS-eiwitten betrokken kunnen zijn bij AD [19]. Receptoren voor angiotensine II zijn aanwezig 
in de hersenen [20] en een verhoogde activatie van RAS wordt gezien in de hersenen van AD 
patiënten [21]. Zoals boven genoemd, is APOE consequent in verband gebracht met AD en er zijn 
steeds meer aanwijzingen dat ook SORL1 een rol speelt in AD [4,22,23]. SORL1 bestaat uit twee 
functionele regio’s, één functionerend in het cholesterol metabolisme en de andere in de verwerking 
van het amyloid voorloper eiwit (APP) [24,25]. Dit gen is recent tevens in verband gebracht met 
cerebrovasculaire ziekte [26] en opvallend genoeg vinden we SORL1 ook in onze verkennende 
vergelijkende analyses van de genoom-wijde associatie studies. 
We bestudeerden eerst alle vijf de varianten in relatie tot de volgende MRI endofenotypes: WML, 
lacunaire infarcten en microbloedingen. We onderzochten dit in de ERF-studie in een subgroep 
van 55 tot 75 jaar met hypertensie (hoofdstuk 8). Alle deelnemers hadden enige mate van WML, 
terwijl lacunair infarcten aanwezig waren in 15,5% en microbloedingen in 23,3% van de deelnemers. 
Homozygositeit voor het APOE ε4 allel werd geassocieerd met lacunaire infarcten (OR, 4.8; 
95% CI, 1.2-19.3). Individuen met twee kopieën van het variant allel van 4 SNPs gelegen aan 
het 3’-einde van SORL1 (rs1699102, rs3824968, rs2282649, rs1010159), hadden een verhoogd 
risico op microbloedingen (hoogste odds ratio, 6.87; 95% CI, 1.78-26.44 ). Dit zou de hypothese 
ondersteunen dat de amyloid cascade betrokken is bij de etiologie van microbloedingen in populaties 
met hypertensie. 
Ten tweede bestudeerden we de relatie tussen het SORL1 gen en hippocampus volume en plasma 
Aβ waarden in hoofdstuk 9. Hiervoor gebruikten we dezelfde subgroep van de ERF-studie. 
Hippocampus volumes werden kwantitatief gemeten met MRI en plasma Aβ waarden werden bepaald 
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in niet-nuchtere bloedmonsters. We bestudeerden het effect van dezelfde 7 varianten binnen SORL1, 
waarvan eerder een relatie met AD was aangetoond. Drie varianten gelegen nabij het 3’-einde van 
SORL1 waren significant geassocieerd met hippocampus volume. De 3-SNP haplotypen voor 
rs1699102, rs3824968 en rs2282649 (CAT) en voor rs3824968, rs2282649 en rs1010159 (ATC) 
waren geassocieerd met grotere hippocampus volumes. We vonden geen significante associaties 
van deze varianten met plasma Aβ waarden. 
Ten derde bestudeerden we de associatie van drie varianten binnen de angiotensine, angiotensine 
II type 1 receptor en adducin genen (AGT-M235T, AGTR1-C573T en ADD 1-Gly460Trp) in relatie 
tot Aβ plasma waarden in dezelfde hypertensieve subgroep van de ERF-studie (hoofdstuk 10). 
Deze varianten werden in eerdere onderzoeken in verband gebracht met vasculaire ziekten van 
hart en hersenen. Het AGT-M235T TT-genotype was significant geassocieerd met hogere waarden 
van plasma Aβ42 (p = 0,008) en van getrunceerd Aβn42 (p = 0,02). De associatie met Aβ42 bleef 
significant na correctie voor potentiële confounders en het toepassen van meerdere testen. We 
vonden geen significante associaties tussen AGTR1-C573T of ADD 1-Gly460Trp en plasma Aβ. 
Samenvattend is de meest interessante bevinding van de bovengenoemde studies de associaties met 
SORL1 die werden gevonden in diverse studie-ontwerpen. Onze kandidaat-gen analyses toonden 
associatie van SORL1 met cognitieve functies evenals met microbloedingen en hippocampus 
volume. SORL1 kwam ook naar voren in onze genoom-wijde associatie meta-analyses van de 
cognitieve functies. Enige terughoudendheid in de interpretatie van onze resultaten is echter nodig: 
onze kandidaat-gen studies werden uitgevoerd in een kleine steekproef en waren beperkt tot 
hypertensieve personen. Onze bevindingen moeten dus gerepliceerd worden en dienen onderzocht 
te worden in grotere cohorten in de algemene bevolking. 
In het derde gedeelte van dit proefschrift bespreken we twee kandidaat-gen studies in AD. Met deze 
studies wilden we de rol van twee interessante pathofysiologische mechanismen nader onderzoeken. 
Eén van de mechanismen is het ijzer-metabolisme, waarvan bekend is dat ijzerstapeling kan bijdragen 
aan het risico op AD. Onze onderzoeksafdeling heeft eerder al de relatie tussen hemochromatose-
genen en AD onderzocht. In deze studies werd een effect van het hemochromatose gen (HFE) 
op de leeftijd waarop AD zich openbaart gevonden [27]. De HFE-63D mutatie was geassocieerd 
met het op jongere leeftijd ontstaan van AD in mensen die het APOE*ε4 allel bij zich dragen, maar 
deze mutatie was niet geassocieerd met een hoger risico op AD. Andere studie-groepen vonden 
associaties tussen AD en andere varianten in de hemochromatose genen HFE-C282Y en -H63D, 
en in het transferrine gen (TF) [22]. In het Epistasis Project, waarin 1757 AD patienten en 6295 
controles zijn geïncludeerd, bestudeerden we vier varianten in twee genen die een rol spelen in het 
ijzer-metabolisme: HFE-C282Y, HFE -H63D, TF-C2 en TF-2G/A (hoofdstuk 7). Wij repliceerden 
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de interactieve werking tussen HFE-282Y en TF-C2 op het risico op AD in Noord-Europeanen. We 
vonden ook een interactie tussen HFE-63HH en TF-2AA, die aanzienlijk werd beïnvloed door de 
leeftijd. De interactie tussen HFE-282Y en TF-C2 is nu twee keer gerepliceerd in een totaal aantal 
van 2313 AD patiënten en 7065 gezonde controles. 
Er zijn desondanks beperkingen in de interpretatie van de resultaten van deze studie, die het trekken 
van harde conclusies belemmeren. Ten eerste werden beide interacties voornamelijk in Noord-
Europeanen gevonden en werd er geen relatie tussen HFE en AD gevonden in een Noord-Spaanse 
populatie. Vanuit statistisch oogpunt is de uitsluiting van de Spaanse gegevens problematisch. 
Hoewel de allel-frequenties in Noord-Spanje verschilden van die in de Noord-Europeanen, betekent 
dit niet dat de relatie met AD anders zou zijn. Een tweede probleem is dat ondanks het samenvoegen 
van de gegevens, de aantallen klein zijn en als gevolg daarvan de statistische power van deze studie 
laag is, waardoor de analyse gevoelig was voor vals-positieve bevindingen. 
De tweede kandidaat-gen studie, die we verrichtten met betrekking tot AD, betrof het Cathepsine D 
gen (CTSD) (hoofdstuk 6). CTSD is betrokken bij het verwerken van het amyloid voorloper eiwit 
(APP) en is daarom een interessant kandidaat-gen voor AD. We onderzochten CTSD in relatie tot 
AD in de Rotterdam Studie, dat een populatie-gebaseerde cohort-studie is (N = 7983). Daarnaast 
deden we een grote meta-analyse waarin onze resultaten werden samengevoegd met resultaten 
van eerder gepubliceerde gegevens. In de Rotterdam Studie vonden we een verhoogd risico op 
AD in deelnemers die het T-allel van CTSD rs17571 droegen (p-waarde 0,007). Deze associatie 
werd voornamelijk gevonden in mensen die niet het APOE*ε4 allel hadden. De meta-analyse toonde 
eveneens een significant verhoogd risico op AD bij dragers van het T-allel van rs17571 (OR 1,22, 
95% CI 1.03-1.44), maar dit risico bleek onafhankelijk van de APOE*ε4 status. 
Naast bovengenoemde genetische studies, hebben we ook een klassieke epidemiologische studie 
verricht in hoofdstuk 2 waarin we een combinatie van cardiovasculaire risicofactoren, samengesteld 
in het metabool syndroom (MetS) onderzochten met betrekking tot cognitieve functies. Diabetes 
type 2 is een bekende risicofactor voor slechtere cognitieve prestaties [28,29], maar er zijn minder 
studies verschenen over de associatie van MetS en bijdragende factoren, zoals insuline-resistentie 
(HOMA-IR), laag adiponectin, en hoge C-reactief proteïne (CRP) waarden in het bloed [30,31]. 
We onderzochten of deze factoren gerelateerd zijn aan cognitieve functies en ook welke MetS 
componenten onafhankelijk geassocieerd zijn. Voor deze studie gebruikten we de ERF-populatie 
waarin uitgebreide gegevens ten aanzien van lichamelijk onderzoek, biomedische bepalingen en 
neuropsychologische testen beschikbaar zijn. We vonden dat overwegend vrouwen met MetS en hoge 
HOMA-IR lagere scores op executieve cognitieve testen hadden (p = 0,03 en p = 0,009). De meest 
consistente individuele component van het MetS, was de systolische bloeddruk. We interpreteerden 
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deze resultaten met voorzichtigheid, aangezien het een cross-sectionele studie betrof en slechts 
borderline significante p-waarden werden gevonden na correctie voor het gebruik van meerdere 
testen. Longitudinale studies zullen nodig zijn om beter inzicht te krijgen in de causaliteit van onze 
bevindingen en zullen moeten bijdragen aan meer definitieve conclusies. 
Een grote uitdaging in genetisch epidemiologisch onderzoek is de validering van kandidaat-genen in 
AD te verbeteren. Er worden jaarlijks vele nieuwe genetische associaties gerapporteerd, maar vrijwel 
geen kunnen worden gerepliceerd. In hoofdstuk 12 hebben we gesproken over de toepassing van 
de zogenaamde Venice-criteria in de validering van genetische associaties in AD. The Venice-criteria 
evalueren de kwaliteit van de sterkte van het epidemiologische bewijs voor genetische associaties 
aan de hand van 3 punten: de hoeveelheid data, de consistentie van replicatie en mate van bias. 
Hoewel de eerste twee punten robuust bleken te zijn, was de laatste moeilijker te objectiveren, 
vooral wanneer milde uitschieters een rol spelen en wanneer de associaties een klein effect hebben. 
Daarom verwachten we dat de toevoeging van nieuwe toekomstige studies de huidige indeling van 
de meest sterk bewezen genetische associaties beïnvloeden en slechts enkele associaties robuust 
zullen blijken. The Venice-criteria vereisen verdere verfijningen voor de praktische toepassing in 
genetisch epidemiologisch onderzoek.
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Cock, om deel uit te maken van jouw onderzoeksteam was een bijzondere ervaring. Ik heb je leren 
kennen als een zeer gedreven onderzoeker en ik ben dankbaar voor de talloze mogelijkheden die je 
me geboden hebt om me te ontwikkelen als een kritisch onderzoeker. Je ongelooflijke geheugen en 
kennis zijn zeer uitdagend en motiverend en bovenal leerzaam.
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erg gewaardeerd dat je de stabiele factor was binnen mijn promotietraject.
Natuurlijk wil ik ook mijn co-promotor, dr. J.C. van Swieten hier bedanken; beste John, zonder jouw 
inmenging was ik nooit betrokken geraakt bij dit promotieonderzoek. Jij zorgde voor de link tussen 
de kliniek en genetische epidemiologie. Jouw input in de stukken was onmisbaar en ik heb het erg 
gewaardeerd dat ik altijd bij je terecht kon.
Zonder de leden van de kleine en grote commissie had deze dag niet plaats kunnen vinden. Dr. 
Bonifati, Dr. Biessels en Prof. Dr. Boomsma, ik wil jullie heel hartelijk danken voor het op zo’n korte 
termijn lezen en beoordelen van het manuscript.
Ook de leden van de grote commissie wil ik danken voor hun tijd om te opponeren. Prof. dr. Koudstaal, 
dank, we zullen elkaar nog veel spreken de komende jaren, ik verheug me erop. Dr. de Leeuw, als 
één van mijn vroegere voorgangers, vind ik het een bijzondere eer dat je tijd hebt genomen in de 
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Het vervolg onderzoek in ERF was nooit gelukt zonder de hulp van Prof. Dr. M.M.B. Breteler en Dr. 
A. van der Lugt. 
Beste Monique, de eerste aanzet van het onderzoek is dankzij jou tot stand gekomen. We hebben 
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bewonder je gedrevenheid en betrokkenheid bij mijn project.
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Verder wil ik Suzanne Gelok en Petra Veraart bedanken. Suzanne, je werd meteen in het diepe 
gegooid en hebt erg veel gedaan om het onderzoek in goede banen te leiden. Samen vroeg in de 
ochtend naar het onderzoekscentrum om de deelnemers te ontvangen en samen laat naar huis na 
het afdraaien en invriezen van het bloed. Ik hoop dat je een hoop hebt geleerd. Ik was onder de 
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Dr. M.W. Vernooij en dr. M.A. Ikram hebben geholpen alle scans te beoordelen. Beste Meike, dank 
voor de wijze lessen voor het opstarten van het onderzoek en het leren lezen van de scans op 
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discussies altijd erg leuk gevonden en was blij dat ik vaak snel bij je terecht kon. Zeker aan het eind, 
omdat je er voor gezorgd hebt dat de replicatie data er op tijd waren. Ik zie je vast nog veel in de 
kliniek.
De andere co-auteurs van de manuscripten wil ik hier ook bedanken.
Beste Carola, Tom, Wiro, Henri, Renske, Fedde, Cecile en Peter: dank voor jullie input in de 
manuscripten!
Peter, je prachtige tekeningen staan nog steeds op het bord. Dank voor de gesprekjes tijdens je werk 
in Rotterdam. Fedde, veel succes met het afronden van je proefschrift!
Cecile, jij was natuurlijk meer dan een co-auteur. Ik heb ontzettend veel van je geleerd, dank voor je 
geduld en uitleg!
Met veel plezier heb ik de afgelopen jaren gewerkt op de 22e. Dankzij de hulp van mijn collega’s 
werden zelfs de ingewikkeldste analyses een uitdaging en werden de dalen minder diep. 
Yurii thanks for explaining the methodological parts and your input in the analyses.
Annelous, er is een hoop veranderd sinds we samen een kamer deelden. Ik heb veel van je geleerd 
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Dat je een olifant niet in één keer op kunt eten, maar beetje bij beetje, stukje voor stukje, herhaal ik 
nog vaak voor mezelf.
Leonieke, ik vond het leuk met je samen te werken. Hoe bevalt je nieuwe baan? Veel succes met het 
afronden van je proefschrift.
Fan, thanks for all the patience in explaining the software and your nice companionship. How are the 
Dutch lessons going?
Aaron, thanks for all the help and the nice chats, especially the ones on Friday!
Maksim, it was nice working with you. I like your sense of humor.
Linda, het manuscript komt tot een eind! Veel succes met de rest van je werk.
Ayse, I enjoyed the dinners with you and Najaf, finally some girl talk.
Sophie, goed dat je de CJD registratie onder je hoede hebt genomen. Veel succes met het afronden 
van je master.
Zonder de volgende mensen zouden er geen genotypes bepaald zijn: Jeannette,
Andy, Bernadette, Sue Ellen en Andrea dank voor jullie hulp in het lab, ook als ik pas laat met 
samples terug kwam. Jeannette, je weet gelukkig altijd alles terug te vinden. Ik vond het een erg 
prettige samenwerking!
Dames van het secretariaat: Marjolein, Brigitte, Marion dank voor jullie hulp.
Jeannette jouw hulp met het verzamelen van alle hoofdstukken en samenbinden van de laatste 
versies was onmisbaar, heel veel dank hiervoor.
Pascual, thanks for being so enthusiastic about your work, it is inspiring. Thanks for your advice on 
the CJD patients. We will keep in touch.
Liesbeth en Danielle, ik vond het erg leuk dat jullie mijn kamergenootjes zijn geworden. Onze trajecten 
verschillen niet zo veel en ik heb veel gehad aan jullie luisterend oor. Liesbeth, voor jou zit het er 
bijna op, veel succes volgende maand. Danielle, veel plezier op je bruiloft volgende maand. Martje, 
heel veel succes.
I also would like to thank the international collaborators.
Tatiana, Irina, Anatoly: thanks for all the work and help. It was nice meeting you guys in person in 
Rotterdam.
Donald: thank you for the fruitfull collaboration.
All the consortia in CHARGE: thank you for your trust in me, so I could do the meta-analyses. Dear 
Tom, Stephanie and Jan, it was nice working with you and hopefully we will continue collaborating in 
the near future.
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Co-dames: hopelijk volgen er nog vele dinertjes! Jullie geven me een hoop energie.
Sun-D: tijden veranderen, wat een verschil met twaalf jaar geleden! Helemaal geweldig dat jullie vrij 
konden nemen om er vandaag bij te zijn. Straks is er meer tijd om weer af te spreken, ik heb er zin 
in.
Riek en Marijke, jullie blijven in mijn gedachten, ik wou dat ik op jullie promoties had kunnen zijn. 
Berit, Christine, Groningen-dames en natuurlijk SHOT! dank voor jullie interesse en geduld, hopelijk 
kan ik me nu weer vaker bij jullie aansluiten, want ik heb een veel verhalen en gezelligheid gemist.
Dear paranimphs, many thanks for being here today! 
Najaf, I enjoyed sharing the office with you. I am happy that we met and we get along so well. I miss 
the coffees in the morning and the chats. Hopefully, we will find more time to drink coffee and have 
dinner together!
Renate, super dat mijn paranimf bent vandaag. Ik ben erg blij dat je altijd in de buurt bent en gelukkig 
wil je meestal wel naar me luisteren, al is het de zoveelste keer hetzelfde probleem. Ik waardeer je 
professionele nuchtere advies. Zoals je weet kan ik me aan het begin van de week al verheugen 
op het vrijdagse biertje. We hebben er nog een hoop uit te proberen, want we zijn nog niet door het 
assortiment heen. 
Sjef, Elly, Inge, Ton: dank voor de interesse in mijn onderzoek en de hulp in ons nieuwe huis!
Pa en ma, jullie weten het wel: onmisbare stabiliteit. Het wordt tijd dat ik weer eens jullie kant op kom 
in plaats van andersom.
Sander, thanks! Zonder jou was het boekje er niet geweest in de vorm zoals die nu is. Ik ben erg blij 
met het resultaat, dankzij jouw perfectionisme is het erg mooi geworden. Ik vind het geweldig dat jij 
en Linda naar Nederland zijn gekomen deze week. Al woon je straks ook een eindje weg, misschien 
zullen we elkaar wat vaker zien. Ik mis de wandelingetjes samen met jou door de stad.
Bas, met jou samen komt alles goed. We hebben drukke tijden gehad, maar samen kunnen we de 
wereld aan. Jij had jouw project en ik het mijne, de volgende doen we samen. Ik verheug me eerst 
eens op een lekker weekendje niet klussen! 
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